

18. (Canceled)

*please search compounds
of formula I (claim 19)*

19. (Currently Amended) A compound of formula (I) as defined in any of claims 1 to 17,

(I):



(I)

Thanks!

Chin

R₁ is H or NH₂;R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl, halogen, OH or OR₁₀;R₄ is H, optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl;R₅ is H or optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, or C₃-C₇ cycloalkyl;or R₅ and R₆ together form a 5 or 6-membered heterocyclic ring;R₁₀ is optionally substituted C₁-C₆alkyl;

or a pharmaceutically acceptable salt or prodrug thereof. PROVIDED THAT: (a) R₂ is not an optionally substituted pyrazolopyridine ring system; and (b) when R₁ and R₃ are hydrogen and R₂ is unsubstituted phenyl then -NR₄R₅ is not -NH₂, NHCH₃ or N(CH₃)₂; and (c) when R₁ is -NH₂ and R₃ is hydrogen, then R₂ is not phenyl or phenyl substituted by one or more substituents selected from halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, nitro, -NH₂, or -NHCOCH₃.

=> d his 138

(FILE 'HCAPLUS' ENTERED AT 12:24:40 ON 06 JUN 2008)


L38 1 S ((L30 OR L31 OR L32 OR L33) AND L14) AND (L1 AND L14)

=> d que 138

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US20070281936/PN


L7 SCR 2043

L8 STR



Structure attributes must be viewed using STN Express query preparation:

Uploading L3.str



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-7 5-11 7-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-11 7-8 7-9

exact bonds :

3-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:Atom

Generic attributes :

11:

Saturation : Unsaturated

```
L14      768 SEA FILE=REGISTRY SSS FUL L8 NOT L7
L30      667 SEA FILE=HCAPLUS ABB=ON  PLU=ON  GILLESPIE R?/AU
L31      615 SEA FILE=HCAPLUS ABB=ON  PLU=ON  TODD R?/AU
L32      99  SEA FILE=HCAPLUS ABB=ON  PLU=ON  STRATTON G?/AU
L33      537 SEA FILE=HCAPLUS ABB=ON  PLU=ON  JORDAN A?/AU
L38      1   SEA FILE=HCAPLUS ABB=ON  PLU=ON  ((L30 OR L31 OR L32 OR L33)
        AND L14) AND (L1 AND L14)
```

=> d his 140

(FILE 'MEDLINE, BIOSIS, DRUGU, EMBASE, PASCAL' ENTERED AT 12:36:29 ON 06 JUN 2008)

```
L40      16 S L37
        SAVE TEMP L40 STO757MULTIN/A
```

FILE 'STNGUIDE' ENTERED AT 12:37:20 ON 06 JUN 2008

=> d que 140

```
L30      667 SEA FILE=HCAPLUS ABB=ON  PLU=ON  GILLESPIE R?/AU
L31      615 SEA FILE=HCAPLUS ABB=ON  PLU=ON  TODD R?/AU
L32      99  SEA FILE=HCAPLUS ABB=ON  PLU=ON  STRATTON G?/AU
L33      537 SEA FILE=HCAPLUS ABB=ON  PLU=ON  JORDAN A?/AU
L34      12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L30 AND ((L31 OR L32 OR L33))

L35      3   SEA FILE=HCAPLUS ABB=ON  PLU=ON  L31 AND ((L32 OR L33))
L36      2   SEA FILE=HCAPLUS ABB=ON  PLU=ON  L32 AND L33
L37      12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L34 OR L35 OR L36)
L40      16 SEA L37
```

=> dup rem 138 140

FILE 'HCAPLUS' ENTERED AT 12:38:33 ON 06 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:38:33 ON 06 JUN 2008

FILE 'BIOSIS' ENTERED AT 12:38:33 ON 06 JUN 2008
 Copyright (c) 2008 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 12:38:33 ON 06 JUN 2008
 COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 12:38:33 ON 06 JUN 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.



FILE 'PASCAL' ENTERED AT 12:38:33 ON 06 JUN 2008
 Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.
 PROCESSING COMPLETED FOR L38
 PROCESSING COMPLETED FOR L40

L41 13 DUP REM L38 L40 (4 DUPLICATES REMOVED)
 ANSWER '1' FROM FILE HCAPLUS
 ANSWERS '2-5' FROM FILE MEDLINE
 ANSWERS '6-11' FROM FILE BIOSIS
 ANSWERS '12-13' FROM FILE DRUGS

=> d l41 1 ibib abs hitstr; d l41 2-13 ibib ab

L41 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:962045 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:266942
 TITLE: Preparation of pyrimidine carboxamides as purine
 receptor, particularly adenosine receptor antagonists
 INVENTOR(S): Gillespie, Roger John; Todd, Richard
 Simon; Stratton, Gemma Caroline;
 Jordan, Allan Michael
 PATENT ASSIGNEE(S): Vernalis R & D Ltd., UK
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079801	A1	20050901	WO 2005-GB498	20050211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1720553	A1	20061115	EP 2005-708321	20050211
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, MK			
US 20070281936	A1	20071206	US 2007-588757	20070625 <--
PRIORITY APPLN. INFO.:			GB 2004-3155	A 20040212
			WO 2005-GB498	W 20050211
OTHER SOURCE(S):	MARPAT 143:266942			
GI				



AB The invention is related to the use of pyrimidines of formula (I) (R1 = H, NH2; R2 = (un)substituted hetero/aryl attached via a C atom; R3 = H, halo, OH and derivs., (un)substituted alk(en/yn)yl, cycloalkyl; R4 = H, (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl; R5 = H, (un)substituted alk(en/yn)yl, cycloalkyl; NR4R5 = 5 or 6-membered heterocycle) and their pharmaceutically acceptable salts and prodrugs, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial, provided that when R2 = (un)substituted aryl the said use is not the manufacture of a medicament for the treatment or prevention of inflammatory pain. I are purine receptor, particularly adenosine receptor antagonists, useful for treatment of movement disorders such as Parkinson disease. The invention is also related to the preparation of pyrimidines I. For example, coupling 2-amino-6-(2-furyl)pyrimidine-4-carboxylic acid (preparation given) with indole-5-methanamine gave pyrimidine carboxamide II in 5% yield. I displayed Ki values of < 5 μ M in an assay measuring in vitro binding to human adenosine A2A receptors.

IT 863546-62-7P, 2-Amino-6-(2-furyl)-N-[(6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-66-1P, 2-Amino-6-(2-furyl)-N-(3-methyl-4-nitrobenzyl)pyrimidine-4-carboxamide 863547-20-8P, 2-Amino-6-(2-furyl)-N-[(1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-23-3P, 2-Amino-N-(6-bromopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-42-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-59-5P 863547-60-8P, 2-Amino-6-(2-furyl)-N-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-61-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[[[tert-butylidimethylsilyl]oxy]methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-62-8P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-56-5P, 2-Amino-6-(2-furyl)-N-[(1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide dihydrochloride


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)

RN 863546-62-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-(hydroxymethyl)-2-

pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-66-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methyl-4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 863547-20-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 863547-23-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-bromo-2-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-42-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-59-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-[(triphenylmethoxy)methyl]-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863547-60-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]methyl]- (CA INDEX NAME)




RN 863547-61-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-pyridinyl]methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-62-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-(hydroxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)



RN 863548-56-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1H-imidazol-2-ylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HC1

IT 863546-30-9P, 2-Amino-N-(2-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-31-0P, 2-Amino-N-(3,4-difluorophenyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-32-1P, 2-Amino-6-(2-furyl)-N-(3-methoxybenzyl)pyrimidine-4-carboxamide 863546-33-2P, 2-Amino-6-(2-furyl)-N,N-dimethylpyrimidine-4-carboxamide 863546-35-4P, 2-Amino-6-(2-furyl)-N-(2-methoxybenzyl)pyrimidine-4-carboxamide 863546-36-5P, 2-Amino-6-(2-furyl)-N-[(2-furyl)methyl]pyrimidine-4-carboxamide 863546-37-6P, 2-Amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-38-7P, 2-Amino-6-(2-furyl)-N-(4-dimethylaminobenzyl)pyrimidine-4-carboxamide 863546-39-8P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-40-1P, 2-Amino-6-(2-furyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-41-2P,

2-Amino-6-(2-furyl)-N-[3-(dimethylaminocarbonyl)benzyl]pyrimidine-4-carboxamide 863546-42-3P, 2-Amino-6-(2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863546-43-4P, 2-Amino-6-(2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863546-44-5P, 2-Amino-6-(2-furyl)-N-(2-methylbenzyl)pyrimidine-4-carboxamide 863546-45-6P, 2-Amino-N-(3-trifluoromethylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-46-7P, 2-Amino-N-(1H-benzimidazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-47-8P, 2-Amino-6-(2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863546-48-9P, 2-Amino-6-(2-furyl)-N-(3-methylbenzyl)pyrimidine-4-carboxamide 863546-49-0P, 2-Amino-6-(2-furyl)-N-[(3-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-50-3P, 2-Amino-6-(2-furyl)-N-[[3-(dimethylamino)methyl]pyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-51-4P, 2-Amino-6-(2-furyl)-N-[[3-[(4-morpholinyl)methyl]pyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-52-5P, 2-Amino-6-(2-furyl)-N-[[3,6-dimethylpyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-53-6P, 2-Amino-6-(2-furyl)-N-[[2-(2-thienyl)thiazol-4-yl]methyl]pyrimidine-4-carboxamide 863546-54-7P, 2-Amino-6-(2-furyl)-N-[(2-thienyl)methyl]pyrimidine-4-carboxamide 863546-55-8P, 2-Amino-6-(2-furyl)-N-[[5-(2-pyridyl)thien-2-yl]methyl]pyrimidine-4-carboxamide 863546-56-9P, 2-Amino-6-(2-furyl)-N-[(5-methyl-2-trifluoromethylfuran-3-yl)methyl]pyrimidine-4-carboxamide 863546-57-0P, 2-Amino-6-(2-furyl)-N-[(5-methylisoxazol-3-yl)methyl]pyrimidine-4-carboxamide 863546-58-1P, 2-Amino-6-(2-furyl)-N-[(2-methoxy-6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-59-2P, 2-Amino-N-[(6-fluoro-[1,3]benzodioxin-8-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-60-5P, 2-Amino-6-(2-furyl)-N-[(6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-61-6P, 2-Amino-6-(2-furyl)-N-[(3-indolyl)methyl]pyrimidine-4-carboxamide 863546-63-8P, 2-Amino-6-(2-furyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863546-64-9P, 2-Amino-6-(2-furyl)-N-[(5-indolyl)methyl]pyrimidine-4-carboxamide 863546-65-0P, 2-Amino-N-(2,3-dimethylindol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-67-3P, N-[[6-[(N-Acetyl-N-methylamino)methyl]-3-methylpyridin-2-yl]methyl]-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-68-3P, 2-Amino-6-(2-furyl)-N-methyl-N-[2-(2-pyridyl)ethyl]pyrimidine-4-carboxamide 863546-69-4P, 2-Amino-6-(2-furyl)-N-[(2-methylindol-5-yl)methyl]pyrimidine-4-carboxamide 863546-70-7P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl isopropylcarbamate 863546-71-8P, 2-Amino-N-benzyl-6-(2-furyl)pyrimidine-4-carboxamide 863546-72-9P, N-Allyl-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-73-0P, (R)-2-Amino-6-(2-furyl)-N-(2-hydroxypropyl)pyrimidine-4-carboxamide 863546-74-1P, 863546-75-2P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethyl-3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-76-3P, Methyl [[[(2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]acetate 863546-77-4P, 2-Amino-6-(2-furyl)-N-[(6-indolyl)methyl]pyrimidine-4-carboxamide 863546-78-5P, 2-Amino-6-(2-furyl)-N-[(quinolin-8-yl)methyl]pyrimidine-4-carboxamide 863546-79-6P, 2-Amino-6-(2-furyl)-N-[2-(pyridin-2-yl)ethyl]pyrimidine-4-carboxamide 863546-80-9P, 2-Amino-N-(2-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-81-0P, 2-Amino-6-(2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863546-82-1P, 2-Amino-N-(2,1,3-benzothiadiazol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-83-2P, [6-[[[(2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl dimethylcarbamate

863546-84-3P, 2-Amino-6-(2-furyl)-N-[(isoquinolin-3-yl)methyl]pyrimidine-4-carboxamide 863546-86-5P, 2-Amino-6-(2-furyl)-N-[(quinolin-2-yl)methyl]pyrimidine-4-carboxamide 863546-87-6P, 2-Amino-N-(benzothiazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-88-7P, 2-Amino-N-[[6-[(cyclopropylmethoxy)methyl]-3-methylpyridin-2-yl]methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-89-8P, (S)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-90-1P, 2-Amino-N-(4-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-91-2P, 2-Amino-N-(4-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-92-3P, (R)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-93-4P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl ester 863546-94-5P, 2-Amino-6-(2-furyl)-N-(4-methoxybenzyl)pyrimidine-4-carboxamide 863546-96-7P, 2-Amino-6-(2-furyl)-N-(2-methoxyethyl)pyrimidine-4-carboxamide 863546-97-8P, 2-Amino-N-(cyanomethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-98-9P, 2-Amino-6-(2-furyl)-N-(4-methylbenzyl)pyrimidine-4-carboxamide 863546-99-0P, 2-Amino-6-(2-furyl)-N-(1-phenyl-1-methylethyl)pyrimidine-4-carboxamide 863547-02-8P, 2-Amino-N-(3-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-03-9P, 2-Amino-N-(3-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-05-1P, 2-Amino-6-(2-furyl)-N-(3-methylphenyl)pyrimidine-4-carboxamide 863547-06-2P, 2-Amino-6-(2-furyl)-N-(3-methylpyridin-2-yl)pyrimidine-4-carboxamide 863547-07-3P, (R)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-08-4P, (S)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-09-5P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl piperidine-1-carboxylate 863547-10-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl pyrrolidine-1-carboxylate 863547-11-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl allylcarbamate 863547-12-0P, 2-Amino-6-(2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-13-1P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-14-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl n-propylcarbamate 863547-15-3P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl tert-butylcarbamate 863547-16-4P, 2-Amino-N-benzyl-6-(2-furyl)-N-methylpyrimidine-4-carboxamide 863547-17-5P, 2-Amino-6-(2-furyl)-N-[(5-methylpyrazin-2-yl)methyl]pyrimidine-4-carboxamide 863547-18-6P, 2-Amino-6-(2-furyl)-N-(1,2,3,4-tetrahydro-1-naphthyl)pyrimidine-4-carboxamide 863547-19-7P, 2-Amino-6-(2-furyl)-N-(2-indanyl)pyrimidine-4-carboxamide 863547-21-1P, 2-Amino-6-(2-furyl)-N-[(1-n-propyl-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-22-2P, 2-Amino-N-(2-bromobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-24-4P, 2-Amino-N-(6-aminopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-25-5P, 2-Amino-6-(2-furyl)-N-[3-(1H-imidazol-1-yl)propyl]pyrimidine-4-carboxamide 863547-26-6P, 2-Amino-6-(2-furyl)-N-[[1-(2-methoxyethyl)-1H-imidazol-2-yl]methyl]pyrimidine-4-carboxamide 863547-27-7P, 2-Amino-N-[(1-ethyl-1H-imidazol-2-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-28-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl benzylcarbamate 863547-29-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl cyclopentylcarbamate

863547-30-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl hexylcarbamate 863547-31-3P, 2-Amino-N-[2-(dimethylamino)-6-methylpyridin-3-ylmethyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-32-4P, (R)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-33-5P, (S)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-34-6P, 2-Amino-N-(2,6-dichlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-35-7P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]-5-methylpyrimidine-4-carboxamide 863547-36-8P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-37-9P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-38-0P, 2-Amino-N-[[6-(n-propyl)pyridin-2-yl]methyl]-6-1H-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-39-1P, 2-Amino-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-40-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-41-5P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]pyrimidine-4-carboxamide 863547-43-7P, [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl tert-butylcarbamate 863547-44-8P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl ester 863547-45-9P, 2-Amino-5-chloro-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-46-0P, 2-Amino-5-bromo-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-47-1P, 2-Amino-5-bromo-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-48-2P, 2-Amino-N-(2-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-49-3P, 2-Amino-N-(3-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-50-6P, 2-Amino-N-(4-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-51-7P, 2-Amino-N-(2-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-52-8P, 2-Amino-N-(3-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-53-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863547-54-0P, 2-Amino-6-(5-methyl-2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863547-55-1P, 2-Amino-N-(2-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-56-2P, 2-Amino-N-(3-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-57-3P, 2-Amino-N-(3-fluorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-58-4P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-63-1P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-64-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(5-methylisoxazol-3-yl)methyl]pyrimidine-4-carboxamide 863547-65-3P, 2-Amino-6-(5-methyl-2-furyl)-N-[(tetrahydrofuran-2-yl)methyl]pyrimidine-4-carboxamide 863547-66-4P, 2-Amino-N-(cyclopropylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-67-5P, 2-Amino-6-(5-methyl-2-furyl)-N-(2-phenylethyl)pyrimidine-4-carboxamide 863547-68-6P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-69-7P, 2-Amino-N-benzyl-N-ethyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-70-0P, 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylpropyl)pyrimidine-4-carboxamide 863547-71-1P, 2-Amino-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-72-2P,

2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-73-3P, (S)-2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-74-4P, 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenyl-1-methylthyl)pyrimidine-4-carboxamide 863547-75-5P, 2-Amino-N-isobutyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-76-6P, 2-Amino-N-hexyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-77-7P, 2-Amino-N-butyl-N-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-78-8P, 2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-pentylpyrimidine-4-carboxamide 863547-79-9P, 2-Amino-N-benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-80-2P, 2-Amino-6-(5-methyl-2-furyl)-N-phenylpyrimidine-4-carboxamide 863547-81-3P, 2-Amino-N-benzyl-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-82-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-5-yl)methyl]pyrimidine-4-carboxamide 863547-83-5P, 2-Amino-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-84-6P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-85-7P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-86-8P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-87-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]pyrimidine-4-carboxamide 863547-88-0P, 2-Amino-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-89-1P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-90-4P, 6-(5-Methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-91-5P, N-Benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-92-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[(isopropoxy)methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-93-7P, 6-(5-Methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-94-8P, N-(3,6-Dimethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-95-9P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-96-0P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-97-1P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-98-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]pyrimidine-4-carboxamide 863547-99-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyrimidin-4-yl)methyl]pyrimidine-4-carboxamide 863548-00-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(4-methylthiazol-2-yl)methyl]pyrimidine-4-carboxamide 863548-01-0P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-02-1P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-03-2P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-3-yl)methyl]pyrimidine-4-carboxamide 863548-04-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-05-4P, 2-Amino-N-(2-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-06-5P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-07-6P, 2-Amino-N-(3-methoxybenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-08-7P, 2-Amino-N-(3-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-09-8P, 2-Amino-N-(3-fluorobenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-10-1P, 2-Amino-N-(3-chlorobenzyl)-6-(4-methylthiazol-2-


yl)pyrimidine-4-carboxamide 863548-11-2P, 2-Amino-N-(6-methylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-12-3P, 2-Amino-6-phenyl-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-13-4P, 2-Amino-6-phenyl-N-(pyridin-2-ylmethyl)pyrimidine-4-carboxamide 863548-14-5P, 2-Amino-6-(2-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-15-6P, 2-Amino-6-(4-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-16-7P, 2-Amino-6-(3-cyanophenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-17-8P, 2-Amino-6-(2-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-18-9P, 2-Amino-6-(3-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-19-0P, 2-Amino-6-(4-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-20-3P, 2-Amino-6-(3-cyanophenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-21-4P, 2-Amino-6-(3-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-22-5P, 2-Amino-6-(3-methoxyphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-23-6P, 2-Amino-6-(3-methoxyphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-24-7P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-phenylpyrimidine-4-carboxamide 863548-59-8P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)


RN 863546-30-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)



RN 863546-31-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-(3,4-difluorophenyl)-6-(2-furanyl)-
(CA INDEX NAME)



RN 863546-32-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methoxyphenyl)methyl]-

(CA INDEX NAME)




RN 863546-33-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N,N-dimethyl- (CA INDEX NAME)




RN 863546-35-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 863546-36-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 863546-37-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-38-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-(dimethylamino)phenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-39-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(6-(methoxymethyl)-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-40-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-41-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[3-[(dimethylamino)carbonyl]phenyl]methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-42-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-43-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-44-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 863546-45-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863546-46-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(1H-benzimidazol-2-ylmethyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-47-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-48-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[3-(methoxymethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863546-49-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[3-(methoxymethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863546-50-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-([3-[(dimethylamino)methyl]-2-pyridinyl]methyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-51-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-([3-(4-morpholinylmethyl)-2-pyridinyl]methyl)- (CA INDEX NAME)




RN 863546-52-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-([3,6-dimethyl-2-pyridinyl]methyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-53-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-([2-(2-thienyl)-4-thiazolyl]methyl)- (CA INDEX NAME)




RN 863546-54-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 863546-55-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-(2-pyridinyl)-2-thienyl)methyl]- (CA INDEX NAME)




RN 863546-56-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-2-(trifluoromethyl)-3-furanyl)methyl]- (CA INDEX NAME)




RN 863546-57-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 863546-58-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methoxy-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-59-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-60-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-61-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[2-(1H-indol-3-yl)ethyl]-
(CA INDEX NAME)




RN 863546-63-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 863546-64-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1H-indol-5-ylmethyl)-
(CA INDEX NAME)




RN 863546-65-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2,3-dimethyl-1H-indol-5-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-67-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[6-[(acetylmethylamino)methyl]-3-methyl-2-pyridinyl]methyl]-2-amino-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-68-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 863546-69-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methyl-1H-indol-5-yl)methyl]- (CA INDEX NAME)



RN 863546-70-7 HCAPLUS


CN Carbamic acid, (1-methylethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)



RN 863546-71-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)

INDEX NAME)



RN 863546-72-9 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-2-propen-1-yl- (CA INDEX NAME)



RN 863546-73-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 863546-74-1 HCAPLUS

CN Carbamic acid, (3,5-dimethyl-4-isoxazolyl)-, [6-[[[(2-amino-6-(2-furanyl)-4-pyrimidinyl)carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863546-75-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-(methoxymethyl)-3-methyl-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863546-76-3 HCAPLUS

CN Glycine, N-[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)




RN 863546-77-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1H-indol-6-ylmethyl)- (CA INDEX NAME)




RN 863546-78-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(8-quinolinylmethyl)-
(CA INDEX NAME)

RN 863546-79-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[2-(2-pyridinyl)ethyl]-
(CA INDEX NAME)

RN 863546-80-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863546-81-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[2-(trifluoromethyl)phenyl]methyl]-
(CA INDEX NAME)




RN 863546-82-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2,1,3-benzothiadiazol-5-ylmethyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-83-2 HCAPLUS

CN Carbamic acid, dimethyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)




RN 863546-84-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-isoquinolinylmethyl)- (CA INDEX NAME)




RN 863546-86-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-quinolinylmethyl)- (CA INDEX NAME)




RN 863546-87-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2-benzothiazolylmethyl)-6-(2-furanyl)-
(CA INDEX NAME)



RN 863546-88-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-[(cyclopropylmethoxy)methyl]-3-methyl-2-pyridinyl]methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-89-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1S)-1-phenylethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 863546-90-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863546-91-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)

RN 863546-92-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1R)-1-phenylethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 863546-93-4 HCAPLUS

CN 4-Morpholinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (CA INDEX NAME)




RN 863546-94-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(4-methoxyphenyl)methyl]-
(CA INDEX NAME)




RN 863546-96-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-methoxyethyl)-
(CA INDEX NAME)




RN 863546-97-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-(cyanomethyl)-6-(2-furanyl)-
(CA INDEX NAME)




RN 863546-98-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(4-methylphenyl)methyl]-
(CA INDEX NAME)


RN 863546-99-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)

RN 863547-02-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)

RN 863547-03-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863547-05-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-methylphenyl)- (CA INDEX NAME)



RN 863547-06-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 863547-07-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-6-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 863547-08-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 863547-09-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (CA INDEX NAME)




RN 863547-10-8 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (CA INDEX NAME)




RN 863547-11-9 HCAPLUS

CN Carbamic acid, 2-propenyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (9CI) (CA INDEX NAME)




RN 863547-12-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 863547-13-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-amino-3-methylphenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-14-2 HCAPLUS

CN Carbamic acid, propyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-15-3 HCAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-16-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-methyl-N-(phenylmethyl)-(CA INDEX NAME)




RN 863547-17-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-2-pyrazinyl)methyl]- (CA INDEX NAME)




RN 863547-18-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




RN 863547-19-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2,3-dihydro-1H-inden-2-yl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1-propyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 863547-22-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-bromophenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-24-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-amino-2-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-25-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 863547-26-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[1-(2-methoxyethyl)-1H-imidazol-2-yl]methyl]- (CA INDEX NAME)




RN 863547-27-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-ethyl-1H-imidazol-2-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-28-8 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-29-9 HCAPLUS

CN Carbamic acid, cyclopentyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)




RN 863547-30-2 HCAPLUS

CN Carbamic acid, hexyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)



RN 863547-31-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[[2-(dimethylamino)-6-methyl-3-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)



RN 863547-32-4 HCAPLUS

CN Benzeacetic acid, α -[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]-, methyl ester, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 863547-33-5 HCAPLUS


CN Benzeacetic acid, α -[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 863547-34-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2,6-dichlorophenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-35-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-5-methyl- (CA INDEX NAME)




RN 863547-36-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-37-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methyl-2-pyridinyl)methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-38-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-propyl-2-pyridinyl)methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-39-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-40-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-41-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]- (CA INDEX NAME)




RN 863547-43-7 HCAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, [6-[[[2-amino-6-(5-methyl-2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-44-8 HCAPLUS

CN 4-Morpholinecarboxylic acid, [6-[[[2-amino-6-(5-methyl-2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (CA INDEX NAME)




RN 863547-45-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-chloro-N-[[6-(methoxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-46-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-bromo-N-[[6-(methoxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-47-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-bromo-6-(5-methyl-2-furanyl)-N-[[2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 863547-48-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-49-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-50-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-51-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-chlorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-52-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-53-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-54-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-55-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-methoxyphenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-56-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methoxyphenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-57-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-58-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-63-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-64-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 863547-65-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 863547-66-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(cyclopropylmethyl)-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-67-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 863547-68-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(3-phenylpropyl)-
(CA INDEX NAME)

RN 863547-69-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-ethyl-6-(5-methyl-2-furanyl)-N-(phenylmethyl)-
(CA INDEX NAME)

RN 863547-70-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-phenylpropyl)-
(CA INDEX NAME)

RN 863547-71-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-6-(5-methyl-2-furanyl)-
(CA INDEX NAME)




RN 863547-72-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-phenylethyl)-
(CA INDEX NAME)

RN 863547-73-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-methyl-6-(5-methyl-2-furanyl)-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 863547-74-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 863547-75-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-methylpropyl)-

(CA INDEX NAME)




RN 863547-76-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-hexyl-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-77-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-butyl-N-methyl-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-78-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-methyl-6-(5-methyl-2-furanyl)-N-pentyl- (CA INDEX NAME)




RN 863547-79-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(phenylmethyl)-
(CA INDEX NAME)


RN 863547-80-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-phenyl- (CA
INDEX NAME)

RN 863547-81-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(phenylmethyl)-
(CA INDEX NAME)

RN 863547-82-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-
pyrazol-5-yl)methyl]- (CA INDEX NAME)


RN 863547-83-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-84-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-85-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-86-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-87-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]- (CA INDEX NAME)




RN 863547-88-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-89-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-90-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 863547-91-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 863547-92-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methylethoxy)methyl]-2-pyridinylmethyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-93-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-94-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,6-dimethyl-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-95-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-96-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-97-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863547-98-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 863547-99-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(4-pyrimidinylmethyl)- (CA INDEX NAME)




RN 863548-00-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[(4-methyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 863548-01-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-02-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-03-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-04-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863548-05-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-methylphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-06-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-07-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methoxyphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-08-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methylphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-09-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-10-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-11-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-methyl-2-pyridinyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-12-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-phenyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863548-13-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-14-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-15-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-16-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-cyanophenyl)-N-(2-pyridinylmethyl)-
(CA INDEX NAME)




RN 863548-17-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-18-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-19-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-20-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-cyanophenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-21-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-22-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-23-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methoxyphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-24-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methyl-2-pyridinyl)methyl]-6-phenyl-
(CA INDEX NAME)

RN 863548-59-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-amino-3-methylphenyl)methyl]-6-(2-furanyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HC1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 13 MEDLINE on STN DUPLICATE 1
 ACCESSION NUMBER: 2006660798 MEDLINE [Full-text](#)
 DOCUMENT NUMBER: PubMed ID: 16971117
 TITLE: Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.
 AUTHOR: Richardson Christine M; Gillespie Roger J; Williamson Douglas S; Jordan Ailan M; Fink Alexandra; Knight Antony R; Sellwood Daniel M; Misra Anil
 CORPORATE SOURCE: Vernalis (R&D) Ltd, Granta Park, Cambridge, CB1 6GB, UK.
 SOURCE: c.richardson@vernalis.com. <c.richardson@vernalis.com>
 Bioorganic & medicinal chemistry letters, (2006 Dec 1) Vol. 16, No. 23, pp. 5993-7. Electronic Publication:

2006-09-12.

Journal code: 9107377. ISSN: 0960-894X.

PUB. COUNTRY: England; United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200701
 ENTRY DATE: Entered STN: 14 Nov 2006
 Last Updated on STN: 9 Jan 2007
 Entered Medline: 8 Jan 2007

AB Database searching led to the identification of potent A(2A) antagonists which do not contain the privileged furan moiety and which show selectivity over A(1) receptors. Simple substructure searching on a proprietary database identified compounds with activities in the low nM range. A targeted approach to the identification of non-furan containing compounds resulted in the identification of two novel series, with potency, selectivity and directional SAR from screening 113 compounds.

L41 ANSWER 3 OF 13 MEDLINE on STN

ACCESSION NUMBER: 2008292312 IN-PROCESS Full-text

DOCUMENT NUMBER: PubMed ID: 18411049

TITLE: Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylurines.

AUTHOR: Gillespie Roger J; Cliffe Ian A; Dawson Claire E;
 Dourish Colin T; Gaur Suneel; Jordan Allan M;
 Knight Antony R; Lerpiniere Joanne; Misra Anil; Pratt Robert M; Roffey Jonathan; Stratton Gemma C;
 Upton Rebecca; Weiss Scott M; Williamson Douglas S

CORPORATE SOURCE: Vernalis (R&D) Ltd, 613 Reading Road, Winnersh RG41 5UA, UK.

SOURCE: Bioorganic & medicinal chemistry letters, (2008 May 1) Vol. 18, No. 9, pp. 2924-9. Electronic Publication: 2008-03-30.
 Journal code: 9107377. E-ISSN: 1464-3405.

PUB. COUNTRY: England; United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English

FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
 ENTRY DATE: Entered STN: 6 May 2008
 Last Updated on STN: 6 May 2008

AB A series of pyrazolo[3,4-d]pyrimidine, pyrrolo[2,3-d]pyrimidine and 6-arylurine adenosine A(2A) antagonists is described. Many examples were highly selective against the human A(1) receptor sub-type and were active in an in vivo model of Parkinson's disease.

L41 ANSWER 4 OF 13 MEDLINE on STN

ACCESSION NUMBER: 2008292282 IN-PROCESS Full-text

DOCUMENT NUMBER: PubMed ID: 18407496

TITLE: Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.

AUTHOR: Gillespie Roger J; Cliffe Ian A; Dawson Claire E;
 Dourish Colin T; Gaur Suneel; Giles Paul R; Jordan Allan M; Knight Antony R; Lawrence Anthony; Lerpiniere Joanne; Misra Anil; Pratt Robert M; Todd Richard S;
 Upton Rebecca; Weiss Scott M; Williamson Douglas S

CORPORATE SOURCE: Vernalis (R&D) Ltd, 613 Reading Road, Winnersh, Wokingham RG41 5UA, UK.

SOURCE: Bioorganic & medicinal chemistry letters, (2008 May 1) Vol. 18, No. 9, pp. 2920-3. Electronic Publication: 2008-03-30. Journal code: 9107377. E-ISSN: 1464-3405.

PUB. COUNTRY: England; United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 6 May 2008
Last Updated on STN: 6 May 2008

AB We describe herein the discovery and development of a series of 4-arylthieno[3,2-d]pyrimidines which are potent adenosine A(2A) receptor antagonists. These novel compounds show high degrees of selectivity against the human A(1), A(2B) and A(3) receptor sub-types. Moreover, a number of these compounds show promising activity in vivo, suggesting potential utility in the treatment of Parkinson's disease.

L41 ANSWER 5 OF 13 MEDLINE on STN

ACCESSION NUMBER: 2008292258 IN-PROCESS [Full-text](#)
DOCUMENT NUMBER: PubMed ID: 18406614
TITLE: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
AUTHOR: Gillespie Roger J; Adams David R; Bebbington David; Benwell Karen; Cliffe Ian A; Dawson Claire E; Dourish Colin T; Fletcher Allan; Gaur Suneel; Giles Paul R; Jordan Allan M; Knight Antony R; Knutsen Lars J S; Lawrence Anthony; Lerpiniere Joanne; Misra Anil; Porter Richard H P; Pratt Robert M; Shepherd Robin; Upton Rebecca; Ward Simon E; Weiss Scott M; Williamson Douglas S
CORPORATE SOURCE: Vernalis (R&D) Ltd, 613 Reading Road, Winnersh, Wokingham RG41 5UA, UK.

SOURCE: Bioorganic & medicinal chemistry letters, (2008 May 1) Vol. 18, No. 9, pp. 2916-9. Electronic Publication: 2008-03-30. Journal code: 9107377. E-ISSN: 1464-3405.

PUB. COUNTRY: England; United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 6 May 2008
Last Updated on STN: 6 May 2008

AB The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity against the A(1) receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease.

L41 ANSWER 6 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2007:88213 BIOSIS [Full-text](#)
DOCUMENT NUMBER: PREV200700093025
TITLE: Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists.
AUTHOR(S): Anonymous; Gillespie, Roger John [Inventor]; Lerpiniere, Joanne [Inventor]; Gaur, Suneel [Inventor]; Bamford, Samantha Jayne [Inventor]; Stratton, Gemma Caroline [Inventor]; Leonardi, Stefania [Inventor];

Weiss, Scott Murray [Inventor]
 CORPORATE SOURCE: Wokingham, United Kingdom
 ASSIGNEE: Vernalis Research Ltd
 PATENT INFORMATION: US 07141575 20061128
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (NOV 28 2006)
 CODEN: OGPUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 31 Jan 2007
 Last Updated on STN: 31 Jan 2007

AB The use of a compound of formula (I): wherein R(1) is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4CONR5, NR4CONR5R6, NR(4)CO(2)R(7) and NR4SO2R7; R(2) is selected from aryl attached via an unsaturated carbon; R(3) is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR(4)NR(5)R(6) and SO2R7; R-4, R(5) and R(6) are independently selected from H, alkyl and aryl or where R(5) and R(6) are in an NR(5)R(6) group, R(5) and R(6) may be linked to form a heterocyclic group, or where R-4, R(5) and R(6) are in a (CONR4NR5R6) group, R(4) and R(5) may be linked to form a heterocyclic group; and R(7) is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A(2A) receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se

L41 ANSWER 7 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:518929 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200600518933
 TITLE: Synthesis and SAR of novel thieno[3,2-d]pyrimidine derivatives as selective antagonists of the adenosine A(2A) receptor.
 AUTHOR(S): Jordan, Allan M. [Reprint Author]; Cliffe, Ian A.; Dawson, Claire E.; Dourish, Colin T.; Giles, Paul R.; Gillespie, Roger.; Knight, Tony R.; Lawrence, Anthony; Lerpiniere, Joanne; Misra, A.; Pratt, Robert M.; Todd, Richard S.; Upton, Rebecca; Weiss, Scott M.
 CORPORATE SOURCE: Vernalis R and D Ltd, Med Chem, Cambridge CB1 6GB, UK
 SOURCE: Abstracts of Papers American Chemical Society, (AUG 28 2005) Vol. 230, pp. U2551-U2553.
 Meeting Info.: 230th National Meeting of the American-Chemical-Society. Washington, DC, USA. August 28 -September 01, 2005.
 CODEN: ACSRAL. ISSN: 0065-7727.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 12 Oct 2006
 Last Updated on STN: 12 Oct 2006

L41 ANSWER 8 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:518927 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200600518931
 TITLE: (-)-Mefloquine as a starting point for the discovery of selective adenosine A(2A) receptor antagonists.
 AUTHOR(S): Jordan, Allan M. [Reprint Author]; Benwell,

Karen; Cliffe, Ian A.; Dourish, Colin T.; Giles, Paul R.; Gillespie, Roger J.; Knights, Tony R.; Lerpiniere, Loanne; Misra, A.; Ward, Simon E.; Weiss, Scott M. Vernalis R and D Ltd, Med Chem, Cambridge CB1 6GB, UK
 CORPORATE SOURCE: Abstracts of Papers American Chemical Society, (AUG 28 2005) Vol. 230, pp. U2550-U2551.
 SOURCE: Meeting Info.: 230th National Meeting of the American-Chemical-Society. Washington, DC, USA. August 28 -September 01, 2005.
 CODEN: ACSRAL. ISSN: 0065-7727.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Oct 2006
 Last Updated on STN: 12 Oct 2006

L41 ANSWER 9 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:67316 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200600067176
 TITLE: Synthesis and SAR of novel thieno[3,2-d]pyrimidine derivatives as selective antagonists of the adenosine A(2A) receptor.
 AUTHOR(S): Todd, Richard S. [Reprint Author]; Lerpiniere, Joanne; Pratt, Robert M.; Giles, Paul R.; Dawson, Claire E.; Gaur, Suneel; Weiss, Scott M.; Knight, Tony R.; Misra, Anil; Lawrence, Anthony; Benwell, Karen; Upton, Rebecca; Dourish, Colin T.; Cliffe, Ian A.; Gillespie, Roger J.
 CORPORATE SOURCE: r.todd@vernalis.com
 SOURCE: Abstracts of Papers American Chemical Society, (MAR 28 2004) Vol. 227, No. Part 2, pp. U52.
 Meeting Info.: 227th National Meeting of the American-Chemical Society. Anaheim, CA, USA. March 28 -April 01, 2004. Amer Chem Soc.
 CODEN: ACSRAL. ISSN: 0065-7727.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 19 Jan 2006
 Last Updated on STN: 19 Jan 2006

L41 ANSWER 10 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:67315 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200600067175
 TITLE: Synthesis and evaluation of novel pyrazolo[3,4-d]pyrimidine derivatives as selective adenosine A(2A) receptor antagonists.
 AUTHOR(S): Stratton, Gemma C. [Reprint Author]; Lerpiniere, Joanne; Gaur, Suneel; Weiss, Scott M.; Knight, Tony R.; Misra, Anil; Jones, Julie; Lawrence, Anthony; Benwell, Karen; Upton, Rebecca; Dourish, Colin T.; Cliffe, Ian A.; Gillespie, Roger J.
 CORPORATE SOURCE: g.stratton@vernalis.com
 SOURCE: Abstracts of Papers American Chemical Society, (MAR 28 2004) Vol. 227, No. Part 2, pp. U52.
 Meeting Info.: 227th National Meeting of the American-Chemical Society. Anaheim, CA, USA. March 28 -April 01, 2004. Amer Chem Soc.
 CODEN: ACSRAL. ISSN: 0065-7727.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; (Meeting Poster)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 19 Jan 2006
 Last Updated on STN: 19 Jan 2006

L41 ANSWER 11 OF 13 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:67314 BIOSIS Full-text

DOCUMENT NUMBER: PREV200600067174

TITLE: Novel purine derivatives as selective adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.

AUTHOR(S): Bamford, Samantha J. [Reprint Author]; Lerpiniere, Joanne; Stratton, Gemma C.; Dawson, Claire E.; Pratt, Robert M.; Gaur, Suneel; Weiss, Scott M.; Knight, Tony R.; Misra, Anil; Jones, Julie; Benwell, Karen; Upton, Rebecca; Dourish, Colin T.; Cliffe, Ian A.; Gillespie, Roger J.

CORPORATE SOURCE: s.bamford@vernalis.com

SOURCE: Abstracts of Papers American Chemical Society, (MAR 28 2004) Vol. 227, No. Part 2, pp. U51-U52.
 Meeting Info.: 227th National Meeting of the American-Chemical Society. Anaheim, CA, USA. March 28 -April 01, 2004. Amer Chem Soc.
 CODEN: ACSRAL. ISSN: 0065-7727.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 19 Jan 2006
 Last Updated on STN: 19 Jan 2006

L41 ANSWER 12 OF 13 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN

ACCESSION NUMBER: 2005-38493 DRUGU C P Full-text

TITLE: Synthesis and SAR of novel thieno[3,2-d]pyrimidine derivatives as selective antagonists of the adenosine A2A receptor.

AUTHOR: Jordan A M; Cliffe I A; Dawson C E; Dourish C T; Giles P R; Gillespie R J; Knight T R; Lawrence A; Lerpiniere J; Misra A

LOCATION: Washington, DC, USA

SOURCE: Abstr.Pap.Am.Chem.Soc. (230 Meet., Pt. 2, MEDI 79, 2005)
 CODEN: ACSRAL ISSN: 0065-7727

AVAIL. OF DOC.: No Reprint Address. (14 Authors).

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AB There is strong evidence that adenosine A2A receptor antagonists may provide a novel therapy for the treatment of Parkinson's disease with a lower risk of dyskinesias. The discovery of a series of thieno[3,2-d]pyrimidine derivatives as potent, selective A2A receptor antagonists, was previously presented. Further development of this series, yielding considerable improvements in both potency and selectivity, were presented in this poster. For example, VER-6623 exhibited a Ki of 1.4 nM at human adenosine A2A receptors and was highly selective over human A1, A2B, and A3 receptors (Ki 273, 821, and 508 nM respectively). Moreover, many of these compounds were active in animal models of Parkinson's disease. The synthesis and evaluation of this series was described. (conference abstract: 230th ACS National Meeting, Washington, District of Columbia, USA, August 28 - September 1, 2005).

L41 ANSWER 13 OF 13 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2005-38492 DRUGU C P [Full-text](#)
 TITLE: (-)-Mefloquine as a starting point for the discovery of
 selective adenosine A2A receptor antagonists.
 AUTHOR: Jordan A M; Benwell K; Cliffe I A; Dourish C T;
 Giles P R; Gillespie K J; Knight T R; Lerpinier J;
 Misra A; Ward S E
 LOCATION: Washington, DC, USA
 SOURCE: Abstr.Pap.Am.Chem.Soc. (230 Meet., Pt. 2, MEDI 77, 2005)
 CODEN: ACSRAL ISSN: 0065-7727
 AVAIL. OF DOC.: No Reprint Address. (11 Authors).
 LANGUAGE: English
 DOCUMENT TYPE: Journal
 FIELD AVAIL.: AB; LA; CT
 FILE SEGMENT: Literature
 AB Blockade of the adenosine A2A receptor has been shown to offer considerable
 promise as a novel treatment for the symptoms of Parkinson's disease. As part
 of ongoing efforts to discover new treatments for this condition, the Authors
 showed that the (-)-enantiomer of the antimalarial drug mefloquine is a
 reasonably potent and moderately selective adenosine A2A receptor antagonist
 (Ki 61 nM, 4-fold selective against A1 receptors). Using this compound as a
 starting point, a series of iterations led to the identification of a novel
 non-xanthine chemical class of adenosine A2A antagonists with improved
 potency and selectivity. For example, VER-4187 exhibited a Ki of 12 nM at
 human adenosine A2A receptors. The evolution and evaluation of this series
 was described. (conference abstract: 230th ACS National Meeting, Washington,
 District of Columbia, USA, August 28 -September 1, 2005).

=> d his l29

(FILE 'HCAPLUS' ENTERED AT 12:24:40 ON 06 JUN 2008)


L29 28 S L22 OR L27 OR L28

=> d que l29

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US20070281936/PN


L7 SCR 2043

L8 STR



Structure attributes must be viewed using STN Express query preparation:

Uploading L3.str



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-7 5-11 7-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-11 7-8 7-9

exact bonds :

3-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:Atom

Generic attributes :

11:

Saturation : Unsaturated

```

L14      768 SEA FILE=REGISTRY SSS FUL L8 NOT L7
L17      38 SEA FILE=HCAPLUS ABB=ON PLU=ON L14
L18      1 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND L1
L20      28 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND 1/SC,SX
L21      28 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND PHARMAC?/SC,SX
L22      28 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 OR L20 OR L21
L24      2102 SEA FILE=HCAPLUS ABB=ON PLU=ON "ADENOSINE RECEPTORS (L)
          A2A"+OLD,UF/CT
L25      1260 SEA FILE=HCAPLUS ABB=ON PLU=ON "PURINOCEPTOR ANTAGONISTS"+OLD
          ,UF/CT
L26      9443 SEA FILE=HCAPLUS ABB=ON PLU=ON PAIN (2A) (NEUROPATH? OR
          INFLAM?)
L27      2 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L24 OR L25)
L28      7 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND L26
L29      28 SEA FILE=HCAPLUS ABB=ON PLU=ON L22 OR L27 OR L28

```

=> d his 139


(FILE 'REGISTRY' ENTERED AT 12:35:06 ON 06 JUN 2008)

L39 0 S L14 AND (MEDLINE/LC OR BIOSIS/LC OR DRUGU/LC OR EMBASE/LC)

=> d que 139


L7 SCR 2043

L8 STR



Structure attributes must be viewed using STN Express query preparation:

Uploading L3.str



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-7 5-11 7-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-11 7-8 7-9

exact bonds :

3-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:Atom

Generic attributes :

11:

Saturation : Unsaturated

L14 768 SEA FILE=REGISTRY SSS FUL L8 NOT L7

L39 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND (MEDLINE/LC OR
BIOSIS/LC OR DRUGU/LC OR EMBASE/LC)

=> d l29 1-28 ibib ed abs hitstr hitind

L29 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:94438 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:191952

TITLE: Pyrimidine derivatives as therapeutic and prophylactic
agents and their preparation and pharmaceutical
compositions

INVENTOR(S): Low, Caroline Minli Rachel; McDonald, Lain Mair;
Pether, Michael John; Spencer, John; Tisselli,

PATENT ASSIGNEE(S): Patrizia; Wright, Paul Trevor
 SOURCE: James Black Foundation Limited, UK
 PCT Int. Appl., 116pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008009963	A2	20080124	WO 2007-GB2767	20070720
WO 2008009963	A3	20080508		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW


RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: GB 2006-14579 A 20060721

OTHER SOURCE(S): MARPAT 148:191952

ED Entered STN: 24 Jan 2008

GI



AB The invention is concerned with pyrimidine derivs. of formula I, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-I or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compds. which are useful as intermediates in such methods. Compds. of formula I wherein R³ and R⁴ are independently H, CO₂H and derivs., SH and derivs., SO₂H and derivs., SO₃H, OH an derivs., halo, etc.; at least one of R¹ and R² are independently substituted (hetero)aryl and substituted (hetero)aryloxy; where one of R¹ and R² is not selected from the above definition, it is H, CO₂H and derivs., SH and derivs., SO₂H and derivs., SO₃H, OH an derivs., halo, etc.; and their salts, solvated and prodrugs thereof, are

claimed. Example compound II•3HCl was prepared by cyclization of 3-oxo-6-phenylhexanoic acid Et ester with cyclohexylamine hydrochloride; the resulting 2-cyclohexyl-6-(3-phenylpropyl)pyrimidin-4-ol underwent chlorination to give 4-chloro-2-cyclohexyl-6-(3-phenylpropyl)pyrimidine, which underwent cross-coupling reaction with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline to give 4-[2-cyclohexyl-6-(3-phenylpropyl)pyrimidin-4-yl]aniline, which underwent condensation with N,N'-bis(tert-butoxycarbonyl)imidazolidine-2-thione to give the corresponding imine, which underwent hydrolysis to give II•3HCl. All the invention compds. were evaluated for their PTH1 binding inhibitory activity. From the assay, it was determined that compound II exhibited pKi_{sem} value of 6.24(2).

IT 1003587-03-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. useful as therapeutic

and

prophylactic agents)


RN 1003587-03-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[4-[(aminoiminomethyl)aminophenyl]-2-cyclohexyl-5-methyl-N-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1003587-02-7

CMF C26 H30 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 1003587-76-5P 1003587-78-7P 1003587-80-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine derivs. useful as therapeutic and

prophylactic agents)


RN 1003587-76-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-cyclohexyl-5-methyl-6-(4-nitrophenyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 1003587-78-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-aminophenyl)-2-cyclohexyl-5-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 1003587-80-1 HCAPLUS

CN Carbamic acid, N,N'-[[4-[2-cyclohexyl-5-methyl-6-[[(phenylmethyl)amino]carbonyl]-4-pyrimidinyl]phenyl]carbonimidoyl]bis-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT	1003585-98-5P	1003585-99-6P	1003586-00-2P	1003586-01-3P
	1003586-02-4P	1003586-03-5P	1003586-04-6P	1003586-05-7P
	1003586-07-9P	1003586-09-1P	1003586-10-4P	1003586-11-5P
	1003586-12-6P	1003586-13-7P	1003586-15-9P	1003586-17-1P
	1003586-18-2P	1003586-20-6P	1003586-22-8P	1003586-23-9P
	1003586-24-0P	1003586-25-1P	1003586-26-2P	1003586-27-3P

1003586-29-5P	1003586-30-8P	1003586-31-9P	1003586-32-0P
1003586-33-1P	1003586-35-3P	1003586-37-5P	1003586-38-6P
1003586-39-7P	1003586-41-1P	1003586-42-2P	1003586-43-3P
1003586-44-4P	1003586-45-5P	1003586-46-6P	1003586-47-7P
1003586-48-8P	1003586-49-9P	1003586-50-2P	1003586-51-3P
1003586-52-4P	1003586-54-6P	1003586-55-7P	1003586-56-8P
1003586-57-9P	1003586-58-0P	1003586-59-1P	1003586-60-4P
1003586-61-5P	1003586-62-6P	1003586-63-7P	1003586-65-9P
1003586-67-1P	1003586-68-2P	1003586-70-6P	1003586-72-8P
1003586-73-9P	1003586-74-0P	1003586-76-2P	1003586-77-3P
1003586-78-4P	1003586-80-8P	1003586-83-1P	1003586-84-2P
1003586-85-3P	1003586-86-4P	1003586-87-5P	1003586-89-7P
1003586-90-0P	1003586-91-1P	1003586-92-2P	1003586-93-3P
1003586-94-4P	1003586-95-5P	1003586-96-6P	1003586-97-7P
1003586-98-8P	1003586-99-9P	1003587-00-5P	1003587-01-6P
1003587-03-8P	1003587-04-9P	1003587-05-0P	1003587-06-1P
1003587-07-2P	1003587-08-3P	1003587-09-4P	1003587-11-8P
1003587-12-9P	1003587-13-0P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. useful as therapeutic

and

prophylactic agents)

IT 26032-72-4P, 2,4-Dichloro-6-phenylpyrimidine 63673-75-6P,
 2-Chloro-4-(4-nitrophenyl)-6-phenylpyrimidine 1003587-19-6P
 1003587-20-9P 1003587-21-0P 1003587-22-1P 1003587-23-2P
 1003587-24-3P 1003587-25-4P 1003587-26-5P 1003587-27-6P
 1003587-28-7P 1003587-29-8P 1003587-30-1P 1003587-31-2P
 1003587-32-3P 1003587-33-4P 1003587-34-5P 1003587-35-6P
 1003587-36-7P 1003587-37-8P 1003587-38-9P 1003587-39-0P
 1003587-40-3P 1003587-41-4P 1003587-42-5P 1003587-43-6P
 1003587-44-7P 1003587-45-8P 1003587-46-9P 1003587-47-0P
 1003587-48-1P 1003587-49-2P 1003587-50-5P 1003587-51-6P
 1003587-52-7P 1003587-53-8P 1003587-54-9P 1003587-55-0P
 1003587-56-1P 1003587-57-2P 1003587-58-3P 1003587-59-4P
 1003587-60-7P 1003587-61-8P 1003587-62-9P 1003587-63-0P
 1003587-65-2P 1003587-67-4P 1003587-70-9P 1003587-72-1P
 1003587-74-3P 1003587-76-5P 1003587-78-7P
 1003587-80-1P 1003587-82-3P, 4,6-Dichloro-2-cyclohexyl-5-
 ethylpyrimidine 1003587-84-5P 1003587-86-7P 1003587-88-9P
 1003587-90-3P, 2-Methyl-6-(3-phenylpropyl)pyrimidin-4-ol 1003587-92-5P,
 2-(4-Bromostyryl)-6-(3-phenylpropyl)pyrimidin-4-ol 1003587-94-7P
 1003587-96-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine derivs. useful as therapeutic and prophylactic agents)

L29 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:12228 HCAPLUS Full-text

DOCUMENT NUMBER: 148:121725

TITLE: Preparation of pyrimidinecarboxamides and analogs thereof as metalloprotease inhibitors

INVENTOR(S): Sucholeiki, Irving; Gege, Christian; Gallagher, Brian M.; Powers, Timothy; Deng, Hongbo; Wu, Xinyuan; Steeneck, Christoph; Kiely, Andrew; Taveras, Arthur

PATENT ASSIGNEE(S): Alantos Pharmaceuticals Holding, Inc., USA

SOURCE: PCT Int. Appl., 219pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008002671	A2	20080103	WO 2007-US15255	20070629
WO 2008002671	A3	20080327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				


US 20080021024 A1 20080124 US 2007-824525 20070629

PRIORITY APPLN. INFO.: US 2006-817562P P 20060629

OTHER SOURCE(S): MARPAT 148:121725

ED Entered STN: 04 Jan 2008

GI



AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, aryl, etc.; R2 = H or (un)substituted alkyl; R3 = H, halo, (un)substituted heterocyclyl, etc.; D = N or (un)substituted C; L = bond, CH2, SO2, etc.; X, Y, and Z independently N or CR4 with provision that X, Y and Z cannot all simultaneously = N; R4 = H, alkyl, cycloalkyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as metalloprotease inhibitors. Thus, e.g., II was prepared by cyclization of corresponding benzonitrile derivative (preparation given) with trimethylsilylazide. In inhibition assays for MMP-13, select compds. of the invention presented IC50 values ranging from > 5 nM to < 1000 nM.

IT 1000804-00-1P 1000804-01-2P 1000804-02-3P
 1000804-03-4P 1000804-04-5P 1000804-05-6P
 1000804-06-7P 1000804-11-4P 1000804-28-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of pyrimidinecarboxamides and analogs thereof as metalloprotease inhibitors)


RN 1000804-00-1 HCAPLUS

CN Benzoic acid, 4-[[[5-[6-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-4-pyrimidinyl]-2H-tetrazol-2-yl]methyl]- (CA INDEX NAME)




RN 1000804-01-2 HCAPLUS

CN Benzoic acid, 4-[[[5-[6-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-4-pyrimidinyl]-2H-tetrazol-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1000804-02-3 HCAPLUS

CN Benzoic acid, 4-[[[5-[6-[[[4-[[[(1,1-dimethylethoxy)carbonyl]phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methyl]amino]carbonyl]-4-pyrimidinyl]-2H-tetrazol-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1000804-03-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[2-(cyclohexylmethyl)-2H-tetrazol-5-yl]-N-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]- (CA INDEX NAME)



RN 1000804-28-3 HCAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-6-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



IC ICM C12N
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT Pain
 (inflammatory pain; novel amide-containing aromatic
 comds. as metalloprotease inhibitors useful in treatment of
 metalloprotease - mediated diseases)
 IT 690998-34-6P 690998-35-7P 903558-42-9P 916213-48-4P 1000802-82-3P
 1000802-83-4P 1000802-84-5P 1000802-85-6P 1000802-86-7P
 1000802-95-8P 1000802-96-9P 1000802-97-0P 1000802-98-1P
 1000802-99-2P 1000803-00-8P 1000803-01-9P 1000803-02-0P
 1000803-03-1P 1000803-04-2P 1000803-05-3P 1000803-08-6P
 1000803-23-5P 1000803-24-6P 1000803-25-7P 1000803-26-8P
 1000803-27-9P 1000803-28-0P 1000803-29-1P 1000803-30-4P
 1000803-31-5P 1000803-32-6P 1000803-33-7P 1000803-34-8P
 1000803-35-9P 1000803-36-0P 1000803-37-1P 1000803-38-2P
 1000803-39-3P 1000803-40-6P 1000803-41-7P 1000803-42-8P
 1000803-43-9P 1000803-44-0P 1000803-45-1P 1000803-46-2P
 1000803-47-3P 1000803-48-4P 1000803-49-5P 1000803-50-8P
 1000803-51-9P 1000803-52-0P 1000803-53-1P 1000803-54-2P
 1000803-55-3P 1000803-56-4P 1000803-57-5P 1000803-58-6P
 1000803-59-7P 1000803-60-0P 1000803-61-1P 1000803-62-2P
 1000803-63-3P 1000803-65-5P 1000803-67-7P 1000803-68-8P
 1000803-69-9P 1000803-70-2P 1000803-71-3P 1000803-72-4P
 1000803-73-5P 1000803-74-6P 1000803-75-7P 1000803-76-8P
 1000803-77-9P 1000803-78-0P 1000803-79-1P 1000803-80-4P
 1000803-81-5P 1000803-82-6P 1000803-83-7P 1000803-84-8P
 1000803-85-9P 1000803-86-0P 1000803-87-1P 1000803-88-2P
 1000803-89-3P 1000803-90-6P 1000803-91-7P 1000803-92-8P
 1000803-93-9P 1000803-94-0P 1000803-95-1P 1000803-96-2P
 1000803-97-3P 1000803-98-4P 1000803-99-5P 1000804-00-1P
 1000804-01-2P 1000804-02-3P 1000804-03-4P
 1000804-04-5P 1000804-05-6P 1000804-06-7P

1000804-09-0P 1000804-10-3P 1000804-11-4P 1000804-12-5P
 1000804-13-6P 1000804-14-7P 1000804-15-8P 1000804-16-9P
 1000804-17-0P 1000804-18-1P 1000804-19-2P 1000804-20-5P
 1000804-21-6P 1000804-22-7P 1000804-23-8P 1000804-24-9P
 1000804-25-0P 1000804-26-1P 1000804-27-2P 1000804-28-3P
 1000804-29-4P 1000804-30-7P 1000804-32-9P 1000804-33-0P
 1000804-34-1P 1000804-35-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrimidinecarboxamides and analogs thereof as
 metalloprotease inhibitors)

L29 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:944190 HCAPLUS Full-text

DOCUMENT NUMBER: 147:300998

TITLE: Pyridine-2-carboxamide derivatives as metabotropic
 glutamate receptor antagonists and their preparation,
 pharmaceutical compositions and use in the treatment
 of diseases

INVENTOR(S): Jaeschke, Georg; Spooren, Will; Vieira, Eric

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.

SOURCE: PCT Int. Appl., 12/pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093542	A1	20070823	WO 2007-EP51165	20070207
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p>				
<p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
US 20070197553	A1	20070823	US 2007-699786	20070130
PRIORITY APPLN. INFO.:			EP 2006-110086	A 20060217
OTHER SOURCE(S): MARPAT 147:300998				
ED Entered STN: 24 Aug 2007				
GI				



AB The invention relates to pyridine-2-carboxamide derivs. of the general formula I useful as metabotropic glutamate receptor antagonists. Compds. of formula I wherein Y is CR4 and Z is CH or N; Y is N and Z is CH; R1 is (un)substituted 5- to 6-membered heterocyclic ring; R2 is H, C1-7 alkyl, C3-6 cycloalkyl and (CH2)1-4-OH and derivs.; R3 is (un)substituted (hetero)aryl; R4 is H, OH, NH2, NH-C1-7 alkyl, CL, F, Br, CF2, CHF2, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their metabotropic glutamate receptor antagonistic activity. From the assay, it was determined that compound II exhibited a Ki value of 3 nM.

IT 947176-97-8P 947176-98-9P 947176-99-0P


947177-00-6P 947177-01-7P 947177-02-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridinecarboxamide derivs. as metabotropic glutamate receptor antagonists useful in treatment and prevention of metabotropic glutamate receptor - mediated diseases)


RN 947176-97-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-difluorophenyl)-2-methyl-N-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 947176-98-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-difluorophenyl)-2-methyl-N-(2-methyl-4-thiazolyl)- (CA INDEX NAME)




RN 947176-99-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-difluorophenyl)-2-methyl-N-(1-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 947177-00-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-(2-chloro-4-pyridinyl)-6-(3,5-difluorophenyl)-2-methyl- (CA INDEX NAME)




RN 947177-01-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-difluorophenyl)-2-methyl-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 947177-02-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-methyl-N-(4-methyl-2-thiazolyl)-6-(3-pyridinyl)- (CA INDEX NAME)

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): i, 63

IT	947176-64-9P	947176-65-0P	947176-66-1P	947176-67-2P	947176-68-3P
	947176-69-4P	947176-70-7P	947176-71-8P	947176-72-9P	947176-73-0P
	947176-74-1P	947176-75-2P	947176-76-3P	947176-77-4P	947176-78-5P
	947176-79-6P	947176-80-9P	947176-81-0P	947176-82-1P	947176-83-2P
	947176-84-3P	947176-85-4P	947176-86-5P	947176-87-6P	947176-88-7P
	947176-90-1P	947176-91-2P	947176-92-3P	947176-93-4P	947176-94-5P
	947176-95-6P	947176-96-7P	947176-97-8P	947176-98-9P	
	947176-99-0P	947177-00-6P	947177-01-7P		

947177-02-8P 947177-03-9P 947177-04-0P 947177-05-1P
 947177-06-2P 947177-07-3P 947177-08-4P 947177-09-5P 947177-10-8P
 947177-11-9P 947177-12-0P 947177-13-1P 947177-14-2P 947177-15-3P
 947177-16-4P 947177-17-5P 947177-18-6P 947177-19-7P 947177-20-0P
 947177-21-1P 947177-22-2P 947177-24-4P 947177-25-5P 947177-27-7P
 947177-28-8P 947177-29-9P 947177-30-2P 947177-31-3P 947177-32-4P
 947177-33-5P 947177-34-6P 947177-35-7P 947177-36-8P 947177-37-9P
 947177-38-0P 947177-39-1P 947177-40-4P 947177-41-5P 947177-42-6P
 947177-43-7P 947177-44-8P 947177-45-9P 947177-46-0P 947177-47-1P
 947177-48-2P 947177-49-3P 947177-50-6P 947177-51-7P 947177-52-8P
 947177-53-9P 947177-54-0P 947177-55-1P 947177-56-2P 947177-57-3P
 947177-58-4P 947177-59-5P 947177-60-8P 947177-61-9P 947177-62-0P
 947177-63-1P 947177-64-2P 947177-66-4P 947177-68-6P 947177-70-0P
 947177-72-2P 947177-74-4P 947177-76-6P 947177-78-8P 947177-80-2P
 947177-81-3P 947177-83-5P 947177-84-6P 947177-85-7P 947177-87-9P
 947177-89-1P 947177-91-5P 947177-93-7P 947177-95-9P 947177-97-1P
 947177-98-2P 947177-99-3P 947178-00-9P 947178-01-0P 947178-02-1P
 947178-03-2P 947178-04-3P 947178-05-4P 947178-07-6P 947178-08-7P
 947178-09-8P 947178-11-2P 947178-12-3P 947178-13-4P 947178-15-6P
 947178-16-7P 947178-18-9P 947178-19-0P 947178-21-4P 947178-23-6P
 947178-25-8P 947178-27-0P 947178-29-2P 947178-30-5P 947178-32-7P
 947178-34-9P 947178-36-1P 947178-37-2P 947178-38-3P 947178-39-4P
 947178-40-7P 947178-41-8P 947178-42-9P 947178-43-0P 947178-44-1P
 947178-45-2P 947178-46-3P 947178-47-4P 947178-48-5P 947178-49-6P
 947178-50-9P 947178-51-0P 947178-52-1P 947178-53-2P 947178-54-3P
 947178-55-4P 947178-56-5P 947178-57-6P 947178-58-7P 947178-59-8P
 947178-60-1P 947178-62-3P 947178-63-4P 947178-64-5P 947178-65-6P
 947178-66-7P 947178-67-8P 947178-68-9P 947178-69-0P 947178-70-3P
 947178-71-4P 947178-72-5P 947178-73-6P 947178-74-7P 947178-75-8P
 947178-76-9P 947178-77-0P 947178-78-1P 947178-79-2P 947178-80-5P
 947178-81-6P 947178-82-7P 947178-83-8P 947178-84-9P 947178-85-0P
 947178-86-1P 947178-87-2P 947178-88-3P 947178-89-4P 947178-90-7P
 947178-91-8P 947178-92-9P 947178-93-0P 947178-94-1P 947178-95-2P
 947229-11-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyridinecarboxamide derivs. as metabotropic
 glutamate receptor antagonists useful in treatment and prevention of
 metabotropic glutamate receptor - mediated diseases)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:816899 HCAPLUS Full-text

DOCUMENT NUMBER: 147:189196

TITLE: Pyrimidine derivatives used as PI-3 kinase inhibitors
 and their preparation, pharmaceutical compositions and
 use in the treatment of cancer

INVENTOR(S): Pick, Teresa; Barsanti, Paul; Iwanowicz, Edwin; Fantl,
 Wendy; Hendryckson, Tom; Knapp, Mark; Meritt, Hanne;
 Voliva, Charles; Wiesmann, Marion; Xin, Xiahua;
 Burger, Matthew; Ni, Zhi-Jie; Pecchi, Sabina; Atallah,
 Gordana; Bartullis, Sarah; Frazier, Kelly; Smith,
 Aaron; Verhagen, Joelle; Zhang, Yanchen; Wagman,
 Allan; Ng, Simon; Pfister, Keith; Poon, Daniel; Louie,
 Alicia

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 258pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007084786	A1	20070726	WO 2007-US1708	20070122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-760789P P 20060120

OTHER SOURCE(S): MARPAT 147:189196

ED Entered SIN: 27 Jul 2007

GI



AB Phosphatidylinositol (PI) 3-kinase inhibitor compds. I, their pharmaceutically acceptable salts, and prodrugs thereof; compns. of the compds., either alone or in combination with at least one addnl. therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compds., either alone or in combination with at least one addnl. therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. Compds. of formula I wherein is CRa and N; Ra is H, CN, halo, Me, CF3, and sulfonamido; R1 and R3 are independently H, CN, NO2, halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc.; R2 is H, CN, NO2, halo, OH, amino, (un)substituted alkyl, etc.; R4 is H, halo; and their stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their PI-3 kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 and EC50 values of > 1 µM.

IT 944398-25-3P 944393-26-9P 944398-27-0P
 944398-28-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/588757

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrimidine derivs. used as PI3 kinase
inhibitors for treating cancer)


RN 944398-25-8 HCAPLUS

CN [4,5'-Bipyrimidine]-6-carboxamide, 2'-amino-2-(4-morpholinyl)- (CA INDEX
NAME)




RN 944398-26-9 HCAPLUS

CN [4,5'-Bipyrimidine]-6-carboxamide, 2'-amino-2-(4-morpholinyl)-N-4-
pyridinyl- (CA INDEX NAME)




RN 944398-27-0 HCAPLUS

CN [4,5'-Bipyrimidine]-6-carboxamide, 2'-amino-2-(4-morpholinyl)-N-3-
pyridinyl- (CA INDEX NAME)



RN 944398-28-1 HCAPLUS

CN [4,5'-Bipyrimidine]-6-carboxamide, 2'-amino-N-methyl-2-(4-morpholinyl)-
(CA INDEX NAME)



CC	28-16 (Heterocyclic Compounds (More Than One Hetero Atom))									
IT	Section cross-reference(s): 1, 63									
	944395-98-6P	944395-99-7P	944396-00-3P	944396-01-4P	944396-02-5P					
	944396-03-6P	944396-04-7P	944396-05-8P	944396-06-9P	944396-07-0P					
	944396-08-1P	944396-09-2P	944396-10-5P	944396-11-6P	944396-12-7P					
	944396-13-8P	944396-14-9P	944396-15-0P	944396-16-1P	944396-19-4P					
	944396-20-7P	944396-21-8P	944396-22-9P	944396-23-0P	944396-26-3P					
	944396-27-4P	944396-28-5P	944396-29-6P	944396-30-9P	944396-31-0P					
	944396-32-1P	944396-33-2P	944396-34-3P	944396-35-4P	944396-36-5P					
	944396-37-6P	944396-38-7P	944396-39-8P	944396-40-1P	944396-41-2P					
	944396-42-3P	944396-43-4P	944396-44-5P	944396-45-6P	944396-46-7P					
	944396-47-8P	944396-48-9P	944396-49-0P	944396-50-3P	944396-51-4P					
	944396-52-5P	944396-53-6P	944396-54-7P	944396-55-8P	944396-56-9P					
	944396-57-0P	944396-58-1P	944396-59-2P	944396-60-5P	944396-61-6P					
	944396-62-7P	944396-63-8P	944396-64-9P	944396-65-0P	944396-66-1P					
	944396-67-2P	944396-68-3P	944396-69-4P	944396-70-7P	944396-71-8P					
	944396-72-9P	944396-73-0P	944396-74-1P	944396-75-2P	944396-76-3P					
	944396-77-4P	944396-78-5P	944396-79-6P	944396-80-9P	944396-81-0P					
	944396-82-1P	944396-83-2P	944396-84-3P	944396-85-4P	944396-86-5P					
	944396-87-6P	944396-88-7P	944396-89-8P	944396-90-1P	944396-91-2P					
	944396-92-3P	944396-93-4P	944396-94-5P	944396-95-6P	944396-96-7P					
	944396-97-8P	944396-98-9P	944396-99-0P	944397-00-6P	944397-01-7P					
	944397-02-8P	944397-03-9P	944397-04-0P	944397-05-1P	944397-06-2P					
	944397-07-3P	944397-08-4P	944397-09-5P	944397-10-8P	944397-11-9P					
	944397-12-0P	944397-13-1P	944397-14-2P	944397-15-3P	944397-16-4P					
	944397-17-5P	944397-18-6P	944397-19-7P	944397-20-0P	944397-21-1P					
	944397-22-2P	944397-23-3P	944397-24-4P	944397-25-5P	944397-26-6P					
	944397-27-7P	944397-28-8P	944397-29-9P	944397-30-2P	944397-31-3P					
	944397-32-4P	944397-33-5P	944397-34-6P	944397-35-7P	944397-36-8P					
	944397-37-9P	944397-38-0P	944397-39-1P	944397-40-4P	944397-41-5P					
	944397-42-6P	944397-43-7P	944397-44-8P	944397-45-9P	944397-46-0P					
	944397-47-1P	944397-48-2P	944397-49-3P	944397-50-6P	944397-51-7P					
	944397-52-8P	944397-53-9P	944397-54-0P	944397-55-1P	944397-56-2P					
	944397-57-3P	944397-58-4P	944397-59-5P	944397-60-8P	944397-61-9P					
	944397-62-0P	944397-63-1P	944397-64-2P	944397-65-3P	944397-66-4P					
	944397-67-5P	944397-68-6P	944397-69-7P	944397-70-0P	944397-71-1P					
	944397-72-2P	944397-73-3P	944397-74-4P	944397-75-5P	944397-76-6P					
	944397-77-7P	944397-78-8P	944397-79-9P	944397-80-2P	944397-81-3P					
	944397-82-4P	944397-83-5P	944397-84-6P	944397-85-7P	944397-86-8P					
	944397-87-9P	944397-88-0P	944397-89-1P	944397-90-4P	944397-91-5P					
	944397-92-6P	944397-93-7P	944397-94-8P	944397-95-9P	944397-96-0P					
	944397-97-1P	944397-98-2P	944397-99-3P	944398-00-9P	944398-01-0P					
	944398-02-1P	944398-03-2P	944398-04-3P	944398-05-4P	944398-06-5P					
	944398-07-6P	944398-08-7P	944398-09-8P	944398-10-1P	944398-11-2P					
	944398-12-3P	944398-13-4P	944398-14-5P	944398-15-6P	944398-16-7P					
	944398-17-8P	944398-18-9P	944398-19-0P	944398-20-3P	944398-21-4P					
	944398-22-5P	944398-23-6P	944398-24-7P	944398-25-8P						
	944398-26-9P	944398-27-0P	944398-28-1P							
	944398-29-2P	944398-30-5P	944398-31-6P	944398-32-7P	944398-33-8P					

944398-34-9P 944398-35-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrimidine derivs. used as PI3 kinase
inhibitors for treating cancer)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:175569 HCAPLUS Full-text

DOCUMENT NUMBER: 146:251733

TITLE: Preparation of acyltryptophanols as FSH antagonists

INVENTOR(S): Wortmann, Lars; Cleve, Arwed; Muhn, Hans-Peter;
Langer, Gernot; Schrey, Anna; Kuehne, Ronald;
Menzenbach, Bernd; Koppitz, Marcus; Kosemund, Dirk

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 404pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017289	A2	20070215	WO 2006-EP7949	20060808
WO 2007017289	A3	20070531		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
DE 102005038632	A1	20070215	DE 2005-102005038632	20050810
DE 102005038632	B4	20080327		
CA 2618888	A1	20070215	CA 2006-2618888	20060808
EP 1912970	A2	20080423	EP 2006-776768	20060808
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20070060573	A1	20070315	US 2006-501228	20060809
PRIORITY APPLN. INFO.:			DE 2005-102005038632A	20050810
			US 2005-706743P	P 20050810
			WO 2006-EP7949	W 20060808

OTHER SOURCE(S): MARPAT 146:251733


ED Entered SIN: 16 Feb 2007

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; R3 = H, OH, halo, etc.; R4-R6 = H, OH, halo, etc.; or R5 and R6 may together form heterocycloalkyl, cycloalkyl; R7, R8 = H, Me, Et (Me and Et may be fluorinated); Q, W = (hetero)aryl; X = a bond, alkylene, alkenylene, etc.; Y = a bond, alkylene] which are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis, were prepared E.g., a multi-step synthesis of II, starting from 5-bromo-DL-tryptophan, was given. II showed IC50 of 7 μ M when tested for FSH antagonistic effect in the HTRF assay. Pharmaceutical composition comprising the compound I is disclosed.
- IT 925938-60-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of acyltryptophanols as FSH antagonists)
- RN 925938-60-9 HCAPLUS
- CN 4-Pyrimidinecarboxamide, N-[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-6-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



- CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 63
- IT 925937-29-7P 925937-30-0P 925937-31-1P 925937-32-2P 925937-33-3P
 925937-34-4P 925937-35-5P 925937-36-6P 925937-37-7P 925937-38-8P
 925937-39-9P 925937-40-2P 925937-41-3P 925937-42-4P 925937-43-5P
 925937-44-6P 925937-45-7P 925937-46-8P 925937-47-9P 925937-48-0P
 925937-49-1P 925937-50-4P 925937-51-5P 925937-52-6P 925937-53-7P
 925937-54-8P 925937-55-9P 925937-56-0P 925937-57-1P 925937-58-2P
 925937-59-3P 925937-60-6P 925937-61-7P 925937-62-8P 925937-63-9P
 925937-64-0P 925937-65-1P 925937-66-2P 925937-67-3P 925937-68-4P
 925937-69-5P 925937-70-8P 925937-71-9P 925937-72-0P 925937-73-1P
 925937-74-2P 925937-76-4P 925937-78-6P 925937-79-7P 925937-80-0P
 925937-81-1P 925937-82-2P 925937-83-3P 925937-84-4P 925937-85-5P
 925937-86-6P 925937-87-7P 925937-88-8P 925937-89-9P 925937-90-2P
 925937-91-3P 925937-92-4P 925937-93-5P 925937-94-6P 925937-95-7P
 925937-96-8P 925937-97-9P 925937-98-0P 925937-99-1P 925938-00-7P
 925938-01-8P 925938-02-9P 925938-03-0P 925938-04-1P 925938-05-2P
 925938-06-3P 925938-07-4P 925938-08-5P 925938-09-6P 925938-10-9P
 925938-11-0P 925938-12-1P 925938-13-2P 925938-14-3P 925938-15-4P
 925938-16-5P 925938-17-6P 925938-18-7P 925938-19-8P 925938-20-1P
 925938-21-2P 925938-22-3P 925938-23-4P 925938-24-5P 925938-25-6P
 925938-26-7P 925938-27-8P 925938-28-9P 925938-29-0P 925938-30-3P
 925938-31-4P 925938-32-5P 925938-33-6P 925938-34-7P 925938-35-8P
 925938-36-9P 925938-37-0P 925938-38-1P 925938-39-2P 925938-40-5P
 925938-41-6P 925938-42-7P 925938-43-8P 925938-44-9P 925938-45-0P
 925938-46-1P 925938-47-2P 925938-48-3P 925938-49-4P 925938-50-7P
 925938-51-8P 925938-52-9P 925938-53-0P 925938-54-1P 925938-55-2P
 925938-56-3P 925938-57-4P 925938-58-5P 925938-59-6P

925938-60-9P 925938-61-0P 925938-62-1P 925938-63-2P
 925938-64-3P 925938-65-4P 925938-66-5P 925938-67-6P 925938-68-7P
 925938-69-8P 925938-76-7P 925938-78-9P 925938-79-0P 925938-80-3P
 925938-81-4P 925938-82-5P 925938-83-6P 925938-84-7P 925938-85-8P
 925938-86-9P 925938-87-0P 925938-88-1P 925938-89-2P 925938-90-5P
 925938-91-6P 925938-92-7P 925938-93-8P 925938-94-9P 925938-95-0P
 925938-96-1P 925938-97-2P 925938-98-3P 925938-99-4P 925939-00-0P
 925939-01-1P 925939-02-2P 925939-03-3P 925939-04-4P 925939-05-5P
 925939-06-6P 925939-07-7P 925939-08-8P 925939-09-9P 925939-11-3P
 925939-12-4P 925939-13-5P 925939-14-6P 925939-15-7P 925939-16-8P
 925939-17-9P 925939-18-0P 925939-19-1P 925939-21-5P 925939-22-6P
 925939-23-7P 925939-24-8P 925939-25-9P 925939-26-0P 925939-27-1P
 925939-28-2P 925939-29-3P 925939-30-6P 925939-31-7P 925939-32-8P
 925939-33-9P 925939-34-0P 925939-35-1P 925939-36-2P 925939-37-3P
 925939-38-4P 925939-39-5P 925939-40-8P 925939-41-9P 925939-42-0P
 925939-43-1P 925939-44-2P 925939-45-3P 925939-46-4P 925939-47-5P
 925939-48-6P 925939-49-7P 925939-50-0P 925939-51-1P 925939-52-2P
 925939-53-3P 925939-54-4P 925939-55-5P 925939-56-6P 925939-57-7P
 925939-58-8P 925939-59-9P 925939-60-2P 925939-61-3P 925939-62-4P
 925939-63-5P 925939-64-6P 925939-65-7P 925939-66-8P 925939-67-9P
 925939-68-0P 925939-69-1P 925939-70-4P 925939-71-5P 925939-72-6P
 925939-73-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of acyltryptophanols as FSH antagonists)

L29 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:171909 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:251843

TITLE: Preparation of benzimidazole derivatives as sirtuin
 modulators

INVENTOR(S): Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie,
 Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.

PATENT ASSIGNEE(S): Sirtis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 593pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019416	A1	20070215	WO 2006-US30660	20060804
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006278396	A1	20070215	AU 2006-278396	20060804
CA 2617557	A1	20070215	CA 2006-2617557	20060804
US 20070037827	A1	20070215	US 2006-499239	20060804

US 20070037809	A1	20070215	US 2006-499876	20060804
US 20070037810	A1	20070215	US 2006-499901	20060804
US 20070037865	A1	20070215	US 2006-499920	20060804
US 20070043050	A1	20070222	US 2006-499919	20060804
US 7345178	B2	20080318		
EP 1909910	A1	20080416	EP 2006-789500	20060804

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR



PRIORITY APPLN. INFO.:

US 2005-705612P	P	20050804
US 2005-741783P	P	20051202
US 2006-779370P	P	20060303
US 2006-792276P	P	20060414
WO 2006-US30660	W	20060804

OTHER SOURCE(S): MARPAT 146:251843

ED Entered STN: 15 Feb 2007

GI



AB The title compds. I [R1, R4, R6 = H or (un)substituted alkyl; R2 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R3 = (un)substituted monocyclic or bicyclic (hetero)aryl; R5, R7 = H or solubilizing group; with provisos] and their analogs which are novel sirtuin-modulating compds. useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 2-step synthesis of II, starting from 1,2-diaminobenzene and 6-aminopyridine-2- carboxylic acid, was given. Exemplified compds. I were tested for sirtuin modulating activity (data given). Also provided are compns. comprising a sirtuin-modulating compound in combination with another therapeutic agent.

IT 925436-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted benzimidazoles and analogs as sirtuin

modulators

useful in treatment and prevention of diseases)

RN 925436-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)



CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Pain

(neuropathic pain; preparation of substituted benzimidazoles and analogs as sirtuin modulators useful in treatment and prevention of diseases)

IT	925435-34-3P	925435-35-4P	925435-36-5P	925435-37-6P	925435-38-7P
	925435-39-8P	925435-40-1P	925435-41-2P	925435-42-3P	925435-43-4P
	925435-44-5P	925435-45-6P	925435-46-7P	925435-47-8P	925435-48-9P
	925435-49-0P	925435-50-3P	925435-51-4P	925435-52-5P	925435-53-6P
	925435-54-7P	925435-55-8P	925435-56-9P	925435-57-0P	925435-58-1P
	925435-59-2P	925435-60-5P	925435-61-6P	925435-62-7P	925435-63-8P
	925435-64-9P	925435-65-0P	925435-66-1P	925435-67-2P	925435-68-3P
	925435-69-4P	925435-70-7P	925435-71-8P	925435-72-9P	925435-73-0P
	925435-74-1P	925435-75-2P	925435-76-3P	925435-77-4P	925435-78-5P
	925435-79-6P	925435-80-9P	925435-81-0P	925435-82-1P	925435-83-2P
	925435-84-3P	925435-85-4P	925435-86-5P	925435-87-6P	925435-88-7P
	925435-89-8P	925435-90-1P	925435-91-2P	925435-92-3P	925435-93-4P
	925435-94-5P	925435-95-6P	925435-96-7P	925435-97-8P	925435-98-9P
	925435-99-0P	925436-00-6P	925436-01-7P	925436-02-8P	925436-03-9P
	925436-04-0P	925436-05-1P	925436-06-2P	925436-07-3P	925436-08-4P
	925436-09-5P	925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P
	925436-14-2P	925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P
	925436-19-7P	925436-20-0P	925436-21-1P	925436-24-4P	
	925436-25-5P	925436-26-6P	925436-27-7P	925436-28-8P	925436-29-9P
	925436-30-2P	925436-31-3P	925436-32-4P	925436-33-5P	925436-34-6P
	925436-35-7P	925436-36-8P	925436-37-9P	925436-38-0P	925436-39-1P
	925436-40-4P	925436-41-5P	925436-42-6P	925436-43-7P	925436-44-8P
	925436-45-9P	925436-47-1P	925436-48-2P	925436-49-3P	925436-50-6P
	925436-51-7P	925436-52-8P	925436-53-9P	925436-55-1P	925436-56-2P
	925436-57-3P	925436-58-4P	925436-59-5P	925436-60-8P	925436-61-9P
	925436-62-0P	925436-63-1P	925436-65-3P	925436-66-4P	925436-69-7P
	925436-71-1P	925436-73-3P	925436-76-6P	925436-78-8P	925436-80-2P
	925436-83-5P	925436-86-8P	925436-89-1P	925436-91-5P	925436-93-7P
	925436-95-9P	925436-97-1P	925436-99-3P	925437-01-0P	925437-03-2P
	925437-05-4P	925437-07-6P	925437-09-8P	925437-10-1P	925437-12-3P
	925437-14-5P	925437-16-7P	925437-18-9P	925437-20-3P	925437-22-5P
	925437-26-9P	925437-28-1P	925437-30-5P	925437-32-7P	925437-33-8P
	925437-34-9P	925437-35-0P	925437-36-1P	925437-37-2P	925437-38-3P
	925437-39-4P	925437-41-8P	925437-42-9P	925437-43-0P	925437-44-1P
	925437-45-2P	925437-46-3P	925437-47-4P	925437-48-5P	925437-49-6P
	925437-50-9P	925437-51-0P	925437-52-1P	925437-53-2P	925437-54-3P

925437-55-4P 925437-56-5P 925437-57-6P 925437-58-7P 925437-59-8P
 925437-60-1P 925437-61-2P 925437-62-3P 925437-63-4P 925437-64-5P
 925437-65-6P 925437-66-7P 925437-68-9P 925437-75-8P 925437-79-2P
 925437-88-3P 925437-94-1P 925438-01-3P 925438-13-7P 925438-46-6P
 925438-69-3P 925438-74-0P 925438-79-5P 925438-81-9P 925443-98-7P
 925443-99-8P 925444-00-4P 925444-01-5P 925444-02-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted benzimidazoles and analogs as sirtuin
 modulators)

useful in treatment and prevention of diseases)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:171908 HCAPLUS Full-text

DOCUMENT NUMBER: 146:274369

TITLE: Preparation of oxazolopyridine derivatives as sirtuin
 modulators

INVENTOR(S): Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie,
 Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.;
 Salzmann, Thomas; Armistead, David

PATENT ASSIGNEE(S): Sirtris Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 579pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019417	A1	20070215	WO 2006-US30661	20060804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006278397	A1	20070215	AU 2006-278397	20060804
CA 2618370	A1	20070215	CA 2006-2618370	20060804
US 20070037827	A1	20070215	US 2006-499239	20060804
US 20070037809	A1	20070215	US 2006-499876	20060804
US 20070037810	A1	20070215	US 2006-499901	20060804
US 20070037865	A1	20070215	US 2006-499920	20060804
US 20070043050	A1	20070222	US 2006-499919	20060804
US 7345178	B2	20080318		
EP 1910380	A1	20080416	EP 2006-800850	20060804
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-705612P	P 20050804
			US 2005-741783P	P 20051202
			US 2006-779370P	P 20060303

10/588757

US 2006-792276P
WO 2006-US30661P 20060414
W 20060804OTHER SOURCE(S): MARPAT 146:274369
ED Entered STN: 15 Feb 2007
GI

AB The title compds. I [X7-X10 = N, CR20, CR22 (wherein R20 = H or solubilizing group; R22 = H, (un)substituted alkyl; one of X7-X10 = N and the others = CR20 or CR22; zero to one R20 is solubilizing group); R19 = 1,2-phenylene, pyridylene, 5-6 membered (hetero)arylene; R21 = (un)substituted NHCO, NHSO₂, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compds. useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-chloropyridin-3-amine and 3-nitrobenzoyl chloride, was given. Exemplified compds. I were tested for sirtuin modulating activity (data given). Also provided are compns. comprising a sirtuin-modulating compound in combination with another therapeutic agent.


IT 925436-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxazolopyridines and analogs as sirtuin modulators useful in treatment and prevention of diseases)

RN 925436-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)



CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Pain

(neuropathic pain; preparation of substituted
oxazolopyridines and analogs as sirtuin modulators useful in treatment
and prevention of diseases)

IT	925435-34-3P	925435-35-4P	925435-36-5P	925435-37-6P	925435-38-7P
	925435-39-8P	925435-40-1P	925435-41-2P	925435-42-3P	925435-43-4P
	925435-44-5P	925435-45-6P	925435-46-7P	925435-47-8P	925435-48-9P
	925435-49-0P	925435-50-3P	925435-51-4P	925435-52-5P	925435-53-6P
	925435-54-7P	925435-55-8P	925435-56-9P	925435-57-0P	925435-58-1P
	925435-59-2P	925435-60-5P	925435-61-6P	925435-62-7P	925435-63-8P
	925435-64-9P	925435-65-0P	925435-66-1P	925435-67-2P	925435-68-3P
	925435-69-4P	925435-70-7P	925435-71-8P	925435-72-9P	925435-73-0P
	925435-74-1P	925435-75-2P	925435-76-3P	925435-77-4P	925435-78-5P
	925435-79-6P	925435-80-9P	925435-81-0P	925435-82-1P	925435-83-2P
	925435-84-3P	925435-85-4P	925435-86-5P	925435-87-6P	925435-88-7P
	925435-89-8P	925435-90-1P	925435-91-2P	925435-92-3P	925435-93-4P
	925435-94-5P	925435-95-6P	925435-96-7P	925435-97-8P	925435-98-9P
	925435-99-0P	925436-00-6P	925436-01-7P	925436-02-8P	925436-03-9P
	925436-04-0P	925436-05-1P	925436-06-2P	925436-07-3P	925436-08-4P
	925436-09-5P	925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P
	925436-14-2P	925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P
	925436-19-7P	925436-20-0P	925436-21-1P	925436-24-4P	
	925436-25-5P	925436-26-6P	925436-27-7P	925436-28-8P	925436-29-9P
	925436-30-2P	925436-31-3P	925436-32-4P	925436-33-5P	925436-34-6P
	925436-35-7P	925436-36-8P	925436-37-9P	925436-38-0P	925436-39-1P
	925436-40-4P	925436-41-5P	925436-42-6P	925436-43-7P	925436-44-8P
	925436-45-9P	925436-47-1P	925436-48-2P	925436-49-3P	925436-50-6P
	925436-51-7P	925436-52-8P	925436-53-9P	925436-55-1P	925436-56-2P
	925436-57-3P	925436-58-4P	925436-59-5P	925436-60-8P	925436-61-9P
	925436-62-0P	925436-63-1P	925436-65-3P	925436-66-4P	925436-69-7P
	925436-71-1P	925436-73-3P	925436-76-6P	925436-78-8P	925436-80-2P
	925436-83-5P	925436-86-8P	925436-89-1P	925436-91-5P	925436-93-7P
	925436-95-9P	925436-97-1P	925436-99-3P	925437-01-0P	925437-03-2P
	925437-05-4P	925437-07-6P	925437-09-8P	925437-10-1P	925437-12-3P
	925437-14-5P	925437-16-7P	925437-18-9P	925437-20-3P	925437-22-5P
	925437-26-9P	925437-28-1P	925437-30-5P	925437-32-7P	925437-33-8P
	925437-34-9P	925437-35-0P	925437-36-1P	925437-37-2P	925437-38-3P
	925437-39-4P	925437-41-8P	925437-42-9P	925437-43-0P	925437-44-1P
	925437-45-2P	925437-46-3P	925437-47-4P	925437-48-5P	925437-49-6P
	925437-50-9P	925437-51-0P	925437-52-1P	925437-53-2P	925437-54-3P
	925437-55-4P	925437-56-5P	925437-57-6P	925437-58-7P	925437-59-8P
	925437-60-1P	925437-61-2P	925437-62-3P	925437-63-4P	925437-64-5P
	925437-65-6P	925437-66-7P	925437-68-9P	925437-75-8P	925437-79-2P
	925437-88-3P	925437-94-1P	925438-01-3P	925438-13-7P	925438-46-6P
	925438-69-3P	925438-74-0P	925438-79-5P	925438-81-9P	925443-98-7P
	925443-99-8P	925444-00-4P	925444-01-5P	925444-02-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of substituted oxazolopyridines and analogs as sirtuin
modulators useful in treatment and prevention of diseases)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:171907 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:274368

TITLE: Preparation of imidazopyridine derivatives as sirtuin



modulators
 INVENTOR(S): Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie, Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.
 PATENT ASSIGNEE(S): Sirtris Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 576pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019345	A1	20070215	WO 2006-US30511	20060804
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006278504	A1	20070215	AU 2006-278504	20060804
CA 2618368	A1	20070215	CA 2006-2618368	20060804
US 20070037827	A1	20070215	US 2006-499239	20060804
US 20070037809	A1	20070215	US 2006-499876	20060804
US 20070037810	A1	20070215	US 2006-499901	20060804
US 20070037865	A1	20070215	US 2006-499920	20060804
US 20070043050	A1	20070222	US 2006-499919	20060804
US 7345178	B2	20080318		
EP 1910362	A1	20080416	EP 2006-789432	20060804
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2005-705612P	P 20050804
			US 2005-741783P	P 20051202
			US 2006-779370P	P 20060303
			US 2006-792276P	P 20060414
			WO 2006-US30511	W 20060804

OTHER SOURCE(S): MARPAT 146:274368

ED Entered STN: 15 Feb 2007

GI



AB The title compds. I [R23, R24 = H, Me or solubilizing agent; R25 = H or solubilizing agent; R19 = 1,2-phenylene, 5-membered heteroarylene; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compds. useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-bromo-2'-nitroacetophenone and 2-aminopyridine, was given. Exemplified compds. I were tested for sirtuin modulating activity (data given). Also provided are compns. comprising a sirtuin-modulating compound in combination with another therapeutic agent.


IT 925436-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted imidazopyridines and analogs as sirtuin modulators useful in treatment and prevention of diseases)

RN 925436-21-1 HCAPLUS

CN 4-Pyrimidinencarboxamide, 6-phenyl-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)



CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Pain

(neuropathic pain; preparation of substituted imidazopyridines and analogs as sirtuin modulators useful in treatment and prevention of diseases)

IT	925435-34-3P	925435-35-4P	925435-36-5P	925435-37-6P	925435-38-7P
	925435-39-8P	925435-40-1P	925435-41-2P	925435-42-3P	925435-43-4P
	925435-44-5P	925435-45-6P	925435-46-7P	925435-47-8P	925435-48-9P
	925435-49-0P	925435-50-3P	925435-51-4P	925435-52-5P	925435-53-6P
	925435-54-7P	925435-55-8P	925435-56-9P	925435-57-0P	925435-58-1P
	925435-59-2P	925435-60-5P	925435-61-6P	925435-62-7P	925435-63-8P
	925435-64-9P	925435-65-0P	925435-66-1P	925435-67-2P	925435-68-3P
	925435-69-4P	925435-70-7P	925435-71-8P	925435-72-9P	925435-73-0P
	925435-74-1P	925435-75-2P	925435-76-3P	925435-77-4P	925435-78-5P
	925435-79-6P	925435-80-9P	925435-81-0P	925435-82-1P	925435-83-2P
	925435-84-3P	925435-85-4P	925435-86-5P	925435-87-6P	925435-88-7P
	925435-89-8P	925435-90-1P	925435-91-2P	925435-92-3P	925435-93-4P
	925435-94-5P	925435-95-6P	925435-96-7P	925435-97-8P	925435-98-9P

925435-99-0P	925436-00-6P	925436-01-7P	925436-02-8P	925436-03-9P
925436-04-0P	925436-05-1P	925436-06-2P	925436-07-3P	925436-08-4P
925436-09-5P	925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P
925436-14-2P	925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P
925436-19-7P	925436-20-0P	925436-21-1P	925436-24-4P	
925436-25-5P	925436-26-6P	925436-27-7P	925436-28-8P	925436-29-9P
925436-30-2P	925436-31-3P	925436-32-4P	925436-33-5P	925436-34-6P
925436-35-7P	925436-36-8P	925436-37-9P	925436-38-0P	925436-39-1P
925436-40-4P	925436-41-5P	925436-42-6P	925436-43-7P	925436-44-8P
925436-45-9P	925436-47-1P	925436-48-2P	925436-49-3P	925436-50-6P
925436-51-7P	925436-52-8P	925436-53-9P	925436-55-1P	925436-56-2P
925436-57-3P	925436-58-4P	925436-59-5P	925436-60-8P	925436-61-9P
925436-62-0P	925436-63-1P	925436-65-3P	925436-66-4P	925436-69-7P
925436-71-1P	925436-73-3P	925436-76-6P	925436-78-8P	925436-80-2P
925436-83-5P	925436-86-8P	925436-89-1P	925436-91-5P	925436-93-7P
925436-95-9P	925436-97-1P	925436-99-3P	925437-01-0P	925437-03-2P
925437-05-4P	925437-07-6P	925437-09-8P	925437-10-1P	925437-12-3P
925437-14-5P	925437-16-7P	925437-18-9P	925437-20-3P	925437-22-5P
925437-26-9P	925437-28-1P	925437-30-5P	925437-32-7P	925437-33-8P
925437-34-9P	925437-35-0P	925437-36-1P	925437-37-2P	925437-38-3P
925437-39-4P	925437-41-8P	925437-42-9P	925437-43-0P	925437-44-1P
925437-45-2P	925437-46-3P	925437-47-4P	925437-48-5P	925437-49-6P
925437-50-9P	925437-51-0P	925437-52-1P	925437-53-2P	925437-54-3P
925437-55-4P	925437-56-5P	925437-57-6P	925437-58-7P	925437-59-8P
925437-60-1P	925437-61-2P	925437-62-3P	925437-63-4P	925437-64-5P
925437-65-6P	925437-66-7P	925437-68-9P	925437-75-8P	925437-79-2P
925437-88-3P	925437-94-1P	925438-01-3P	925438-13-7P	925438-46-6P
925438-69-3P	925438-74-0P	925438-79-5P	925438-81-9P	925443-98-7P
925443-99-8P	925444-00-4P	925444-01-5P	925444-02-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of substituted imidazopyridines and analogs as sirtuin
modulators useful in treatment and prevention of diseases)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:171906 HCAPLUS Full-text

DOCUMENT NUMBER: 146:274349

TITLE: Preparation of benzothiazoles and thiazolopyridines as
sirtuin modulators

INVENTOR(S): Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie,
Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.;
Salzmann, Thomas; Armistead, David

PATENT ASSIGNEE(S): Sirtis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 574pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019346	A1	20070215	WO 2006-US30512	20060804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,				
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,				

MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TI, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2006278505	A1	20070215	AU 2006-278505	20060804
CA 2618360	A1	20070215	CA 2006-2618360	20060804
US 20070037827	A1	20070215	US 2006-499239	20060804
US 20070037809	A1	20070215	US 2006-499876	20060804
US 20070037810	A1	20070215	US 2006-499901	20060804
US 20070037865	A1	20070215	US 2006-499920	20060804
US 20070043050	A1	20070222	US 2006-499919	20060804
US 7345178	B2	20080318		
EP 1910385	A1	20080416	EP 2006-789433	20060804

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR


PRIORITY APPLN. INFO.:

US 2005-705612P	P	20050804
US 2005-741783P	P	20051202
US 2006-779370P	P	20060303
US 2006-792276P	P	20060414
WO 2006-US30512	W	20060804


OTHER SOURCE(S): MARPAT 146:274349

ED Entered STN: 15 Feb 2007

GI



I



II

AB The title compds. I [X7-X10 = N, CR20 or CR11 (wherein R20 = H or solubilizing group; R11 = H, (un)substituted alkyl); R19 = phenylene, pyridylene, etc.; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with proviso] and their analogs which are novel sirtuin-modulating compds. useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were

prepared E.g., a multi-step synthesis of II, starting from 4-aminopyridin-3-yl diisopropylcarbamodithioate and 3-nitrobenzoyl chloride, was given. Exemplified compds. I were tested for sirtuin modulating activity (data given). Also provided are compns. comprising a sirtuin-modulating compound in combination with another therapeutic agent.


IT 925436-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzothiazoles and thiazolopyridines as sirtuin modulators useful in treatment and prevention of diseases)

RN 925436-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)



CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Pain

(neuropathic pain; preparation of benzothiazoles and thiazolopyridines as sirtuin modulators useful in treatment and prevention of diseases)

IT	925435-34-3P	925435-35-4P	925435-36-5P	925435-37-6P	925435-38-7P
	925435-39-8P	925435-40-1P	925435-41-2P	925435-42-3P	925435-43-4P
	925435-44-5P	925435-45-6P	925435-46-7P	925435-47-8P	925435-48-9P
	925435-49-0P	925435-50-3P	925435-51-4P	925435-52-5P	925435-53-6P
	925435-54-7P	925435-55-8P	925435-56-9P	925435-57-0P	925435-58-1P
	925435-59-2P	925435-60-5P	925435-61-6P	925435-62-7P	925435-63-8P
	925435-64-9P	925435-65-0P	925435-66-1P	925435-67-2P	925435-68-3P
	925435-69-4P	925435-70-7P	925435-71-8P	925435-72-9P	925435-73-0P
	925435-74-1P	925435-75-2P	925435-76-3P	925435-77-4P	925435-78-5P
	925435-79-6P	925435-80-9P	925435-81-0P	925435-82-1P	925435-83-2P
	925435-84-3P	925435-85-4P	925435-86-5P	925435-87-6P	925435-88-7P
	925435-89-8P	925435-90-1P	925435-91-2P	925435-92-3P	925435-93-4P
	925435-94-5P	925435-95-6P	925435-96-7P	925435-97-8P	925435-98-9P
	925435-99-0P	925436-00-6P	925436-01-7P	925436-02-8P	925436-03-9P
	925436-04-0P	925436-05-1P	925436-06-2P	925436-07-3P	925436-08-4P
	925436-09-5P	925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P
	925436-14-2P	925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P
	925436-19-7P	925436-20-0P	925436-21-1P	925436-24-4P	
	925436-25-5P	925436-26-6P	925436-27-7P	925436-28-8P	925436-29-9P
	925436-30-2P	925436-31-3P	925436-32-4P	925436-33-5P	925436-34-6P
	925436-35-7P	925436-36-8P	925436-37-9P	925436-38-0P	925436-39-1P
	925436-40-4P	925436-41-5P	925436-42-6P	925436-43-7P	925436-44-8P
	925436-45-9P	925436-47-1P	925436-48-2P	925436-49-3P	925436-50-6P
	925436-51-7P	925436-52-8P	925436-53-9P	925436-55-1P	925436-56-2P
	925436-57-3P	925436-58-4P	925436-59-5P	925436-60-8P	925436-61-9P
	925436-62-0P	925436-63-1P	925436-65-3P	925436-66-4P	925436-69-7P
	925436-71-1P	925436-73-3P	925436-76-6P	925436-78-8P	925436-80-2P

925436-83-5P 925436-86-8P 925436-89-1P 925436-91-5P 925436-93-7P
 925436-95-9P 925436-97-1P 925436-99-3P 925437-01-0P 925437-03-2P
 925437-05-4P 925437-07-6P 925437-09-8P 925437-10-1P 925437-12-3P
 925437-14-5P 925437-16-7P 925437-18-9P 925437-20-3P 925437-22-5P
 925437-26-9P 925437-28-1P 925437-30-5P 925437-32-7P 925437-33-8P
 925437-34-9P 925437-35-0P 925437-36-1P 925437-37-2P 925437-38-3P
 925437-39-4P 925437-41-8P 925437-42-9P 925437-43-0P 925437-44-1P
 925437-45-2P 925437-46-3P 925437-47-4P 925437-48-5P 925437-49-6P
 925437-50-9P 925437-51-0P 925437-52-1P 925437-53-2P 925437-54-3P
 925437-55-4P 925437-56-5P 925437-57-6P 925437-58-7P 925437-59-8P
 925437-60-1P 925437-61-2P 925437-62-3P 925437-63-4P 925437-64-5P
 925437-65-6P 925437-66-7P 925437-68-9P 925437-75-8P 925437-79-2P
 925437-88-3P 925437-94-1P 925438-01-3P 925438-13-7P 925438-46-6P
 925438-69-3P 925438-74-0P 925438-79-5P 925438-81-9P 925443-98-7P
 925443-99-8P 925444-00-4P 925444-01-5P 925444-02-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzothiazoles and thiazolopyridines as sirtuin modulators
 useful in treatment and prevention of diseases)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:171905 HCAPLUS Full-text

DOCUMENT NUMBER: 146:274367

TITLE: Preparation of imidazo[2,1-b]thiazole derivatives as
 sirtuin modulators

INVENTOR(S): Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie,
 Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.

PATENT ASSIGNEE(S): Sirtris Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 581pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019344	A1	20070215	WO 2006-US30510	20060804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006278503	A1	20070215	AU 2006-278503	20060804
CA 2617532	A1	20070215	CA 2006-2617532	20060804
US 20070037827	A1	20070215	US 2006-499239	20060804
US 20070037809	A1	20070215	US 2006-499876	20060804
US 20070037810	A1	20070215	US 2006-499901	20060804
US 20070037865	A1	20070215	US 2006-499920	20060804
US 20070043050	A1	20070222	US 2006-499919	20060804

US 7345178 B2 20080318
 EP 1910384 A1 20080416 EP 2006-789431 20060804
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 PRIORITY APPLN. INFO.: US 2005-705612P P 20050804
 US 2005-741783P P 20051202
 US 2006-779370P P 20060303
 US 2006-792276P P 20060414
 WO 2006-US30510 W 20060804

OTHER SOURCE(S): MARPAT 146:274367
 ED Entered SIN: 15 Feb 2007
 GI



AB The title compds. I [R19 = 1,2-phenylene, 5-6 membered 1,2-heteroarylene; R20 = H or solubilizing group; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compds. useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-aminothiazole and 2-bromo-2'-nitroacetophenone, was given. Exemplified compds. I were tested for sirtuin modulating activity (data given). Also provided are compns. comprising a sirtuin-modulating compound in combination with another therapeutic agent.


IT 925436-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted imidazo[2,1-b]thiazoles and analogs as sirtuin modulators useful in treatment and prevention of diseases)

RN 925436-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)



CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT Pain
(neuropathic pain; preparation of substituted
imidazo[2,1-b]thiazoles and analogs as sirtuin modulators useful in
treatment and prevention of diseases)

IT	925435-34-3P	925435-35-4P	925435-36-5P	925435-37-6P	925435-38-7P
	925435-39-8P	925435-40-1P	925435-41-2P	925435-42-3P	925435-43-4P
	925435-44-5P	925435-45-6P	925435-46-7P	925435-47-8P	925435-48-9P
	925435-49-0P	925435-50-3P	925435-51-4P	925435-52-5P	925435-53-6P
	925435-54-7P	925435-55-8P	925435-56-9P	925435-57-0P	925435-58-1P
	925435-59-2P	925435-60-5P	925435-61-6P	925435-62-7P	925435-63-8P
	925435-64-9P	925435-65-0P	925435-66-1P	925435-67-2P	925435-68-3P
	925435-69-4P	925435-70-7P	925435-71-8P	925435-72-9P	925435-73-0P
	925435-74-1P	925435-75-2P	925435-76-3P	925435-77-4P	925435-78-5P
	925435-79-6P	925435-80-9P	925435-81-0P	925435-82-1P	925435-83-2P
	925435-84-3P	925435-85-4P	925435-86-5P	925435-87-6P	925435-88-7P
	925435-89-8P	925435-90-1P	925435-91-2P	925435-92-3P	925435-93-4P
	925435-94-5P	925435-95-6P	925435-96-7P	925435-97-8P	925435-98-9P
	925435-99-0P	925436-00-6P	925436-01-7P	925436-02-8P	925436-03-9P
	925436-04-0P	925436-05-1P	925436-06-2P	925436-07-3P	925436-08-4P
	925436-09-5P	925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P
	925436-14-2P	925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P
	925436-19-7P	925436-20-0P	925436-21-1P	925436-24-4P	
	925436-25-5P	925436-26-6P	925436-27-7P	925436-28-8P	925436-29-9P
	925436-30-2P	925436-31-3P	925436-32-4P	925436-33-5P	925436-34-6P
	925436-35-7P	925436-36-8P	925436-37-9P	925436-38-0P	925436-39-1P
	925436-40-4P	925436-41-5P	925436-42-6P	925436-43-7P	925436-44-8P
	925436-45-9P	925436-47-1P	925436-48-2P	925436-49-3P	925436-50-6P
	925436-51-7P	925436-52-8P	925436-53-9P	925436-55-1P	925436-56-2P
	925436-57-3P	925436-58-4P	925436-59-5P	925436-60-8P	925436-61-9P
	925436-62-0P	925436-63-1P	925436-65-3P	925436-66-4P	925436-69-7P
	925436-71-1P	925436-73-3P	925436-76-6P	925436-78-8P	925436-80-2P
	925436-83-5P	925436-86-8P	925436-89-1P	925436-91-5P	925436-93-7P
	925436-95-9P	925436-97-1P	925436-99-3P	925437-01-0P	925437-03-2P
	925437-05-4P	925437-07-6P	925437-09-8P	925437-10-1P	925437-12-3P
	925437-14-5P	925437-16-7P	925437-18-9P	925437-20-3P	925437-22-5P
	925437-26-9P	925437-28-1P	925437-30-5P	925437-32-7P	925437-33-8P
	925437-34-9P	925437-35-0P	925437-36-1P	925437-37-2P	925437-38-3P
	925437-39-4P	925437-41-8P	925437-42-9P	925437-43-0P	925437-44-1P
	925437-45-2P	925437-46-3P	925437-47-4P	925437-48-5P	925437-49-6P
	925437-50-9P	925437-51-0P	925437-52-1P	925437-53-2P	925437-54-3P
	925437-55-4P	925437-56-5P	925437-57-6P	925437-58-7P	925437-59-8P
	925437-60-1P	925437-61-2P	925437-62-3P	925437-63-4P	925437-64-5P
	925437-65-6P	925437-66-7P	925437-68-9P	925437-75-8P	925437-79-2P
	925437-88-3P	925437-94-1P	925438-01-3P	925438-13-7P	925438-46-6P
	925438-69-3P	925438-74-0P	925438-79-5P	925438-81-9P	925443-98-7P
	925443-99-8P	925444-00-4P	925444-01-5P	925444-02-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted imidazo[2,1-b]thiazoles and analogs as sirtuin modulators useful in treatment and prevention of diseases)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1253175 HCAPLUS Full-text

DOCUMENT NUMBER: 146:27856

TITLE: Preparation of 4-amino pyrimidine compounds as modulators of ATP-binding cassette transporters for treating disease

INVENTOR(S): Hadida Ruah, Sara S.; Hazlewood, Anna R.; Grootenhuys, Peter D. J.; Singh, Ashvani K.; Cleveland, Thomas; Van Goor, Frederick F.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 106pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127588	A2	20061130	WO 2006-US19712	20060522
WO 2006127588	A3	20070726		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006251624	A1	20061130	AU 2006-251624	20060522
CA 2609392	A1	20061130	CA 2006-2609392	20060522
US 20070105833	A1	20070510	US 2006-438636	20060522
EP 1891018	A2	20080227	EP 2006-770825	20060522
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
IN 2007KN04531	A	20080208	IN 2007-KN4531	20071123
PRIORITY APPLN. INFO.:			US 2005-683982P	P 20050524
			WO 2006-US19712	W 20060522

OTHER SOURCE(S): MARPAT 146:27856

ED Entered SIN: 01 Dec 2006

GI



- AB 4-Amido-pyrimidine compds., derivs. and compns. thereof, and synthetic methods described are useful for modulating ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. The compds. of the invention have general formula I (wherein Ra = H, (un)substituted aliphatic, (un)substituted aryl, etc.; Rb = (un)substituted aliphatic, (un)substituted aryl, etc.; Rc = H, (un)substituted heterocycloaliph., (un)substituted cycloaliph., or aliphatic; Rd = H, (un)substituted aliphatic or aryl, etc.; A = (un)substituted aryl or heteroaryl). For example, 2-(dimethylamino)-6-(2-methoxyphenyl)pyrimidine-4-carboxamide was prepared in 5 steps via dioxobutanoic acid, methylthio, and sulfinyl intermediates.
- IT 378766-17-7P, 2-Morpholino-6-phenylpyrimidine-4-carboxamide 379252-37-6P, 2-Diethylamino-6-phenylpyrimidine-4-carboxamide 380576-38-1P, 2-Cyclohexylamino-6-phenylpyrimidine-4-carboxamide 380872-86-6P, 2-(Azepan-1-yl)-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 380875-22-3P, 2-Methylamino-6-phenylpyrimidine-4-carboxamide 380887-56-9P, 6-Phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide 381680-86-0P, 2-(Azepan-1-yl)-6-phenylpyrimidine-4-carboxamide 381711-06-4P, 2-Benzylamino-6-phenylpyrimidine-4-carboxamide 552285-77-5P, 2-Diethylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 552287-09-9P, 6-(4-Methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-12-1P, 2-(Dimethylamino)-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915963-23-4P, 2-(N-Methyl-N-phenethylamino)-6-phenylpyrimidine-4-carboxamide 915963-31-4P, 2-Diethylamino-6-(2,6-dimethoxyphenyl)pyrimidine-4-carboxamide 915963-41-6P, 2-(4-Acetyl-4-phenyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915963-43-8P, 2-[(Cyclopropylmethyl)amino]-N-methyl-6-phenylpyrimidine-4-carboxamide 915963-45-0P, 2-(4-Methyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915963-47-2P, 6-(3-Methoxyphenyl)-2-morpholinopyrimidine-4-carboxamide 915963-49-4P, 2-[[[(2-Furyl)methyl]amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915963-51-8P, 2-[(Butyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide 915963-53-0P, N-Methyl-2-methylamino-6-phenylpyrimidine-4-carboxamide 915963-55-2P, 2-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915963-57-4P, 2-Ethylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915963-59-6P, 6-(3,5-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-61-0P, 2-Diethylamino-6-(6-methoxy-3-pyridyl)pyrimidine-4-carboxamide 915963-63-2P, 2-Diisobutylamino-6-phenylpyrimidine-4-carboxamide 915963-65-4P, 6-(3-Furyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-67-6P, 2-[[[(2-Furyl)methyl]amino]-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915963-69-8P, 2-[(Methyl)(pentyl)amino]-6-phenylpyrimidine-4-carboxamide 915963-71-2P, 6-(2,3-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915963-73-4P,

3-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic acid isopropyl ester 915963-75-6P, 6-(2,3-Difluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-77-8P, 2-(2,6-Dimethylmorpholin-4-yl)-6-phenylpyrimidine-4-carboxamide 915963-79-0P, 2-(Azepan-1-yl)-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide 915963-81-4P, 6-Phenyl-2-(pyrrolidin-1-yl)pyrimidine-4-carboxamide 915963-83-6P, 6-(2,5-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-85-8P, 2-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915963-87-0P, 6-(4-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915963-89-2P, 6-(2,5-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-91-6P, 6-(Benzothiophen-3-yl)-2-diethylaminopyrimidine-4-carboxamide 915963-93-8P, 2-[(Cyclopropylmethyl)amino]-6-phenylpyrimidine-4-carboxamide 915963-95-0P, 2-Diethylamino-6-(3-ethoxyphenyl)pyrimidine-4-carboxamide 915963-97-2P, 2-[(Allyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915964-01-1P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-03-3P, 2-Dibenzylamino-6-phenylpyrimidine-4-carboxamide 915964-05-5P, 2-[(Butyl)(ethyl)amino]-6-phenylpyrimidine-4-carboxamide 915964-07-7P, 6-(3-Fluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-09-9P, 2-Diethylamino-6-(3,5-difluorophenyl)pyrimidine-4-carboxamide 915964-11-3P, 6-(5-Isopropyl-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-13-5P, 2-Diethylamino-N-ethyl-6-phenylpyrimidine-4-carboxamide 915964-15-7P, 2-[(4-Carbamoyl-6-phenylpyrimidin-2-yl)methylamino]acetic acid ethyl ester 915964-17-9P, 2-[Ethyl(2-hydroxyethyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-19-1P, 2-Diethylamino-6-(2-fluorophenyl)pyrimidine-4-carboxamide 915964-21-5P, 2-(1-Piperidyl)-6-[2-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915964-23-7P, 2-[4-[(4-Methoxyphenyl)sulfonyl]piperazin-1-yl]-6-phenylpyrimidine-4-carboxamide 915964-25-9P 915964-27-1P, 6-(4-Ethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-29-3P, 2-Cyclopentylamino-6-phenylpyrimidine-4-carboxamide 915964-31-7P, 2-Dipropylamino-6-phenylpyrimidine-4-carboxamide 915964-36-2P, 2-Dimethylamino-6-phenylpyrimidine-4-carboxamide 915964-38-4P, 2-Diethylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-40-8P, 2-Diethylamino-6-(5-methyl-2-thienyl)pyrimidine-4-carboxamide 915964-42-0P, 2-Allylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-44-2P, 2-[[1-(3,4-Dimethoxyphenyl)-cyclopentylmethyl]amino]-6-phenylpyrimidine-4-carboxamide 915964-46-4P, 2-Diethylamino-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915964-48-6P, 2-(Azepan-1-yl)-N-methyl-6-phenylpyrimidine-4-carboxamide 915964-50-0P, 2-(1-Piperidyl)-6-(p-tolyl)pyrimidine-4-carboxamide 915964-52-2P, 2-Diethylamino-6-(5-fluoro-2-methoxyphenyl)pyrimidine-4-carboxamide 915964-54-4P, 6-(3-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915964-56-6P, 2-[(Cyclopropylmethyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-58-8P, 2-Diethylamino-6-(4-isobutylphenyl)pyrimidine-4-carboxamide 915964-60-2P, 2-Diethylamino-6-(5-isopropyl-2-methoxyphenyl)pyrimidine-4-carboxamide 915964-62-4P, 6-Phenyl-2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915964-64-6P, 2-Diethylamino-6-(3,4-dimethylphenyl)pyrimidine-4-carboxamide 915964-67-9P, 6-(3-Chlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915964-69-1P, 2-Diethylamino-6-(3,4-dimethoxyphenyl)pyrimidine-4-

carboxamide 915964-71-5P, 2-Diethylamino-6-[3-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915964-73-7P, 6-(3,4-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915964-75-9P, 6-(2-Methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-77-1P, 6-Phenyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine-4-carboxamide 915964-79-3P, 2-Diethylamino-6-(m-tolyl)pyrimidine-4-carboxamide 915964-82-8P, 6-(5-Chloro-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-84-0P, 2-Diethylamino-6-(2,5-dimethoxyphenyl)pyrimidine-4-carboxamide 915964-86-2P, 6-Phenyl-2-(4-propyl-1-piperidyl)pyrimidine-4-carboxamide 915964-88-4P, 6-(4-Isopropylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-90-8P, 2-Dimethylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-92-0P, 2-Diethylamino-6-(4-fluoro-3-methylphenyl)pyrimidine-4-carboxamide 915964-94-2P, 2-Diethylamino-6-(p-tolyl)pyrimidine-4-carboxamide 915964-96-4P, N,N-Dimethyl-6-phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-98-6P, 2-Diethylamino-6-[3-(hydroxymethyl)phenyl]pyrimidine-4-carboxamide 915965-00-3P, 2-Diethylamino-6-(4-ethylphenyl)pyrimidine-4-carboxamide 915965-02-5P, 2-[Ethyl(2-hydroxyethyl)amino]-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915965-04-7P, 6-Phenyl-2-(thiazolidin-3-yl)pyrimidine-4-carboxamide 915965-06-9P, 2-(1,2,3,4,4a,5,6,7,8,8a-Decahydroisoquinolin-2-yl)-6-phenylpyrimidine-4-carboxamide 915965-08-1P, 6-(2-Fluoro-3-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-10-5P, 2-[4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridin-1-yl]-6-phenylpyrimidine-4-carboxamide 915965-13-8P, 2-Allylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915965-15-0P, 2-[(2-Furyl)methylamino]-N-methyl-6-phenylpyrimidine-4-carboxamide 915965-17-2P, 2-Diethylamino-6-(2-phenoxyphenyl)pyrimidine-4-carboxamide 915965-19-4P, 6-(Benzo[thiophen-3-yl]-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-21-8P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915965-23-0P, 6-Phenyl-2-(1,4-thiazinan-4-yl)pyrimidine-4-carboxamide 915965-25-2P, 2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-6-phenylpyrimidine-4-carboxamide 915965-28-5P, 6-Phenyl-2-propylaminopyrimidine-4-carboxamide 915965-30-9P, 6-(2,3-Dimethylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-32-1P, 2-[(Methyl)(prop-2-ynyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-34-3P, 6-(2-Fluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-36-5P, 2-[(2-Furyl)methyl(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-38-8P, 6-(2,5-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915965-41-2P, 3-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic acid methyl ester 915965-43-4P, 6-(3,5-Difluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-45-6P, 6-Phenyl-2-tert-butylaminopyrimidine-4-carboxamide 915965-47-8P, 2-(1-Piperidyl)-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915965-49-0P, 2-[(Benzyl)(ethyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-51-4P, 6-(2,4-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-53-6P, 2-[(2-Furyl)methylamino]-6-phenylpyrimidine-4-carboxamide 915965-55-8P, 6-(6-Methoxy-3-pyridyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-57-0P, 2-[Ethyl[2-(2-pyridyl)ethyl]amino]-6-phenylpyrimidine-4-carboxamide 915965-59-2P, 2-[(2-Hydroxyethyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-61-1P, 2-Diethylamino-6-(2,4-dimethoxypyrimidin-5-yl)pyrimidine-4-carboxamide 915965-64-9P, 6-(2-Ethoxyphenyl)-2-

(1-piperidyl)pyrimidine-4-carboxamide 915965-66-1P,
 6-(3-Methoxyphenyl)-2-methylaminopyrimidine-4-carboxamide
 915965-68-3P, 2-(4-Cyano-4-phenyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915965-70-7P, 2-[3-(Diethylcarbamoyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915965-72-9P,
 2-Ethylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide
 915965-74-1P, 6-(3,4-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-75-2P, 6-(4-Cyanophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-76-3P,
 2-(1-Piperidyl)-6-[3-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915965-77-4P, 2-[Ethyl(2-methylprop-2-enyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-78-5P,
 2-[Bis(2-ethoxyethyl)amino]-6-phenylpyrimidine-4-carboxamide
 915965-79-6P, 2-Diethylamino-6-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915965-80-9P, 4-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic acid methyl ester 915965-81-0P,
 6-(Benzothiophen-2-yl)-2-diethylaminopyrimidine-4-carboxamide
 915965-82-1P, 6-(2-Phenoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-83-2P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-85-4P,
 2-Diethylamino-6-(4-ethylsulfonylphenyl)pyrimidine-4-carboxamide
 915965-86-5P, 6-(4-Methyl-2-thienyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-88-7P, 6-(4-Chlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915965-89-8P,
 3-[6-Carbamoyl-2-(1-piperidyl)pyrimidin-4-yl]benzoic acid isopropyl ester
 915965-91-2P, 2-Diethylamino-6-(4-ethoxyphenyl)pyrimidine-4-carboxamide 915965-93-4P, 2-Diethylamino-6-(2,3-dimethylphenyl)pyrimidine-4-carboxamide 915965-95-6P,
 6-(m-Tolyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-97-8P,
 2-(1-Piperidyl)-6-[2-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide
 915965-98-9P, 2-[(Cyclopropylmethyl)(propyl)amino]-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide 915966-00-6P,
 2-[(Ethyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide
 915966-02-8P, 2-[4-(4-Fluorobenzoyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-04-0P,
 2-Dibutylamino-6-phenylpyrimidine-4-carboxamide 915966-06-2P,
 6-(4-Fluoro-3-methylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915966-08-4P, 2-Isopropylamino-6-phenylpyrimidine-4-carboxamide
 915966-09-5P, 6-(5-Fluoro-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-11-9P,
 6-(3-Ethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915966-13-1P, 6-(3,4-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-15-3P, 2-[Methyl(3-pyridyl)methyl]amino]-6-phenylpyrimidine-4-carboxamide 915966-17-5P,
 2-Diethylamino-6-(4-fluorophenyl)pyrimidine-4-carboxamide
 915966-19-7P, 2-Diethylamino-6-(4-methyl-2-thienyl)pyrimidine-4-carboxamide 915966-21-1P, N-Methyl-6-phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-23-3P,
 2-Diethylamino-6-(2-ethoxyphenyl)pyrimidine-4-carboxamide
 915966-25-5P, 2-Isobutylamino-6-phenylpyrimidine-4-carboxamide
 915966-27-7P, 2-Diisopentylamino-6-phenylpyrimidine-4-carboxamide
 915966-29-9P, 2-[(Cyanomethyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-32-4P, 2-[4-(2-Hydroxyethyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-34-6P,
 6-(3,5-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide
 915966-36-8P, 2-[Ethyl(2-hydroxyethyl)amino]-N-methyl-6-phenylpyrimidine-4-carboxamide 915966-38-0P,
 2-(4-Benzyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide
 915966-40-4P, 2-Diethylamino-N,N-diethyl-6-phenylpyrimidine-4-carboxamide 915966-42-6P, 2-[(Benzyl)(butyl)amino]-6-

phenylpyrimidine-4-carboxamide 915966-44-8P,
 2-[4-(4-Chlorobenzoyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide
 915966-46-8P, 2-Diethylamino-6-(2,4-difluorophenyl)pyrimidine-4-
 carboxamide 915966-48-2P, 1-(4-Carbamoyl-6-phenylpyrimidin-2-
 yl)piperidine-3-carboxylic acid ethyl ester 915966-50-6P,
 2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-phenylpyrimidine-4-
 carboxamide 915966-52-8P, 6-(2,3-Dichlorophenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915966-54-0P,
 6-(3-Methoxyphenyl)-2-[(prop-2-ynyl)amino]pyrimidine-4-carboxamide
 915966-56-2P, 2-[3-(Hydroxymethyl)-1-piperidyl]-6-phenylpyrimidine-
 4-carboxamide 915966-58-4P, 2-Diethylamino-6-(4-
 isopropylphenyl)pyrimidine-4-carboxamide 915966-60-8P,
 6-(3-Methoxyphenyl)-2-(3-methoxypropylamino)pyrimidine-4-carboxamide
 915966-62-0P, 2-Diethylamino-N-methyl-6-phenylpyrimidine-4-
 carboxamide 915966-64-2P, 6-(3-Cyanophenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915966-66-4P,
 6-(5-Chloro-2-methoxyphenyl)-2-diethylaminopyrimidine-4-carboxamide
 915966-67-5P, 2-(4-Benzyl-4-hydroxy-1-piperidyl)-6-
 phenylpyrimidine-4-carboxamide 915966-68-6P,
 N-Benzyl-2-diethylamino-6-phenylpyrimidine-4-carboxamide
 915966-69-7P, 2-[(Benzyl)(methyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915966-70-6P, 2-Diethylamino-6-(3-
 fluorophenyl)pyrimidine-4-carboxamide 915966-71-1P,
 1-(4-Carbamoyl-6-phenylpyrimidin-2-yl)piperidine-4-carboxylic acid ethyl
 ester 915966-72-2P, 2-(1H-Imidazol-1-yl)-6-phenylpyrimidine-4-
 carboxamide 915966-73-3P, 2-(2,5-Dihydro-1H-pyrrol-1-yl)-6-
 phenylpyrimidine-4-carboxamide 915966-74-4P,
 2-(Azocan-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-75-5P,
 6-(2,4-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915966-76-6P, 2-Dimethylamino-6-(4-methoxyphenyl)pyrimidine-4-
 carboxamide 915966-77-7P, 2-(Azepan-1-yl)-6-(3-
 methoxyphenyl)pyrimidine-4-carboxamide 915966-78-8P,
 2-[4-(2-Oxo-1,3-dihydrobenzimidazol-1-yl)-1-piperidyl]-6-phenylpyrimidine-
 4-carboxamide 915966-79-9P, 2-(1-Piperidyl)-6-[3-
 (trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915966-80-2P,
 2-Allylamino-6-(2-methoxyphenyl)pyrimidine-4-carboxamide
 915966-81-3P, 2-[(Ethyl)(propyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915966-82-4P, 6-Phenyl-2-(1H-pyrazol-1-yl)pyrimidine-
 4-carboxamide 915966-83-5P, 2-Diallylamino-6-phenylpyrimidine-4-
 carboxamide 915966-84-6P, 2-[(Hexyl)(methyl)amino]-6-
 phenylpyrimidine-4-carboxamide 915966-85-7P,
 2-Diethylamino-6-(2,4-dimethoxyphenyl)pyrimidine-4-carboxamide
 915966-86-8P, 6-Phenyl-2-[(prop-2-ynyl)amino]pyrimidine-4-
 carboxamide 915966-87-9P, 2-(3-Methyl-1-piperidyl)-6-
 phenylpyrimidine-4-carboxamide 915966-88-0P,
 2-(Azetidin-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-89-1P,
 2-(3,5-Dimethyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide
 915966-90-4P, 2-[Butyl(cyanomethyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915966-91-5P, 6-(Benzothiophen-2-yl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915966-92-6P,
 2-[(2-Hydroxy-2-phenylethyl)(methyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915966-93-7P, 6-(2,4-Dichlorophenyl)-2-
 diethylaminopyrimidine-4-carboxamide 915966-94-8P,
 2-[[1-(3,4-Dimethoxyphenyl)cyclopropyl]methyl]amino]-6-phenylpyrimidine-4-
 carboxamide 915966-95-9P, 2-[Butyl(2-hydroxyethyl)amino]-6-
 phenylpyrimidine-4-carboxamide 915966-96-0P,
 6-(2-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-
 carboxamide 915966-97-1P, 6-(3-Methoxyphenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915966-98-2P,
 N-Methyl-6-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-

carboxamide 915966-99-3P, 2-[(Cyclopropylmethyl)amino]-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915967-00-3P, 2-Diethylamino-6-[4-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915967-01-0P, 2-Diethylamino-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915967-02-1P, 2-[[2-(Furyl)methyl]amino]-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide 915967-03-2P, 6-Phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915967-04-3P, 2-[Ethyl(2-hydroxyethyl)amino]-6-phenylpyrimidine-4-carboxamide 915967-05-4P, 2-[[2-(1H-Indol-3-yl)ethyl][methyl]amino]-6-phenylpyrimidine-4-carboxamide 915967-06-5P


, 6-(3-Acetylaminophenyl)-2-diethylaminopyrimidine-4-carboxamide 915967-07-6P, 2-Ethylamino-6-phenylpyrimidine-4-carboxamide 915967-08-7P, 2-[Bis(2-hydroxyethyl)amino]-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915967-09-8P, 2-Diethylamino-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide 915967-10-1P, 2-Diethylamino-6-(2,5-difluorophenyl)pyrimidine-4-carboxamide 915967-11-2P 915967-12-3P, 6-(3,4-Dimethylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915967-13-4P, 6-(Benzodioxol-5-yl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915967-14-5P, 2-Diethylamino-6-(o-tolyl)pyrimidine-4-carboxamide 915967-15-6P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915967-17-8P, 2-[(Isopentyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915967-18-9P, 2-[(Isobutyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915967-19-0P, 2-Diethylamino-6-(2,6-difluorophenyl)pyrimidine-4-carboxamide 915967-20-3P, 6-(o-Tolyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915967-21-4P, 2-Amino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-amino pyrimidine compds. as modulators of ATP-binding cassette transporters for treating disease)


RN 378766-17-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(4-morpholinyl)-6-phenyl- (CA INDEX NAME)




RN 379252-37-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-phenyl- (CA INDEX NAME)




RN 380578-38-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(cyclohexylamino)-6-phenyl- (CA INDEX NAME)




RN 380872-86-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-6-(4-methoxyphenyl)-
(CA INDEX NAME)


RN 380875-22-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methylamino)-6-phenyl- (CA INDEX NAME)




RN 380887-56-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(1-piperidinyl)- (CA INDEX NAME)




RN 381680-86-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-6-phenyl- (CA INDEX NAME)




RN 381711-06-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 552285-77-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 552287-09-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-methoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915963-12-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915963-23-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[methyl(2-phenylethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915963-31-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,6-dimethoxyphenyl)- (CA INDEX NAME)




RN 915963-41-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(4-acetyl-4-phenyl-1-piperidiny)-6-phenyl-
(CA INDEX NAME)


RN 915963-43-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)amino]-N-methyl-6-phenyl-
(CA INDEX NAME)


RN 915963-45-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(4-methyl-1-piperidiny)-6-phenyl- (CA INDEX
NAME)

RN 915963-47-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-(4-morpholinyl)- (CA INDEX
NAME)

RN 915963-49-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)amino]-6-(3-methoxyphenyl)-
(CA INDEX NAME)


RN 915963-51-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(butylpropylamino)-6-phenyl- (CA INDEX NAME)




RN 915963-53-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-methyl-2-(methylamino)-6-phenyl- (CA INDEX NAME)




RN 915963-55-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-6-phenyl- (CA INDEX NAME)




RN 915963-57-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylamino)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 915963-59-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-dichlorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915963-61-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 915963-63-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[bis(2-methylpropyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915963-65-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-furanyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915963-67-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)amino]-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 915963-69-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methylpentylamino)-6-phenyl- (CA INDEX NAME)




RN 915963-71-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,3-dichlorophenyl)-2-(diethylamino)- (CA INDEX NAME)




RN 915963-73-4 HCAPLUS

CN Benzoic acid, 3-[6-(aminocarbonyl)-2-(diethylamino)-4-pyrimidinyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 915963-75-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,3-difluorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915963-77-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-dimethyl-4-morpholinyl)-6-phenyl- (CA INDEX NAME)




RN 915963-79-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-N,N-dimethyl-6-phenyl- (CA INDEX NAME)




RN 915963-81-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 915963-83-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(2,5-dimethoxyphenyl)-2-(1-piperidiny)- (CA INDEX NAME)




RN 915963-85-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-


piperidinyl]-6-phenyl- (CA INDEX NAME)




CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-1(2H)-pyridinyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)



4-Pyrimidinecarboxamide, 6-(2,5-dichlorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




CN 4-Pyrimidinecarboxamide, 6-benzo[b]thien-3-yl-2-(diethylamino)- (CA INDEX
NAME)




RN 915963-93-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915963-95-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3-ethoxyphenyl)- (CA INDEX NAME)



RN 915963-97-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(methyl-2-propen-1-ylamino)-6-phenyl- (CA INDEX NAME)



RN 915964-01-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)propylamino]-6-(3-

methoxyphenyl)- (CA INDEX NAME)




RN 915964-03-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[bis(phenylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915964-05-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(butylethylamino)-6-phenyl- (CA INDEX NAME)




RN 915964-07-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-fluorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915964-09-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3,5-difluorophenyl)- (CA INDEX NAME)




RN 915964-11-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[2-methoxy-5-(1-methylethyl)phenyl]-2-(1-piperidiny)- (CA INDEX NAME)




RN 915964-13-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-N-ethyl-6-phenyl- (CA INDEX NAME)




RN 915964-15-7 HCAPLUS

CN Glycine, N-[4-(aminocarbonyl)-6-phenyl-2-pyrimidinyl]-N-methyl-, ethyl ester (CA INDEX NAME)




RN 915964-17-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 915964-19-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2-fluorophenyl)- (CA INDEX NAME)




RN 915964-21-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-piperidinyl)-6-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 915964-23-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]-6-phenyl- (CA INDEX NAME)




RN 915964-25-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-[(tetrahydro-2-furanyl)methylamino]- (CA INDEX NAME)




RN 915964-27-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-ethoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915964-29-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(cyclopentylamino)-6-phenyl- (CA INDEX NAME)




RN 915964-31-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dipropylamino)-6-phenyl- (CA INDEX NAME)




RN 915964-36-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-phenyl- (CA INDEX NAME)




RN 915964-38-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 915964-40-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(5-methyl-2-thienyl)- (CA INDEX NAME)




RN 915964-42-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-(2-propen-1-ylamino)- (CA INDEX NAME)




RN 915964-44-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[[[1-(3,4-dimethoxyphenyl)cyclopentyl]methyl]amino]-6-phenyl- (CA INDEX NAME)




RN 915964-46-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915964-48-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-N-methyl-6-phenyl-
(CA INDEX NAME)

RN 915964-50-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(4-methylphenyl)-2-(1-piperidynyl)- (CA INDEX
NAME)

RN 915964-52-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(5-fluoro-2-methoxyphenyl)-
(CA INDEX NAME)

RN 915964-54-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-1(2H)-pyridinyl)-6-(3-methoxyphenyl)-
(CA INDEX NAME)




RN 915964-56-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)amino]-6-(3-methoxyphenyl)-
(CA INDEX NAME)

RN 915964-58-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(2-methylpropyl)phenyl]-
(CA INDEX NAME)

RN 915964-60-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[2-methoxy-5-(1-methylethyl)phenyl]-
(CA INDEX NAME)


RN 915964-62-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-6-phenyl-
(CA INDEX NAME)




RN 915964-64-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3,4-dimethylphenyl)- (CA
INDEX NAME)




RN 915964-67-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-chlorophenyl)-2-(diethylamino)- (CA INDEX
NAME)




RN 915964-69-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3,4-dimethoxyphenyl)- (CA
INDEX NAME)




RN 915964-71-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)

RN 915964-73-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(3,4-dichlorophenyl)-2-(diethylamino)- (CA
INDEX NAME)

RN 915964-75-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-(1-piperidinyl)- (CA INDEX
NAME)


RN 915964-77-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3,4-dihydro-2(1H)-isoquinolinyl)-6-phenyl-
(CA INDEX NAME)




RN 915964-79-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3-methylphenyl)- (CA INDEX NAME)




RN 915964-82-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-chloro-2-methoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915964-84-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 915964-86-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(4-propyl-1-piperidiny)- (CA INDEX NAME)




RN 915964-88-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[4-(1-methylethyl)phenyl]-2-(1-piperidiny)- (CA INDEX NAME)




RN 915964-90-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 915964-92-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-fluoro-3-methylphenyl)- (CA INDEX NAME)




RN 915964-94-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-methylphenyl)- (CA INDEX NAME)




RN 915964-96-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, N,N-dimethyl-6-phenyl-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915964-98-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[3-(hydroxymethyl)phenyl]- (CA INDEX NAME)




RN 915965-00-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-ethylphenyl)- (CA INDEX NAME)




RN 915965-02-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915965-04-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(3-thiazolidinyl)- (CA INDEX NAME)



RN 915965-06-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(octahydro-2(1H)-isoquinolinyl)-6-phenyl- (CA INDEX NAME)




RN 915965-08-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-fluoro-3-methoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)


RN 915965-17-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2-phenoxyphenyl)- (CA INDEX NAME)




RN 915965-19-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-benzo[b]thien-3-yl-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-21-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)propylamino]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915965-23-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 915965-25-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-6-phenyl-
(CA INDEX NAME)

RN 915965-28-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(propylamino)- (CA INDEX NAME)



RN 915965-30-9 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(2,3-dimethylphenyl)-2-(1-piperidinyl)- (CA
INDEX NAME)

RN 915965-32-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methyl-2-propyn-1-ylamino)-6-phenyl- (CA
INDEX NAME)


RN 915965-41-2 HCAPLUS

CN Benzoic acid, 3-[6-(aminocarbonyl)-2-(diethylamino)-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 915965-43-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,5-difluorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-45-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(1,1-dimethylethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915965-47-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-piperidinyl)-6-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 915965-49-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl(phenylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915965-51-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,4-dichlorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-53-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915965-55-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(6-methoxy-3-pyridinyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-57-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl[2-(2-pyridinyl)ethyl]amino]-6-phenyl- (CA INDEX NAME)




RN 915965-59-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-hydroxyethyl)propylamino]-6-phenyl- (CA INDEX NAME)




RN 915965-62-7 HCAPLUS

CN [4,5'-Bipyrimidine]-6-carboxamide, 2-(diethylamino)-2',4'-dimethoxy- (CA INDEX NAME)




RN 915965-64-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-ethoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-66-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-(methylamino)- (CA INDEX NAME)



RN 915965-68-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(4-cyano-4-phenyl-1-piperidinyl)-6-phenyl- (CA INDEX NAME)



RN 915965-70-7 HCAPLUS


10/588757

CN 4-Pyrimidinecarboxamide, 2-[3-[(diethylamino)carbonyl]-1-piperidinyl]-6-phenyl- (CA INDEX NAME)




RN 915965-72-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylamino)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 915965-74-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,4-dichlorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-75-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-cyanophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-76-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-piperidinyl)-6-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 915965-77-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl(2-methyl-2-propen-1-yl)amino]-6-phenyl-
(CA INDEX NAME)




RN 915965-78-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[bis(2-ethoxyethyl)amino]-6-phenyl- (CA INDEX
NAME)




RN 915965-79-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[3-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)

RN 915965-80-9 HCAPLUS


CN Benzoic acid, 4-[6-(aminocarbonyl)-2-(diethylamino)-4-pyrimidinyl]-,
methyl ester (CA INDEX NAME)

RN 915965-81-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-benzo[b]thien-2-yl-2-(diethylamino)- (CA INDEX
NAME)


RN 915965-82-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-phenoxyphenyl)-2-(1-piperidinyl)- (CA INDEX
NAME)




RN 915965-83-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)propylamino]-6-phenyl- (CA INDEX NAME)




RN 915965-85-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(ethylsulfonyl)phenyl]- (CA INDEX NAME)




RN 915965-86-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-methyl-2-thienyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-88-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-chlorophenyl)-2-(diethylamino)- (CA INDEX NAME)




RN 915965-89-8 HCAPLUS

CN Benzoic acid, 3-[6-(aminocarbonyl)-2-(1-piperidinyl)-4-pyrimidinyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 915965-91-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 915965-93-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,3-dimethylphenyl)- (CA INDEX NAME)




RN 915965-95-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-methylphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915965-97-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-piperidinyl)-6-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 915965-98-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)propylamino]-N,N-dimethyl-6-phenyl- (CA INDEX NAME)




RN 915966-00-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylmethylamino)-6-phenyl- (CA INDEX NAME)




RN 915966-02-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-(4-fluorobenzoyl)-1-piperidiny]-6-phenyl- (CA INDEX NAME)




RN 915966-04-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dibutylamino)-6-phenyl- (CA INDEX NAME)




RN 915966-06-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(4-fluoro-3-methylphenyl)-2-(1-piperidiny)- (CA INDEX NAME)




RN 915966-08-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(1-methylethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-09-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-fluoro-2-methoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-11-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-ethoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-13-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-15-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[methyl(3-pyridinylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-17-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 915966-19-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(4-methyl-2-thienyl)- (CA INDEX NAME)




RN 915966-21-1 HCAPLUS
 CN 4-Pyrimidinecarboxamide, N-methyl-6-phenyl-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-23-3 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2-ethoxyphenyl)- (CA INDEX NAME)



RN 915966-25-5 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[(2-methylpropyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-27-7 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[bis(3-methylbutyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-29-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyanomethyl)methylamino]-6-phenyl- (CA INDEX NAME)




RN 915966-32-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-(2-hydroxyethyl)-1-piperidiny]-6-phenyl- (CA INDEX NAME)




RN 915966-34-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(3,5-dichlorophenyl)-2-(diethylamino)- (CA INDEX NAME)




RN 915966-36-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-N-methyl-6-phenyl-
(CA INDEX NAME)

RN 915966-38-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-phenyl-2-[4-(phenylmethyl)-1-piperidiny]- (CA
INDEX NAME)

RN 915966-40-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-N,N-diethyl-6-phenyl- (CA INDEX
NAME)

RN 915966-42-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[butyl(phenylmethyl)amino]-6-phenyl- (CA INDEX
NAME)




RN 915966-44-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-(4-chlorobenzoyl)-1-piperidinyl]-6-phenyl-
(CA INDEX NAME)

RN 915966-46-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,4-difluorophenyl)- (CA
INDEX NAME)

RN 915966-48-2 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-(aminocarbonyl)-6-phenyl-2-pyrimidinyl]-
, ethyl ester (CA INDEX NAME)


RN 915966-50-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6-phenyl- (CA INDEX NAME)




RN 915966-52-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,3-dichlorophenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-54-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-(2-propyn-1-ylamino)- (CA INDEX NAME)




RN 915966-56-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[3-(hydroxymethyl)-1-piperidinyl]-6-phenyl- (CA INDEX NAME)




RN 915966-58-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(1-methylethyl)phenyl]-
(CA INDEX NAME)

RN 915966-60-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-[(3-methoxypropyl)amino]-
(CA INDEX NAME)

RN 915966-62-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-N-methyl-6-phenyl- (CA INDEX
NAME)


RN 915966-64-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-cyanophenyl)-2-(1-piperidinyl)- (CA INDEX
NAME)




RN 915966-66-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-chloro-2-methoxyphenyl)-2-(diethylamino)-
(CA INDEX NAME)




RN 915966-67-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-6-phenyl-
(CA INDEX NAME)




RN 915966-68-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-phenyl-N-(phenylmethyl)-
(CA INDEX NAME)




RN 915966-69-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[methyl(phenylmethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-70-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 915966-71-1 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-(aminocarbonyl)-6-phenyl-2-pyrimidinyl]-, ethyl ester (CA INDEX NAME)




RN 915966-72-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1H-imidazol-1-yl)-6-phenyl- (CA INDEX NAME)




RN 915966-73-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,5-dihydro-1H-pyrrol-1-yl)-6-phenyl- (CA INDEX NAME)




RN 915966-74-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1(2H)-azocinyl)-6-phenyl- (CA INDEX NAME)




RN 915966-75-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,4-dimethoxyphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915966-76-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 915966-77-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-6-(3-methoxyphenyl)-
(CA INDEX NAME)




RN 915966-78-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-6-phenyl- (CA INDEX NAME)




RN 915966-79-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-piperidinyl)-6-[3-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 915966-80-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-(2-propen-1-ylamino)- (CA INDEX NAME)




RN 915966-81-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylpropylamino)-6-phenyl- (CA INDEX NAME)




RN 915966-82-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 915966-83-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(di-2-propen-1-ylamino)-6-phenyl- (CA INDEX NAME)




RN 915966-84-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylmethylamino)-6-phenyl- (CA INDEX NAME)




RN 915966-85-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 915966-86-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-phenyl-2-(2-propyn-1-ylamino)- (CA INDEX NAME)




RN 915966-87-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3-methyl-1-piperidinyl)-6-phenyl- (CA INDEX NAME)




RN 915966-88-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-azetidiny1)-6-phenyl- (CA INDEX NAME)




RN 915966-89-1 HCAPLUS

4-Pyrimidininecarboxamide, 2-(3,5-dimethyl-1-piperidinyl)-6-phenyl- (CA
INDEX NAME)




RN 915966-90-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[butyl(cyanomethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915966-91-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 6-benzo[b]thien-2-yl-2-(1-piperidinyl)- (CA
INDEX NAME)



RN 915966-92-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(2-hydroxy-2-phenylethyl)methylamino]-6-phenyl-
(CA INDEX NAME)

RN 915966-93-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,4-dichlorophenyl)-2-(diethylamino)- (CA
INDEX NAME)

RN 915966-94-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[[[1-(3,4-dimethoxyphenyl)cyclopropylmethyl]amino]-6-phenyl- (CA INDEX NAME)



RN 915966-95-9 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[butyl(2-hydroxyethyl)amino]-6-phenyl- (CA

INDEX NAME)




RN 915966-96-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-1(2H)-pyridinyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915966-97-1 HCAPLUS

CN 4-Pyrimidinencarboxamide, 6-(3-methoxyphenyl)-2-(1-piperidiny)- (CA INDEX NAME)




RN 915966-98-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-1(2H)-pyridinyl)-N-methyl-6-phenyl-
(CA INDEX NAME)




RN 915966-99-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)amino]-6-(4-methoxyphenyl)-
(CA INDEX NAME)




RN 915967-00-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 915967-01-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 915967-02-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)amino]-N,N-dimethyl-6-phenyl-
(CA INDEX NAME)




RN 915967-03-2 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(3,6-dihydro-1(2H)-pyridinyl)-6-phenyl- (CA INDEX NAME)



RN 915967-04-3 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-6-phenyl- (CA INDEX NAME)




RN 915967-05-4 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-phenyl- (CA INDEX NAME)




RN 915967-06-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[3-(acetylamino)phenyl]-2-(diethylamino)- (CA INDEX NAME)




RN 915967-07-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylamino)-6-phenyl- (CA INDEX NAME)




RN 915967-08-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[bis(2-hydroxyethyl)amino]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 915967-09-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-N,N-dimethyl-6-phenyl- (CA INDEX NAME)




RN 915967-10-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,5-difluorophenyl)- (CA INDEX NAME)




RN 915967-11-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3-methoxyphenyl)-2-[[tetrahydro-2-furanyl)methyl]amino]- (CA INDEX NAME)




RN 915967-12-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(3,4-dimethylphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915967-13-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(1,3-benzodioxol-5-yl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915967-14-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2-methylphenyl)- (CA INDEX NAME)




RN 915967-15-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(cyclopropylmethyl)propylamino]-6-(4-methoxyphenyl)- (CA INDEX NAME)



RN 915967-17-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[methyl(3-methylbutyl)amino]-6-phenyl- (CA INDEX NAME)



RN 915967-18-9 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-[methyl(2-methylpropyl)amino]-6-phenyl- (CA

INDEX NAME)




RN 915967-19-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-(2,6-difluorophenyl)- (CA INDEX NAME)




RN 915967-20-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2-methylphenyl)-2-(1-piperidinyl)- (CA INDEX NAME)




RN 915967-21-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methoxyphenyl)- (CA INDEX NAME)




IT 915963-17-6P, 6-(2-Methoxyphenyl)-2-(methylthio)pyrimidine-4-carboxamide 915963-19-8P, 6-(2-Methoxyphenyl)-2-(methylsulfinyl)pyrimidine-4-carboxamide 915963-21-2P, 6-(2-Methoxyphenyl)-2-(methylsulfonyl)pyrimidine-4-carboxamide 915963-27-8P, 2-(Methylthio)-6-phenylpyrimidine-4-carboxamide 915963-29-8P, 2-(Methylsulfonyl)-6-phenylpyrimidine-4-carboxamide 915963-36-9P, 6-(2,6-Dimethoxyphenyl)-2-methylsulfonylpyrimidine-4-carboxamide 915963-38-1P, 6-(2,6-Dimethoxyphenyl)-2-methylsulfonylpyrimidine-4-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-amino pyrimidine compds. as modulators of ATP-binding cassette transporters for treating disease)
 RN 915963-17-6 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-(methylthio)- (CA INDEX NAME)



RN 915963-19-8 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-(methylsulfinyl)- (CA INDEX NAME)




RN 915963-21-2 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 6-(2-methoxyphenyl)-2-(methylsulfonyl)- (CA INDEX NAME)




RN 915963-27-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methylthio)-6-phenyl- (CA INDEX NAME)




RN 915963-29-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methylsulfonyl)-6-phenyl- (CA INDEX NAME)




RN 915963-36-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,6-dimethoxyphenyl)-2-(methylthio)- (CA INDEX NAME)



RN 915963-38-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(2,6-dimethoxyphenyl)-2-(methylsulfonyl)- (CA INDEX NAME)



IC ICM A61K
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 378766-17-7P, 2-Morpholino-6-phenylpyrimidine-4-carboxamide
 379252-37-6P, 2-Diethylamino-6-phenylpyrimidine-4-carboxamide
 380578-36-1P, 2-Cyclohexylamino-6-phenylpyrimidine-4-carboxamide
 380972-36-6P, 2-(Azepan-1-yl)-6-(4-methoxyphenyl)pyrimidine-4-carboxamide
 380875-22-9P, 2-Methylamino-6-phenylpyrimidine-4-carboxamide
 380887-56-9P, 6-Phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide
 381680-86-0P, 2-(Azepan-1-yl)-6-phenylpyrimidine-4-carboxamide
 381711-06-4P, 2-Benzylamino-6-phenylpyrimidine-4-carboxamide
 552285-77-5P, 2-Diethylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide
 552287-99-9P, 6-(4-Methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915963-12-1P, 2-(Dimethylamino)-6-(2-methoxyphenyl)pyrimidine-4-carboxamide
 915963-23-4P, 2-(N-Methyl-N-phenethylamino)-6-phenylpyrimidine-4-carboxamide
 915963-31-4P, 2-Diethylamino-6-(2,6-dimethoxyphenyl)pyrimidine-4-carboxamide
 915963-41-6P, 2-(4-Acetyl-1-phenyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide
 915963-43-8P, 2-[(Cyclopropylmethyl)amino]-N-methyl-6-phenylpyrimidine-4-carboxamide
 915963-45-0P, 2-(4-Methyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide
 915963-47-2P, 6-(3-Methoxyphenyl)-2-morpholinopyrimidine-4-carboxamide
 915963-49-4P, 2-[(2-Furyl)methyl]amino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide
 915963-51-8P, 2-[(Butyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide
 915963-53-0P, N-Methyl-2-methylamino-6-phenylpyrimidine-4-carboxamide
 915963-55-2P, 2-[4-(Chlorophenyl)-4-hydroxy-1-piperidyl]-6-phenylpyrimidine-4-carboxamide
 915963-57-4P, 2-Ethylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide
 915963-59-6P, 6-(3,5-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915963-61-0P, 2-Diethylamino-6-(6-methoxy-3-pyridyl)pyrimidine-4-carboxamide
 915963-63-2P, 2-Diisobutylamino-6-phenylpyrimidine-4-carboxamide
 915963-65-4P, 6-(3-Furyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915963-67-6P, 2-[[2-(Furyl)methyl]amino]-6-(4-methoxyphenyl)pyrimidine-4-carboxamide
 915963-69-8P, 2-[(Methyl)(pentyl)amino]-6-phenylpyrimidine-4-carboxamide
 915963-71-2P, 6-(2,3-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide
 915963-73-4P, 3-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic acid isopropyl ester
 915963-75-6P, 6-(2,3-Difluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915963-77-8P, 2-(2,6-Dimethylmorpholin-4-yl)-6-phenylpyrimidine-4-carboxamide
 915963-79-0P, 2-(Azepan-1-yl)-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide
 915963-81-4P, 6-Phenyl-2-(pyrrolidin-1-yl)pyrimidine-4-carboxamide
 915963-83-6P, 6-(2,5-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915963-85-3P, 2-[4-Hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide

915963-87-9P, 6-(4-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915963-89-2P, 6-(2,5-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915963-91-6P, 6-(Benzothiophen-3-yl)-2-diethylaminopyrimidine-4-carboxamide 915963-93-8P, 2-[(Cyclopropylmethyl)amino]-6-phenylpyrimidine-4-carboxamide 915963-95-9P, 2-Diethylamino-6-(3-ethoxyphenyl)pyrimidine-4-carboxamide 915963-97-2P, 2-[(Allyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915963-99-4P, (2,5-Dihydro-1H-pyrrol-1-yl)[2-(2,5-dihydro-1H-pyrrol-1-yl)-6-phenylpyrimidin-4-yl]methanone 915964-61-1P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-03-3P, 2-Dibenzylamino-6-phenylpyrimidine-4-carboxamide 915964-05-5P, 2-[(Butyl)(ethyl)amino]-6-phenylpyrimidine-4-carboxamide 915964-07-7P, 6-(3-Fluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-09-9P, 2-Diethylamino-6-(3,5-difluorophenyl)pyrimidine-4-carboxamide 915964-11-3P, 6-(5-Isopropyl-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-13-5P, 2-Diethylamino-N-ethyl-6-phenylpyrimidine-4-carboxamide 915964-15-7P, 2-[(4-Carbamoyl-6-phenylpyrimidin-2-yl)methylamino]acetic acid ethyl ester 915964-17-9P, 2-[Ethyl(2-hydroxyethyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-19-1P, 2-Diethylamino-6-(2-fluorophenyl)pyrimidine-4-carboxamide 915964-21-5P, 2-(1-Piperidyl)-6-[2-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915964-23-7P, 2-[4-[(4-Methoxyphenyl)sulfonyl]piperazin-1-yl]-6-phenylpyrimidine-4-carboxamide 915964-25-9P 915964-27-1P, 6-(4-Ethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-29-3P, 2-Cyclopentylamino-6-phenylpyrimidine-4-carboxamide 915964-31-7P, 2-Dipropylamino-6-phenylpyrimidine-4-carboxamide 915964-33-9P, (2-Diethylamino-6-phenylpyrimidin-4-yl)(1-piperidyl)methanone 915964-36-2P, 2-Dimethylamino-6-phenylpyrimidine-4-carboxamide 915964-38-4P, 2-Diethylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-40-8P, 2-Diethylamino-6-(5-methyl-2-thienyl)pyrimidine-4-carboxamide 915964-42-0P, 2-Allylamino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-44-2P, 2-[1-(3,4-Dimethoxyphenyl)-cyclopentylmethyl]amino]-6-phenylpyrimidine-4-carboxamide 915964-46-4P, 2-Diethylamino-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915964-48-6P, 2-(Azepan-1-yl)-N-methyl-6-phenylpyrimidine-4-carboxamide 915964-50-0P, 2-(1-Piperidyl)-6-(p-tolyl)pyrimidine-4-carboxamide 915964-52-2P, 2-Diethylamino-6-(5-fluoro-2-methoxyphenyl)pyrimidine-4-carboxamide 915964-54-4P, 6-(3-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915964-56-6P, 2-[(Cyclopropylmethyl)amino]-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915964-58-8P, 2-Diethylamino-6-(4-isobutylphenyl)pyrimidine-4-carboxamide 915964-60-2P, 2-Diethylamino-6-(5-isopropyl-2-methoxyphenyl)pyrimidine-4-carboxamide 915964-62-4P, 6-Phenyl-2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915964-64-6P, 2-Diethylamino-6-(3,4-dimethylphenyl)pyrimidine-4-carboxamide 915964-67-9P, 6-(3-Chlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915964-69-1P, 2-Diethylamino-6-(3,4-dimethoxyphenyl)pyrimidine-4-carboxamide 915964-71-5P, 2-Diethylamino-6-[3-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915964-73-7P, 6-(3,4-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915964-75-9P, 6-(2-Methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915964-77-1P, 6-Phenyl-2-(1,2,3,4-

tetrahydroisoquinolin-2-yl)pyrimidine-4-carboxamide 915964-79-3P,
 2-Diethylamino-6-(m-tolyl)pyrimidine-4-carboxamide 915964-82-8P,
 6-(5-Chloro-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915964-84-0P, 2-Diethylamino-6-(2,5-dimethoxyphenyl)pyrimidine-4-
 carboxamide 915964-86-2P, 6-Phenyl-2-(4-propyl-1-
 piperidyl)pyrimidine-4-carboxamide 915964-88-4P,
 6-(4-Isopropylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915964-90-8P, 2-Dimethylamino-6-(3-methoxyphenyl)pyrimidine-4-
 carboxamide 915964-92-0P, 2-Diethylamino-6-(4-fluoro-3-
 methylphenyl)pyrimidine-4-carboxamide 915964-94-2P,
 2-Diethylamino-6-(p-tolyl)pyrimidine-4-carboxamide 915964-96-4P,
 N,N-Dimethyl-6-phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide
 915964-98-6P, 2-Diethylamino-6-[3-(hydroxymethyl)phenyl]pyrimidine-
 4-carboxamide 915965-00-3P, 2-Diethylamino-6-(4-
 ethylphenyl)pyrimidine-4-carboxamide 915965-02-5P,
 2-[Ethyl(2-hydroxyethyl)amino]-6-(2-methoxyphenyl)pyrimidine-4-carboxamide
 915965-04-7P, 6-Phenyl-2-(thiazolidin-3-yl)pyrimidine-4-
 carboxamide 915965-06-9P, 2-(1,2,3,4,4a,5,6,7,8,8a-
 Decahydroisoquinolin-2-yl)-6-phenylpyrimidine-4-carboxamide
 915965-08-1P, 6-(2-Fluoro-3-methoxyphenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915965-10-5P,
 2-[4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridin-1-yl]-6-phenylpyrimidine-4-
 carboxamide 915965-13-8P, 2-Allylamino-6-(4-
 methoxyphenyl)pyrimidine-4-carboxamide 915965-15-0P,
 2-[(2-Furyl)methyl]amino-N-methyl-6-phenylpyrimidine-4-carboxamide
 915965-17-2P, 2-Diethylamino-6-(2-phenoxyphenyl)pyrimidine-4-
 carboxamide 915965-19-4P, 6-(Benzo[thiophen-3-yl]-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915965-21-8P,
 2-[(Cyclopropylmethyl)(propyl)amino]-6-(2-methoxyphenyl)pyrimidine-4-
 carboxamide 915965-23-0P, 6-Phenyl-2-(1,4-thiazinan-4-
 yl)pyrimidine-4-carboxamide 915965-25-2P, 2-(1,4-Dioxo-8-
 azaspiro[4.5]decan-8-yl)-6-phenylpyrimidine-4-carboxamide
 915965-28-5P, 6-Phenyl-2-propylaminopyrimidine-4-carboxamide
 915965-30-9P, 6-(2,3-Dimethylphenyl)-2-(1-piperidyl)pyrimidine-4-
 carboxamide 915965-32-1P, 2-[(Methyl)(prop-2-ynyl)amino]-6-
 phenylpyrimidine-4-carboxamide 915965-34-3P,
 6-(2-Fluorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915965-36-5P, 2-[(2-Furyl)methyl](methyl)amino-6-
 phenylpyrimidine-4-carboxamide 915965-39-8P,
 6-(2,5-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide
 915965-41-2P, 3-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic
 acid methyl ester 915965-43-4P, 6-(3,5-Difluorophenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915965-45-6P,
 6-Phenyl-2-tert-butylaminopyrimidine-4-carboxamide 915965-47-8P,
 2-(1-Piperidyl)-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide
 915965-49-0P, 2-[(Benzyl)ethyl]amino-6-phenylpyrimidine-4-
 carboxamide 915965-51-4P, 6-(2,4-Dichlorophenyl)-2-(1-
 piperidyl)pyrimidine-4-carboxamide 915965-53-6P,
 2-[(2-Furyl)methyl]amino-6-phenylpyrimidine-4-carboxamide
 915965-55-8P, 6-(6-Methoxy-3-pyridyl)-2-(1-piperidyl)pyrimidine-4-
 carboxamide 915965-57-6P, 2-[Ethyl[2-(2-pyridyl)ethyl]amino]-6-
 phenylpyrimidine-4-carboxamide 915965-59-2P,
 2-[(2-Hydroxyethyl)[propyl]amino]-6-phenylpyrimidine-4-carboxamide
 915965-62-7P, 2-Diethylamino-6-(2,4-dimethoxypyrimidin-5-
 yl)pyrimidine-4-carboxamide 915965-64-9P, 6-(2-Ethoxyphenyl)-2-
 (1-piperidyl)pyrimidine-4-carboxamide 915965-66-1P,
 6-(3-Methoxyphenyl)-2-methylaminopyrimidine-4-carboxamide
 915965-68-3P, 2-(4-Cyano-4-phenyl-1-piperidyl)-6-phenylpyrimidine-
 4-carboxamide 915965-70-7P, 2-[3-(Diethylcarbamoyl)-1-piperidyl]-
 6-phenylpyrimidine-4-carboxamide 915965-72-9P,

2-Ethylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide
 915965-74-1P, 6-(3,4-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-75-2P, 6-(4-Cyanophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-76-3P, 2-(1-Piperidyl)-6-[3-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915965-77-4P, 2-[Ethyl(2-methylprop-2-enyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-78-5P, 2-[Bis(2-ethoxyethyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-79-6P, 2-Diethylamino-6-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915965-80-9P, 4-(6-Carbamoyl-2-diethylaminopyrimidin-4-yl)benzoic acid methyl ester 915965-81-0P, 6-(Benzothiophen-2-yl)-2-diethylaminopyrimidine-4-carboxamide 915965-82-1P, 6-(2-Phenoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-83-2P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide 915965-85-4P, 2-Diethylamino-6-(4-ethylsulfonylphenyl)pyrimidine-4-carboxamide 915965-86-5P, 6-(4-Methyl-2-thienyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-88-7P, 6-(4-Chlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915965-89-8P, 3-[6-Carbamoyl-2-(1-piperidyl)pyrimidin-4-yl]benzoic acid isopropyl ester 915965-91-2P, 2-Diethylamino-6-(4-ethoxyphenyl)pyrimidine-4-carboxamide 915965-93-4P, 2-Diethylamino-6-(2,3-dimethylphenyl)pyrimidine-4-carboxamide 915965-95-6P, 6-(m-Tolyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915965-97-8P, 2-(1-Piperidyl)-6-[2-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915965-98-9P, 2-[(Cyclopropylmethyl)(propyl)amino]-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide 915966-00-6P, 2-[(Ethyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-02-8P, 2-[4-(4-Fluorobenzoyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-04-0P, 2-Dibutylamino-6-phenylpyrimidine-4-carboxamide 915966-06-2P, 6-(4-Fluoro-3-methylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-08-4P, 2-Isopropylamino-6-phenylpyrimidine-4-carboxamide 915966-09-5P, 6-(5-Fluoro-2-methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-11-9P, 6-(3-Ethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-13-1P, 6-(3,4-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-15-3P, 2-[Methyl(3-pyridyl)methyl]amino]-6-phenylpyrimidine-4-carboxamide 915966-17-5P, 2-Diethylamino-6-(4-fluorophenyl)pyrimidine-4-carboxamide 915966-19-7P, 2-Diethylamino-6-(4-methyl-2-thienyl)pyrimidine-4-carboxamide 915966-21-1P, N-Methyl-6-phenyl-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-23-3P, 2-Diethylamino-6-(2-ethoxyphenyl)pyrimidine-4-carboxamide 915966-25-5P, 2-Isobutylamino-6-phenylpyrimidine-4-carboxamide 915966-27-7P, 2-Diisopentylamino-6-phenylpyrimidine-4-carboxamide 915966-29-9P, 2-[(Cyanomethyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-32-4P, 2-[4-(2-Hydroxyethyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-34-6P, 6-(3,5-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915966-36-8P, 2-[Ethyl(2-hydroxyethyl)amino]-N-methyl-6-phenylpyrimidine-4-carboxamide 915966-38-0P, 2-(4-Benzyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915966-40-4P, 2-Diethylamino-N,N-diethyl-6-phenylpyrimidine-4-carboxamide 915966-42-6P, 2-[(Benzyl)(butyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-44-8P, 2-[4-(4-Chlorobenzoyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-46-0P, 2-Diethylamino-6-(2,4-difluorophenyl)pyrimidine-4-carboxamide 915966-48-2P, 1-(4-Carbamoyl-6-phenylpyrimidin-2-yl)piperidine-3-carboxylic acid ethyl ester 915966-50-6P,

2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-phenylpyrimidine-4-carboxamide 915966-52-8P, 6-(2,3-Dichlorophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-53-6P, 6-(3-Methoxyphenyl)-2-[(prop-2-ynyl)amino]pyrimidine-4-carboxamide 915966-56-2P, 2-[3-(Hydroxymethyl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-58-4P, 2-Diethylamino-6-(4-isopropylphenyl)pyrimidine-4-carboxamide 915966-60-8P, 6-(3-Methoxyphenyl)-2-(3-methoxypropylamino)pyrimidine-4-carboxamide 915966-62-0P, 2-Diethylamino-N-methyl-6-phenylpyrimidine-4-carboxamide 915966-64-2P, 6-(3-Cyanophenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-66-4P, 6-(5-Chloro-2-methoxyphenyl)-2-diethylaminopyrimidine-4-carboxamide 915966-67-5P, 2-(4-Benzyl-4-hydroxy-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915966-68-6P, N-Benzyl-2-diethylamino-6-phenylpyrimidine-4-carboxamide 915966-69-7P, 2-[(Benzyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-70-0P, 2-Diethylamino-6-(3-fluorophenyl)pyrimidine-4-carboxamide 915966-71-1P, 1-(4-Carbamoyl-6-phenylpyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester 915966-72-2P, 2-(1H-Imidazol-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-73-3P, 2-(2,5-Dihydro-1H-pyrrol-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-74-4P, 2-(Azocan-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-75-5P, 6-(2,4-Dimethoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-76-6P, 2-Dimethylamino-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915966-77-7P, 2-(Azepan-1-yl)-6-(3-methoxyphenyl)pyrimidine-4-carboxamide 915966-78-8P, 2-[4-(2-Oxo-1,3-dihydrobenzimidazol-1-yl)-1-piperidyl]-6-phenylpyrimidine-4-carboxamide 915966-79-9P, 2-(1-Piperidyl)-6-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915966-80-2P, 2-Allylamino-6-(2-methoxyphenyl)pyrimidine-4-carboxamide 915966-81-3P, 2-[(Ethyl)(propyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-82-4P, 6-Phenyl-2-(1H-pyrazol-1-yl)pyrimidine-4-carboxamide 915966-83-5P, 2-Diallylamino-6-phenylpyrimidine-4-carboxamide 915966-84-6P, 2-[(Hexyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-85-7P, 2-Diethylamino-6-(2,4-dimethoxyphenyl)pyrimidine-4-carboxamide 915966-86-8P, 6-Phenyl-2-[(prop-2-ynyl)amino]pyrimidine-4-carboxamide 915966-87-9P, 2-(3-Methyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915966-88-0P, 2-(Azetidin-1-yl)-6-phenylpyrimidine-4-carboxamide 915966-89-1P, 2-(3,5-Dimethyl-1-piperidyl)-6-phenylpyrimidine-4-carboxamide 915966-90-4P, 2-[Butyl(cyanomethyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-91-5P, 6-(Benzo[thiophen-2-yl]-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-92-6P, 2-[(2-Hydroxy-2-phenylethyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-93-7P, 6-(2,4-Dichlorophenyl)-2-diethylaminopyrimidine-4-carboxamide 915966-94-8P, 2-[[1-(3,4-Dimethoxyphenyl)cyclopropyl]methyl]amino]-6-phenylpyrimidine-4-carboxamide 915966-95-9P, 2-[Butyl(2-hydroxyethyl)amino]-6-phenylpyrimidine-4-carboxamide 915966-96-0P, 6-(2-Methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915966-97-1P, 6-(3-Methoxyphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915966-98-2P, N-Methyl-6-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide 915966-99-3P, 2-[(Cyclopropylmethyl)amino]-6-(4-methoxyphenyl)pyrimidine-4-carboxamide 915967-00-9P, 2-Diethylamino-6-[4-(trifluoromethyl)phenyl]pyrimidine-4-carboxamide 915967-01-0P, 2-Diethylamino-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915967-02-1P, 2-[[2-(Furyl)methyl]amino]-N,N-

dimethyl-6-phenylpyrimidine-4-carboxamide 915967-03-2F,
 6-Phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)pyrimidine-4-carboxamide
 915967-04-3P, 2-[Ethyl(2-hydroxyethyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915967-05-4P, 2-[[2-(1H-Indol-3-
 yl)ethyl][methyl]amino]-6-phenylpyrimidine-4-carboxamide
 915967-06-5P, 6-(3-Acetylaminophenyl)-2-diethylaminopyrimidine-4-
 carboxamide 915967-07-6P, 2-Ethylamino-6-phenylpyrimidine-4-
 carboxamide 915967-08-7P, 2-[Bis(2-hydroxyethyl)amino]-6-(2-
 methoxyphenyl)pyrimidine-4-carboxamide 915967-09-8P,
 2-Diethylamino-N,N-dimethyl-6-phenylpyrimidine-4-carboxamide
 915967-10-1P, 2-Diethylamino-6-(2,5-difluorophenyl)pyrimidine-4-
 carboxamide 915967-11-2F 915967-12-3P,
 6-(3,4-Dimethylphenyl)-2-(1-piperidyl)pyrimidine-4-carboxamide
 915967-13-4P, 6-(Benzodioxol-5-yl)-2-(1-piperidyl)pyrimidine-4-
 carboxamide
 915967-14-5P, 2-Diethylamino-6-(o-tolyl)pyrimidine-4-carboxamide
 915967-15-6P, 2-[(Cyclopropylmethyl)(propyl)amino]-6-(4-
 methoxyphenyl)pyrimidine-4-carboxamide 915967-17-8P,
 2-[(Isopentyl)(methyl)amino]-6-phenylpyrimidine-4-carboxamide
 915967-18-9P, 2-[(Isobutyl)(methyl)amino]-6-phenylpyrimidine-4-
 carboxamide 915967-19-0P, 2-Diethylamino-6-(2,6-
 difluorophenyl)pyrimidine-4-carboxamide 915967-20-3P,
 6-(o-Tolyl)-2-(1-piperidyl)pyrimidine-4-carboxamide 915967-21-4P
 , 2-Amino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of 4-amino pyrimidine compds. as modulators of
 ATP-binding cassette transporters for treating disease)

- IT 5817-92-5P, 2,4-Dioxo-4-phenylbutanoic acid 6301-33-3P,
 6-Chloro-2-methylsulfanylpurimidine-4-carboxamide 6311-74-6P,
 6-Chloro-2-methylsulfanylpurimidine-4-carboxylic acid methyl ester
 6314-14-3P, 2-Methylsulfanyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid
 77664-74-5P, 2,4-Dioxo-4-(2-methoxyphenyl)butyric acid 915963-15-4P,
 6-(2-Methoxyphenyl)-2-(methylthio)pyrimidine-4-carboxylic acid
 915963-17-6P, 6-(2-Methoxyphenyl)-2-(methylthio)pyrimidine-4-
 carboxamide 915963-19-8P, 6-(2-Methoxyphenyl)-2-
 (methylsulfinyl)pyrimidine-4-carboxamide 915963-21-2P,
 6-(2-Methoxyphenyl)-2-(methylsulfonyl)pyrimidine-4-carboxamide
 915963-25-6P, 2-Methylsulfanyl-6-phenylpyrimidine-4-carboxylic acid
 915963-27-8P, 2-(Methylthio)-6-phenylpyrimidine-4-carboxamide
 915963-29-0P, 2-(Methylsulfonyl)-6-phenylpyrimidine-4-carboxamide
 915963-36-9P, 6-(2,6-Dimethoxyphenyl)-2-methylsulfanylpurimidine-4-
 carboxamide 915963-38-1P, 6-(2,6-Dimethoxyphenyl)-2-
 methylsulfanylpurimidine-4-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of 4-amino pyrimidine compds. as modulators of ATP-binding
 cassette transporters for treating disease)

L29 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1159256 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:471852

TITLE: Preparation of N-(4-pyrimidinylcarbonyl) amino acid
 piperazides and their use as P2Y12 receptor
 antagonists


INVENTOR(S): Caroff, Eva; Fretz, Heinz; Hilpert, Kurt; Houille,
 Olivier; Hubler, Francis; Meyer, Emmanuel

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd, Switz.


SOURCE: PCT Int. Appl., 381pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114774	A2	20061102	WO 2006-IB51318	20060427
WO 2006114774	A3	20070208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006241260 A1 20061102 AU 2006-241260 20060427 CA 2604967 A1 20061102 CA 2006-2604967 20060427 EP 1893634 A2 20080305 EP 2006-728064 20060427 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR MX 200713436 A 20080116 MX 2007-13436 20071026 CN 101166756 A 20080423 CN 2006-80014374 20071026 KR 2008004608 A 20080109 KR 2007-726652 20071116 NO 2007006094 A 20080125 NO 2007-6094 20071127 IN 2007CN05449 A 20080328 IN 2007-CN5449 20071128 PRIORITY APPLN. INFO.: WO 2005-EP4578 A 20050428 WO 2005-IB53711 A 20051110 WO 2006-IB51318 W 20060427 OTHER SOURCE(S): MARPAT 145:471852 ED Entered STN: 03 Nov 2006 GI				



I



II

- AB The invention relates to the preparation of title compds. I [R1 = (un)substituted Ph; W = a bond and R2 = CN, halo/alkoxy/heterocyclyl/cyclo/cycloalkyl/alkyl, hetero/aryl/, heterocyclyl, (partially) saturated heterocyclyl; (un)substituted hydroxyalkyl; W = CH2 and R2 = NR7R8, SR9, SO2R10; W = O, S, and R2 = alkoxy/heterocyclyl/carboxy/hydroxy/alkoxy/heterocyclyl/cyclo/ar/heteroaryl/alkyl, hetero/aryl; W = NH and derivs. and R2 = H, dialkylamino/alkoxy/heterocyclyl/hydroxy/alkoxy/cyclo/heterocyclyl/cycloalkyl/a r/diphenyl/heteroaryl/alkyl, aryl, 2-phenylcyclopropyl, COR11, SO2R12, (un)substituted carboxyalkyl; W = CH:CH and R2 = hydroxy/alkoxy/alkyl alkoxy/heterocyclyl, Ph, or CONR13R14; ; or W = C.tplbond.C and R2 = H, hydroxy/alkoxy/alkyl; or W = CO and R2 = alkyl; W = NR3 and NR2R3 = 4-7 membered heterocyclyl; or W = NR3 and NR2R3 = (un)substituted imidazolyl, pyrazolyl, 1,2,3-triazolyl, etc.; R5a, R5b = independently H, Me; R3 = H, alkyl; R7 aryl/alkyl; or NR7R8 = (un)substituted 4-7 membered heterocyclyl; R9 = cycloalkyl, aryl; R10 = cyclo/alkyl, aryl; R11 = alkoxy/alkyl, hetero/aryl, etc.; R12 = alkyl, aryl; R13, R14 = independently alkyl; X = CO and R6 = cyclo/alkyl, alk(ynyl)oxy, aryloxy, aralkoxy, hetero/aryl, aralkyl or NH2 and derivs.; or X = SO2 and R6 = alkyl; Y = a bond and Z = H, aryl substituted by carboxyalkoxy; or Y = alkoxy/Ph/alkoxyphenyl/alkylene, alkoxyphenylene and Z = H, OH, NH2, CO2H, tetrazolyl, CONH2, COOR17, NHCOR17, NHSO2R17; R17 = alkyl, as P2Y12 receptor antagonists. The invention also relates to the use of pyrimidines I and their stereoisomers, salts, solvent complexes and morphol. forms, in the treatment and/or prevention of peripheral vascular, visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases (no data) or conditions associated with platelet aggregation (no data), particularly thrombosis (no data). Thus, a multi-step synthesis starting from Z-L-Glu(Ot-Bu)-OH (Z = benzyloxycarbonyl) and 1-ethoxycarbonylpiperazine was given for amino acid piperazide II. In a P2Y12 binding assay, II had an IC50 = 117 nM.
- II 913948-93-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2,6-diphenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-94-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-(o-tolyl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-95-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-(m-tolyl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester


913948-96-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-97-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-98-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-11-8P 913949-15-2P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-92-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-83-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-08-9P, 4-[(S)-4-Carboxy-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-11-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-56-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-57-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-58-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-([1,2,4]triazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-59-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-60-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-61-8P, 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-63-6P 913951-69-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-71-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-84-5P 913951-87-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-03-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-04-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazines and their use as P2Y12 receptor antagonists)

RN 913948-93-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-94-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-95-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-96-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-97-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(3-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1-(1,1-dimethylethyl) ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-98-8 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(4-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1-(1,1-dimethylethyl) ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913949-11-8 HCAPLUS
 CN Benzoic acid, 4-[(2S)-2-[[[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 913949-15-2 HCAPLUS
 CN 1-Piperazinehexanoic acid, δ -[[[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- ϵ -oxo-, 1,1-dimethylethyl ester, (δS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-82-3 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-83-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-08-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(4-oxo-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-11-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(4-oxo-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-56-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-57-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-58-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-

phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-,
1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-59-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-60-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-61-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4-butyl-1H-1,2,3-triazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-63-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-69-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(3-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-70-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(4-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-71-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(2-thiazolyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-84-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-87-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-3-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-03-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-2-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-04-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-oxido-4-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 913947-86-1P, 4-[(S)-4-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-87-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-88-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-89-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-90-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-91-8P, 4-[(S)-4-Carboxy-2-[[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-04-6P, 4-[2-[[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913948-08-0P, 4-[(S)-2-[[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-11-5P 913948-15-9P, 4-[(S)-5-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-38-9P, 4-[(S)-4-Carboxy-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-39-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-10-4P 913950-30-8P 913950-31-9P, 4-[(S)-4-Carboxy-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-32-0P 913950-33-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-([1,2,4]triazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-34-2P 913950-35-3P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-36-4P, 4-[(S)-4-Carboxy-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-37-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-([1,2,3]triazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-38-6P, 4-[(S)-2-[[[6-(4-Butyl-1,2,3-triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
 913950-65-9P, 4-[(S)-4-Carboxy-2-[[[6-(4-oxo-4H-pyridin-1-yl)-2-phenylpyrimidin-4-

yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-66-0P, 4-[(S)-4-Carboxy-2-[[[6-(3-methyl-5-oxo-2,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-87-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-88-6P, 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-89-7P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylsulfonylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-90-6P, 4-[(S)-2-[[[6-(4-Acetylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-91-1P, 4-[(S)-4-Carboxy-2-[[[6-(2-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-92-2P, 4-[(S)-4-Carboxy-2-[[[6-(3-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-93-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-94-4P, 4-[(S)-4-Carboxy-2-[[[6-(4-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-95-5P, 4-[(S)-4-Carboxy-2-[[[6-(furan-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-96-6P, 4-[(S)-2-[[[6-(Benzodioxol-5-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-97-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-98-6P, 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxymethylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-99-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-00-5P, 4-[(S)-4-Carboxy-2-[[[6-(4-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-01-6P, 4-[(S)-4-Carboxy-2-[[[6-(3-chlorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-02-7P, 4-[(S)-2-[[[6-(Biphenyl-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-03-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(1H-pyrazol-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-05-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(3-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-06-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-07-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-08-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-22-1P, 4-[(S)-4-Carboxy-2-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-25-4P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-30-8P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-01-3P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

10/588757

ethyl ester 913952-20-2F, 4-[(S)-4-Carboxy-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazines and their use as P2Y12 receptor antagonists)

RN 913947-86-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-87-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-88-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-89-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-90-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-91-8 HCAPLUS


CN 1-Piperazinepentanoic acid, γ-[[[6-(4-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913948-04-6 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)



RN 913948-08-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-3-methyl-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-11-5 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-15-9 HCAPLUS

CN 1-Piperazinehexanoic acid, δ -[[[(2,6-diphenyl-4-pyrimidinyl)carbonylamino]-4-(ethoxycarbonyl)- δ -oxo-, (δS)- (CA INDEX NAME)]


Absolute stereochemistry.



RN 913949-38-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonylamino]- δ -oxo-, (γS)- (CA INDEX NAME)]


Absolute stereochemistry.



RN 913949-39-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]carbonylamino]-, (γS)- (CA INDEX NAME)]


Absolute stereochemistry.



RN 913950-10-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-hydroxy-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-30-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4,5-dihydro-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 913950-31-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-

oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-32-0 HCAPLUS


CN 1-Piperazinepentanoic acid, γ-[[[6-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-31-9

CMF C27 H33 N7 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 913950-33-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-34-2 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-33-1

CMF C25 H28 N8 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 913950-35-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-36-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-37-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-1,2,3-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-38-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4-butyl-1H-1,2,3-triazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-65-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(4-oxo-1(4H)-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-66-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-87-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(3-thienyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-88-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-89-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[4-(methylsulfonyl)phenyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-90-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4-acetylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-91-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-fluorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-92-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3-cyanophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-93-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-fluorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-94-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-95-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-furanyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-96-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(1,3-benzodioxol-5-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-97-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-98-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[4-(hydroxymethyl)phenyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-99-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(2-thienyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-00-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4-cyanophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-01-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(3-chlorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-02-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1,1'-biphenyl)-4-yl-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-03-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-pyrazol-4-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-05-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-06-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(3-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-07-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(4-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-08-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(2-thiazolyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-22-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-25-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-3-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-00-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-2-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-01-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-4-pyrimidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-17-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[2-(ethoxycarbonyl)-1-cyclohexen-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-19-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4,5-dihydro-3-furanyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 28, 63

IT 913946-66-4P 913946-67-5P 913946-68-6P, 4-[(S)-5-Carboxy-2-[[[6-

cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913946-71-1P 913946-72-2P, 4-[(S)-4-Carbamoyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-73-3P 913946-76-6P, 4-[(S)-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-hydroxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913947-30-5P 913947-34-9P 913948-20-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-21-7P 913948-22-8P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913948-23-9P, 4-[(S)-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-[(ethoxycarbonyl)methoxy]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-24-0P 913948-25-1P 913948-26-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-carboxymethoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-27-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-propoxypropyl-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-28-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(2-hydroxyethoxy)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-29-5P, 4-[(S)-2-[[[(6-(Benzyl)oxy)-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-30-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(cyclopropylmethoxy)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-31-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclohexyloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-32-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-isopropoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-33-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-methoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-34-2P, 4-[2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-[3-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-35-3P, 4-[2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-[2-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-36-4P, 4-[(S)-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-2-[4-[(ethoxycarbonyl)methoxy]phenyl]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913948-37-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester 913948-38-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester 913948-39-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester 913948-40-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2-dimethylpropyl ester 913948-41-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester 913948-42-2P 913948-43-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester 913948-44-4P 913948-45-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester 913948-46-6P 913948-47-7P, (S)-4-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-[(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid tert-butyl ester 913948-48-8P 913948-49-9P 913948-50-2P 913948-51-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-methylamino-2-phenylpyrimidin-4-

yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-52-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-propylamino]pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-53-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isopropylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-54-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-butylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-55-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isobutylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-56-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopropylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-57-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-58-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclohexylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-59-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(ethoxycarbonyl)methyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-60-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-61-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-62-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-63-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-tert-butoxycarbonyl)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-64-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-dimethylamino)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-65-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-dimethylamino)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-66-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-morpholin-4-yl)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-67-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-morpholin-4-yl)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-68-2P, 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-69-3P 913948-70-6P 913948-71-7P 913948-72-8P 913948-73-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenethylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-74-0P 913948-75-1P 913948-76-2P 913948-77-3P 913948-78-4P 913948-79-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(indan-2-yl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-80-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-dimethylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-81-9P, 4-[(S)-2-[[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-82-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-83-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-84-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(butyl)(methyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913948-85-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-86-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-87-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-methyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-88-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-isopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-89-7P, 4-[4-tert-Butoxycarbonyl-2-[[6-butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butyl]piperazine-1-carboxylic acid ethyl ester 913948-90-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-isobutyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-91-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-92-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-93-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-94-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[12-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-95-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[12-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-96-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[12-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-97-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-98-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-99-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-00-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(3-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-01-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(2-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-02-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(4-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-03-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(3-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-04-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(2-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-05-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-methyl-2-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-06-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-methyl-2-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-07-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-08-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-09-4P 913949-10-7P 913949-11-8P 913949-12-9P 913949-13-0P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-14-1P, 4-[(S)-2-[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-tert-butoxycarbonyl]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-15-2P, 4-[(S)-5-tert-Butoxycarbonyl-2-

[[(2,6-diphenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-16-3P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[6-cyclopropyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-66-3P 913949-67-4P 913949-68-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-[(isopropyl)(methyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-69-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-71-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-72-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-73-2P 913949-74-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-[(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-75-4P 913949-76-5P 913949-77-6P 913949-78-7P 913949-79-8P 913949-80-1P 913949-81-2P 913949-82-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-83-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-84-5P 913949-85-6P 913949-86-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-87-8P 913949-88-9P 913949-89-0P 913949-90-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-propylsulfanylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-91-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(isopropylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-92-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(cyclopentylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-93-6P 913949-94-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(cyclohexylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-95-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-[(ethoxycarbonyl)methyl]sulfanyl]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-96-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-[(2-ethoxycarbonyl)ethyl]sulfanyl]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-97-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-phenylsulfanylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-98-1P, 4-[(S)-2-[[6-(Benzylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(ethynyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-00-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-01-3P 913950-02-4P 913950-03-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-04-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(3-hydroxypropyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-05-7P 913950-06-8P 913950-07-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(3-hydroxy-3-methylbutyl)-2-

phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-08-6P, 4-[(S)-4-Carboxy-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-09-1P, 4-[(S)-4-Carboxy-2-[[[6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-11-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-12-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-47-0P 913951-48-1P 913951-49-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methoxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-50-5P 913951-51-6P 913951-52-7P 913951-53-8P 913951-54-9P 913951-55-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-56-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-57-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-58-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-[(1,2,4)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-59-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-60-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-61-8P, 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-62-9P, 4-[(S)-2-[[[6-Amino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-63-6P 913951-64-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(ethylsulfonylethyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-65-2P 913951-66-3P 913951-67-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(cyclopentylsulfanylmethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-68-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(cyclopentylsulfonylethyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-69-6P

, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-71-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-72-1P, 4-[(S)-2-[[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-73-2P 913951-74-3P 913951-75-4P 913951-76-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-77-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-78-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methoxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piper

azine-1-carboxylic acid ethyl ester 913951-79-8P 913951-80-1P
 913951-81-2P 913951-82-3P 913951-83-4P 913951-84-5P
 913951-85-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[12-phenyl-6-(
 (tetrahydropyran-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-86-7P 913951-87-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-
 4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913951-88-9P 913951-89-0P 913951-90-3P 913951-91-4P 913951-92-5P
 913951-93-6P 913951-94-7P 913951-95-8P 913951-96-9P 913951-97-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[12-phenyl-6-trifluoromethylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913951-98-1P, 4-[(S)-2-[[6-tert-Butyl-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-4-(tert-butyloxycarbonyl)butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-
 [[6-phenoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913952-03-1P, 4-[(S)-4-tert-
 Butoxycarbonyl-2-[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-04-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(1-oxopyridin-4-
 yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913952-05-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(2-
 hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913967-11-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid
 piperazides and their use as P2Y12 receptor antagonists)
 IT 913946-69-7P, 4-[2-[[6-Cyclopentylloxy-2-phenylpyrimidin-4-
 yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913946-70-0P, 4-[(S)-2-[[6-Cyclopentylloxy-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913946-74-4P, 4-[(S)-6-Amino-2-[[6-cyclopentylloxy-2-
 phenylpyrimidin-4-yl]carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid
 ethyl ester 913946-75-5P 913946-77-7P, 4-[(S)-2-[[6-Cyclopentylloxy-2-
 phenylpyrimidin-4-yl]carbonyl]amino]-5-hydroxypentanoyl]piperazine-1-
 carboxylic acid ethyl ester 913946-78-8P, 4-[(S)-2-[[6-Cyclopentylloxy-2-
 phenylpyrimidin-4-yl]carbonyl]amino]-6-hydroxyhexanoyl]piperazine-1-
 carboxylic acid ethyl ester 913946-79-9P 913946-80-2P 913946-81-3P
 913946-82-4P, 4-[(S)-4-(Carboxymethoxy)-2-[[6-cyclopentylloxy-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913946-83-5P 913946-84-6P, 4-[(S)-2-[[6-Cyclopentylloxy-2-
 phenylpyrimidin-4-yl]carbonyl]amino]-4-(1H-tetrazol-5-
 yl)butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-85-7P
 913946-86-8P 913946-87-9P 913946-88-0P, 4-[(S)-4-Carboxy-2-[[6-
 carboxymethoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913946-89-1P, 4-[(S)-4-Carboxy-2-[[12-phenyl-
 6-propoxypyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913946-90-4P, 4-[(S)-4-Carboxy-2-[[6-(2-hydroxyethoxy)-
 2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913946-91-5P, 4-[(S)-2-[[6-(Benzyl)oxy]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-
 carboxylic acid ethyl ester 913946-92-6P, 4-[(S)-4-Carboxy-2-[[6-
 (cyclopropylmethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piper-
 azine-1-carboxylic acid ethyl ester 913946-93-7P,
 4-[(S)-4-Carboxy-2-[[6-cyclohexyloxy-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913946-94-8P, 4-[(S)-4-Carboxy-2-[[6-isopropoxy-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913946-95-9P, 4-[(S)-4-Carboxy-2-[[6-methoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913946-96-0P, 4-[3-(3-Carboxymethoxyphenyl)-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913946-97-1P, 4-[3-(2-Carboxymethoxyphenyl)-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913946-98-2P, 4-[(S)-2-(4-Carboxymethoxyphenyl)-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester
 913946-99-3P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester
 913947-00-9P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester
 913947-01-0P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester
 913947-02-1P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2,2-dimethylpropyl ester
 913947-03-2P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester
 913947-04-3P, (S)-4-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-[4-[[furan-2-yl)carbonyl]piperazin-1-yl]-5-oxopentanoic acid
 913947-05-4P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester
 913947-06-5P, (S)-5-(4-Benzoylpiperazin-1-yl)-4-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxopentanoic acid
 913947-07-6P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester
 913947-08-7P, (S)-5-(4-Butyrylpiperazin-1-yl)-4-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxopentanoic acid
 913947-09-8P, (S)-4-[[6-(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-[(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid
 913947-10-1P 913947-11-2P 913947-12-3P
 913947-13-4P, 4-[(S)-4-Carboxy-2-[[6-(6-methylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-14-5P 913947-15-6P, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-propylaminopyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-16-7P 913947-17-8P, 4-[(S)-4-Carboxy-2-[[6-(6-isopropylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-22-5P 913947-23-6P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopropylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-24-7P 913947-25-8P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclopentylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-26-9P 913947-27-0P, 4-[(S)-4-Carboxy-2-[[6-(6-cyclohexylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-28-1P 913947-29-2P, 4-[(S)-4-Carboxy-2-[[6-[[ethoxycarbonyl)methyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-31-6P 913947-32-7P 913947-33-8P, 4-[(S)-4-Carboxy-2-[[6-[[2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-35-0P 913947-36-1P 913947-37-2P, 4-[(S)-4-Carboxy-2-[[6-[[3-carboxypropyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-38-3P 913947-39-4P, 4-[(S)-4-Carboxy-2-[[6-[[2-dimethylaminoethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-40-7P 913947-41-8P, 4-[(S)-4-Carboxy-2-[[[6-[[3-(dimethylaminopropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-42-9P 913947-43-0P, 4-[(S)-4-Carboxy-2-[[[6-[[2-(morpholin-4-yl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-44-1P 913947-45-2P, 4-[(S)-4-Carboxy-2-[[[6-[[3-(morpholin-4-yl)propyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-46-3P 913947-47-4P, 4-[(S)-2-[[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-48-5P 913947-49-6P 913947-50-9P 913947-51-0P 913947-52-1P 913947-53-2P 913947-54-3P 913947-55-4P, 4-[(S)-4-Carboxy-2-[[[6-phenethylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-56-5P 913947-57-6P 913947-58-7P 913947-59-8P 913947-60-1P 913947-61-2P 913947-62-3P 913947-63-4P 913947-64-5P 913947-65-6P, 4-[(S)-4-Carboxy-2-[[[6-[(indan-2-yl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-66-7P 913947-67-8P, 4-[(S)-4-Carboxy-2-[[[6-(dimethylamino)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-68-9P 913947-69-0P, 4-[(S)-2-[[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-70-3P 913947-71-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-72-5P 913947-73-6P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-74-7P 913947-75-8P, 4-[(S)-2-[[[6-(Butyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-76-9P 913947-77-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-78-1P 913947-79-2P, 4-[(S)-4-Carboxy-2-[[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-80-5P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-81-6P, 4-[(S)-4-Carboxy-2-[[[6-isopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-82-7P, 4-[(S)-2-[[[6-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-83-8P, 4-[(S)-4-Carboxy-2-[[[6-isobutyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-84-9P, 4-[(S)-4-Carboxy-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-85-0P, 4-[(S)-4-Carboxy-2-[[[6-cyclopentyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-86-1P, 4-[(S)-4-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-87-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-88-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-89-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-90-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-91-8P, 4-[(S)-4-Carboxy-2-[[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913947-92-9P, 4-[(S)-4-Carboxy-2-[[[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-93-0P, 4-[(S)-4-Carboxy-2-[[[2-(3-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-94-1P, 4-[(S)-4-Carboxy-2-[[[2-(2-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-95-2P, 4-[(S)-4-Carboxy-2-[[[2-(4-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-96-3P, 4-[(S)-4-Carboxy-2-[[[2-(3-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-97-4P, 4-[(S)-4-Carboxy-2-[[[2-(2-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-98-5P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913947-99-6P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-00-2P, 4-[(S)-4-Carboxy-2-[[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-01-3P, 4-[(S)-4-Carboxy-2-[[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-02-4P, 4-[2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913948-03-5P, 4-[2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913948-04-6P, 4-[2-[[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913948-05-7P, 4-[2-[[[6-Cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
 913948-06-8P, 4-[(S)-2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-07-9P, 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-08-0P, 4-[(S)-2-[[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-09-1P 913948-10-4P 913948-11-5P 913948-12-6P
 913948-13-7P, 4-[(S)-5-Carboxy-2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-14-8P, 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-carboxypentanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-15-9P, 4-[(S)-5-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-16-0P, 4-[(S)-5-Carboxy-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
 913948-17-1P 913948-18-2P 913948-19-3P 913949-17-4P 913949-18-5P
 913949-19-6P, 4-[(S)-4-Carboxy-2-[[[6-[(Isopropyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-20-9P 913949-21-0P, 4-[(S)-4-Carboxy-2-[[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-22-1P 913949-23-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-24-3P 913949-25-4P 913949-26-5P, 4-[(S)-4-Carboxy-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester dihydrochloride
 913949-27-6P
 913949-28-7P, 4-[(S)-4-Carboxy-2-[[[6-[(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913949-29-8P 913949-30-1P 913949-31-2P 913949-32-3P
 913949-33-4P 913949-34-5P 913949-35-6P 913949-36-7P 913949-37-8P
 913949-38-9P, 4-[(S)-4-Carboxy-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913945-39-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-40-3P 913949-41-4P 913949-42-5P, 4-[(S)-4-Carboxy-2-[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-43-6P 913949-44-7P 913949-45-8P 913949-46-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-propylsulfanylpiperidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-47-0P, 4-[(S)-4-Carboxy-2-[[[6-isopropylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-48-1P, 4-[(S)-4-Carboxy-2-[[[6-cyclopentylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-49-2P 913949-50-5P, 4-[(S)-4-Carboxy-2-[[[6-cyclohexylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-51-6P, 4-[(S)-4-Carboxy-2-[[[6-[(ethoxycarbonyl)methyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-52-7P, 4-[(S)-4-Carboxy-2-[[[6-(2-ethoxycarbonylethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-53-8P, 4-[(S)-4-Carboxy-2-[[[6-(carboxymethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-54-9P, 4-[(S)-4-Carboxy-2-[[[6-[(2-carboxyethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-55-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylsulfanylpiperidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-56-1P, 4-[(S)-2-[[[6-Benzylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913949-57-2P, 4-[(S)-4-Carboxy-2-[[[6-ethynyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-58-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-59-4P 913949-60-7P 913949-61-8P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-62-9P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxypropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-63-0P 913949-64-1P 913949-65-2P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methylbutyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-10-4P 913950-13-7P 913950-14-8P 913950-15-9P 913950-16-0P 913950-17-1P, 4-[(S)-4-Carboxy-2-[[[6-(4-methoxyppiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-18-2P 913950-19-3P 913950-20-6P 913950-21-7P 913950-22-8P 913950-23-9P 913950-24-0P 913950-25-1P 913950-26-2P 913950-27-3P 913950-28-4P 913950-29-5P 913950-30-8P 913950-31-9P, 4-[(S)-4-Carboxy-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-32-0P 913950-33-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,4)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-34-2P 913950-35-3P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-36-4P, 4-[(S)-4-Carboxy-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-37-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,3)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-38-6P, 4-[(S)-2-[[[6-(4-Butyl-1,2,3)triazol-

zine-1-carboxylic acid ethyl ester 913950-67-1P 913950-68-2P
 913950-69-3P, 4-[(S)-2-[[[6-[(Benzyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-70-6P, 4-[(S)-4-Carboxy-2-[[[6-[(4-ethoxycarbonylpiperidin-1-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-71-7P 913950-72-8P, 4-[(S)-4-Carboxy-2-[[[6-[(4-methoxycarbonylpiperidin-1-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-73-9P 913950-74-0P 913950-75-1P, 4-[(S)-4-Carboxy-2-[[[6-[(morpholin-4-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-76-2P 913950-77-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(piperidin-1-yl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-78-4P 913950-79-5P, 4-[(S)-4-Carboxy-2-[[[6-[(ethyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-80-8P, 4-[(S)-4-Carboxy-2-[[[6-diethylaminomethyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-81-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(pyrrolidin-1-yl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-82-0P, 4-[(S)-4-Carboxy-2-[[[6-(ethylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-83-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(phenylsulfonyl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-84-2P, 4-[(S)-2-[[[6-[(Phenyl)sulfonyl]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-85-3P, 4-[(S)-4-Carboxy-2-[[[6-(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-86-4P, 4-[(S)-4-Carboxy-2-[[[6-(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-87-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-88-6P, 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-89-7P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylsulfonylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-90-9P, 4-[(S)-2-[[[6-(4-Acetylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-91-1P, 4-[(S)-4-Carboxy-2-[[[6-(2-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-92-2P, 4-[(S)-4-Carboxy-2-[[[6-(3-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-93-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-94-4P, 4-[(S)-4-Carboxy-2-[[[6-(4-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-95-5P, 4-[(S)-4-Carboxy-2-[[[6-(furan-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-96-6P, 4-[(S)-2-[[[6-(Benzodioxol-5-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-97-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-98-8P, 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxymethylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913950-99-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-00-5P, 4-[(S)-4-Carboxy-2-[[[6-(4-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-01-6P, 4-[(S)-4-Carboxy-2-[[[6-(3-chlorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-02-7P, 4-[(S)-2-[[[6-(Biphenyl-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-03-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(1H-pyrazol-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-04-9P 913951-05-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(3-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-06-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-07-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-08-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-09-4P, 4-[(S)-2-[[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-10-7P 913951-11-8P 913951-12-9P 913951-13-0P, 4-[(S)-4-Carboxy-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-14-1P, 4-[(S)-4-(Ethoxycarbonyl)-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-15-2P, 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-16-3P, 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-17-4P 913951-18-5P 913951-19-6P 913951-20-9P 913951-21-0P 913951-22-1P, 4-[(S)-4-Carboxy-2-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-23-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(tetrahydropyran-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-24-3P 913951-25-4P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-26-5P 913951-27-6P 913951-28-7P 913951-29-8P 913951-30-1P 913951-31-2P 913951-32-3P, 4-[(S)-4-Carboxy-2-[[[6-(cyano-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-33-4P 913951-34-5P 913951-35-6P 913951-36-7P 913951-37-8P, 4-[(S)-4-Carboxy-2-[[[6-(ethoxymethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-38-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(trifluoromethylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-39-0P, 4-[(S)-2-[[[6-(tert-Butyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-40-3P, 4-[(S)-4-Carboxy-2-[[[6-(phenoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-41-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-3-yl)oxy]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-42-5P, (S)-5-[4-(tert-Butylcarbamoyl)piperazin-1-yl]-4-[[[6-(cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxopentanoic acid 913951-43-6P, (S)-4-[[[6-(Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-[4-(isopropylcarbamoyl)piperazin-1-yl]-5-oxopentanoic acid 913951-44-7P, (S)-4-[[[6-(Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-(thien-2-

yl)carbonyl]piperazin-1-yl]pentanoic acid 913951-45-8P,
 (S)-5-[4-(Cyclopentylcarbonyl)piperazin-1-yl]-4-[[6-(cyclopentyloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxopentanoic acid 913951-46-9P,
 (S)-4-[[[6-(Cyclopentyloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-[(piperidin-1-yl)carbonyl]piperazin-1-yl]pentanoic acid
 913952-00-8P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-01-9P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-02-0P, 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-06-4P 913952-07-5P 913952-08-6P 913952-09-7P,
 4-[(S)-4-Carboxy-2-[[[6-[(carboxymethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-10-0P, 4-[(S)-4-Carboxy-2-[[[6-[(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-11-1P, 4-[(S)-4-Carboxy-2-[[[6-[(2-carboxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-12-2P, 4-[(S)-4-Carboxy-2-[[[6-[(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-13-3P 913952-14-4P
 913952-15-5P 913952-16-6P, 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-17-7P, 4-[(S)-4-Carboxy-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-18-8P 913952-19-9P, 4-[(S)-4-Carboxy-2-[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-20-2P, 4-[(S)-4-Carboxy-2-[[[6-(4,5-dihydroprazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-38-5P 913967-10-9P 913967-12-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)
 IT 3282-30-2P, Pivaloyl chloride 13514-79-9P, 6-Methyl-2-phenylpyrimidin-4-ol 13754-38-6P, (Phenyl)(piperazin-1-yl)methanone 24779-45-1P, trans-2,5-Dimethylpiperazine-1-carboxylic acid ethyl ester 26531-82-8P, (S)-Amino(4-hydroxyphenyl)ethanoic acid methyl ester 29509-92-0P, 4-Chloro-6-methyl-2-phenylpyrimidine 50606-33-2P 73955-54-1P, 6-Methyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 81925-29-3P, 3-(Tributylstannanyl)prop-2-en-1-ol 84477-85-0P, 3-Methylpiperazine-1-carboxylic acid benzyl ester 85815-04-9P, 6-Methoxy-2-phenylpyrimidine-4-carboxylic acid 89581-58-8P, 2-Chloro-6-methylpyrimidine-4-carboxylic acid 90152-49-1P, 3-Methylpiperazine-1-carboxylic acid ethyl ester 120737-73-7P, 2-Methylpiperazine-1-carboxylic acid ethyl ester 122135-83-5P, 2-[(Trifluoromethylsulfonyl)oxy]cyclohex-1-ene-1-carboxylic acid ethyl ester 123334-59-8P, 3-(3-Benzyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid 123593-66-8P, (S)-(4-Benzyloxyphenyl)-tert-butoxycarbonylaminoethanoic acid 162536-44-9P, 2-Amino-3-(3-hydroxyphenyl)propionic acid methyl ester 170011-47-9P, Trifluoromethanesulfonic acid 1,4-dioxaspiro[4.5]dec-7-en-8-yl ester 179187-31-6P, 2-[(tert-Butoxycarbonyl)amino]-3-(2-hydroxyphenyl)propionic acid methyl ester 188975-30-6P, Trifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester 209535-63-7P, 4-Methyl-2-phenyl-6-trifluoromethylpyrimidine 225517-15-7P, (S)-(tert-Butoxycarbonylamino)(4-hydroxyphenyl)ethanoic acid methyl ester 282100-79-2P, 2-[(tert-Butoxycarbonyl)amino]-3-(3-hydroxyphenyl)propionic acid methyl

ester 325685-59-4P, 4-Chloro-6-(methoxymethyl)-2-phenylpyrimidine
 325685-75-4P, (6-Chloro-2-phenylpyrimidin-4-yl)methanol 339278-89-6P,
 6-Methoxymethyl-2-phenylpyrimidin-4-ol 359821-46-8P,
 4-(2-Aminoacetyl)piperazine-1-carboxylic acid ethyl ester 361547-56-0P,
 3-[(tert-Butyldimethylsilyl)oxy]-2,2-dimethylpropionic acid methyl ester
 368424-88-8P, 4-Benzoylpiperazine-1-carboxylic acid benzyl ester
 528602-18-8P, 3-[(tert-Butyldimethylsilyl)oxy]-2,2-dimethylpropionic
 acid 710335-28-7P, 4-((S)-2-Amino-4-tert-butoxycarbonylbutanoyl)piperazi
 ne-1-carboxylic acid ethyl ester 710335-29-8P, 4-[(S)-2-
 [(Benzoyloxycarbonyl)amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-
 carboxylic acid ethyl ester 757168-92-6P, 2-Amino-3-(2-
 hydroxyphenyl)propionic acid methyl ester 856840-41-0P,
 1-(Piperazin-1-yl)butan-1-one hydrochloride 858269-17-7P,
 6-Methyl-2-phenylpyrimidine-4-carboxylic acid 859525-60-3P,
 1-[(Propan-1-yl)sulfonyl]piperazine hydrochloride 907951-69-3P,
 (S)-(4-Benzyloxyphenyl)(tert-butoxycarbonylamino)ethanoic acid methyl
 ester 913952-21-3P, 4-Cyclopentyl-6-(methoxymethyl)-2-
 phenylpyrimidine 913952-22-4P, (6-Cyclopentyl-2-phenylpyrimidin-4-
 yl)methanol 913952-23-5P, 6-Cyclopentyl-2-phenylpyrimidine-4-
 carboxaldehyde 913952-24-6P, 6-Cyclopentyl-2-phenylpyrimidine-4-
 carboxylic acid 913952-25-7P 913952-26-8P 913952-27-9P,
 4-[(S)-2-[(Benzoyloxycarbonyl)amino]-5-tert-butoxycarbonylpentanoyl]piperaz
 ine-1-carboxylic acid ethyl ester 913952-28-0P,
 4-((S)-2-Amino-5-tert-butoxycarbonylpentanoyl)piperazine-1-carboxylic acid
 ethyl ester 913952-29-1P, 4-[2-(Benzoyloxycarbonylamino)acetyl]piperazine-
 1-carboxylic acid ethyl ester 913952-30-4P, 4-[(S)-2-[(tert-
 Butoxycarbonyl)amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913952-31-5P, 4-((S)-2-Amino-3-methylbutanoyl)piperazine-1-
 carboxylic acid ethyl ester hydrochloride 913952-32-6P 913952-33-7P
 913952-34-8P, 4-[(S)-2-[(tert-Butoxycarbonyl)amino]-4-
 carbamoylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913952-35-9P,
 4-((S)-2-Amino-4-carbamoylbutanoyl)piperazine-1-carboxylic acid ethyl
 ester hydrochloride 913952-36-0P 913952-37-1P 913952-38-2P
 913952-39-3P, 4-[(S)-6-[(Benzoyloxycarbonyl)amino]-2-[(tert-
 butoxycarbonyl)amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-40-6P, 4-[(S)-2-Amino-6-[(benzyloxycarbonyl)amino]hexanoyl]piperazi
 ne-1-carboxylic acid ethyl ester hydrochloride 913952-41-7P,
 4-[(S)-6-[(Benzoyloxycarbonyl)amino]-2-[[6-(cyclopentyl-2-
 phenylpyrimidin-4-yl)carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid
 ethyl ester 913952-42-8P 913952-43-9P 913952-44-0P 913952-45-1P
 913952-46-2P, 4-[(S)-4-Cyano-2-[[6-(cyclopentyl-2-phenylpyrimidin-4-
 yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-47-3P 913952-48-4P 913952-49-5P 913952-50-8P 913952-51-9P
 913952-52-0P 913952-53-1P 913952-54-2P 913952-55-3P 913952-56-4P,
 [(6-Methyl-2-phenylpyrimidin-4-yl)oxy]acetic acid methyl ester
 913952-57-5P, 6-[(Methoxycarbonyl)methoxy]-2-phenylpyrimidine-4-carboxylic
 acid 913952-58-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-
 [(methoxycarbonyl)methoxy]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-59-7P, 6-Chloro-2-phenylpyrimidine-4-carboxylic acid
 913952-60-0P, 2-Phenyl-6-propoxypyrimidine-4-carboxylic acid
 913952-61-1P, 6-(2-Hydroxyethoxy)-2-phenylpyrimidine-4-carboxylic acid
 913952-62-2P, 6-Benzyloxy-2-phenylpyrimidine-4-carboxylic acid
 913952-63-3P, 6-Cyclopropylmethoxy-2-phenylpyrimidine-4-carboxylic acid
 913952-64-4P, 6-Cyclohexyloxy-2-phenylpyrimidine-4-carboxylic acid
 913952-65-5P, 6-Isopropoxy-2-phenylpyrimidine-4-carboxylic acid
 913952-66-6P, 3-(3-Benzyloxyphenyl)-2-1-(tert-butoxycarbonyl)amino]propioni
 c acid methyl ester 913952-67-7P, 4-[3-(3-Benzyloxyphenyl)-2-1-(tert-
 butoxycarbonyl)amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913952-68-8P, 4-[2-Amino-3-(3-benzyloxyphenyl)propionyl]piperazine-1-

carboxylic acid ethyl ester hydrochloride 913952-69-9P,
 4-[3-(3-Benzoyloxyphenyl)-2-[[6-(cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913952-70-2P, 4-[2-[[6-(Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-(3-hydroxyphenyl)propionyl]piperazine-1-carboxylic acid ethyl ester 913952-71-3P, 3-(2-Benzoyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid methyl ester 913952-72-4P,
 3-(2-Benzoyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid 913952-73-5P, 4-[3-(2-Benzoyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionyl]piperazine-1-carboxylic acid ethyl ester 913952-74-6P, 4-[2-Amino-3-(2-Benzoyloxyphenyl)propionyl]piperazine-1-carboxylic acid ethyl ester hydrochloride 913952-75-7P 913952-76-8P,
 4-[2-[[6-(Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-(2-hydroxyphenyl)propionyl]piperazine-1-carboxylic acid ethyl ester 913952-77-9P, 4-[(S)-2-(4-Benzoyloxyphenyl)-2-(tert-butoxycarbonyl)amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913952-78-0P, 4-[(S)-2-Amino-2-(4-benzoyloxyphenyl)ethanoyl]piperazine-1-carboxylic acid ethyl ester hydrochloride 913952-79-1P,
 4-[(S)-2-(4-Benzoyloxyphenyl)-2-[[6-(cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913952-80-4P, 4-[(S)-2-[[6-(Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-2-(4-hydroxyphenyl)ethanoyl]piperazine-1-carboxylic acid ethyl ester 913952-81-5P 913952-82-6P 913952-83-7P
 913952-84-8P 913952-85-9P, 4-Butyrylpiperazine-1-carboxylic acid tert-butyl ester 913952-86-0P, 4-[(Propan-1-yl)sulfonyl]piperazine-1-carboxylic acid tert-butyl ester 913952-87-1P 913952-88-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-89-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-chloro-6-methylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-90-6P, 4-[2-[[6-(Chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester 913952-91-7P, 4-[(S)-2-[[6-(Chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913952-92-8P
 913952-93-9P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[6-(chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913952-94-0P 913952-95-1P 913952-96-2P 913952-97-3P 913952-98-4P
 913952-99-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-00-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(1,4-dioxaspiro[4.5]decan-8-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-01-2P, 4-[(S)-4-Carboxy-2-[[6-(chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-02-3P, 4-[(S)-2-[[6-(Azido-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913953-03-4P 913953-04-5P 913953-05-6P 913953-06-7P,
 6-Formyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-07-8P,
 6-Hydroxymethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-08-9P, 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-09-0P, 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid 913953-10-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(chloromethyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-11-4P 913953-12-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-vinylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-14-7P 913953-15-8P 913953-16-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(2-oxopropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-17-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(2-

ethoxycarbonylcyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-18-1P 913953-19-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydrofuran-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-20-5P, 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-21-6P, 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid 913953-22-7P, 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-23-8P, 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid 913953-24-9P, 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-25-0P, 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid 913953-26-1P, 6-(2-Hydroxy-2-phenylethyl)-2-phenylpyrimidine-4-carboxylic acid 913953-27-2P, 2-Phenyl-6-trifluoromethylpyrimidine-4-carboxylic acid 913953-28-3P, Acetic acid 5,5-dimethyl-4-oxo-2-hexynyl ester 913953-29-4P, Acetic acid 6-tert-butyl-2-phenylpyrimidin-4-ylmethyl ester 913953-30-7P, (6-tert-Butyl-2-phenylpyrimidin-4-yl)methanol 913953-31-8P, 6-tert-Butyl-2-phenylpyrimidine-4-carboxylic acid 913953-32-9P, Acetic acid 6-[(tert-butyl)dimethylsilyl]oxy]-5,5-dimethyl-4-oxo-2-hexynyl ester 913953-33-0P, Acetic acid [6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-ylmethyl ester 913953-34-1P, [6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-ylmethyl ester 913953-35-2P, 6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidine-4-carboxylic acid 913953-36-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-37-4P, [2-(Tributylstannanyl)cyclopropyl]methanol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)

L29 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:976769 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:356777

TITLE: Benzazole derivatives and their preparation, compositions, and methods of use as β -secretase inhibitors

INVENTOR(S): Mjalli, Adnan M.; Jones, David; Gohimmukkula, Devi Reddy; Huang, Guoxiang; Zhu, Jeff; Rao, Mohan; Andrews, Robert C.; Ren, Tan

PATENT ASSIGNEE(S): Transtech Pharma, Inc., USA

SOURCE: PCT Int. Appl., 268pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006099379	A2	20060921	WO 2006-US9049	20060314
WO 2006099379	A3	20070614		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 AU 2006223070 A1 20060921 AU 2006-223070 20060314
 CA 2600570 A1 20060921 CA 2006-2600570 20060314
 US 20060223849 A1 20061005 US 2006-374723 20060314
 EP 1863771 A2 20071212 EP 2006-738139 20060314
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 MX 200711234 A 20071112 MX 2007-11234 20070913
 CN 101142194 A 20080312 CN 2006-80008417 20070914
 PRIORITY APPLN. INFO.: US 2005-661349P P 20050314
 WO 2006-US9049 W 20060314
 OTHER SOURCE(S): MARPAT 145:356777
 ED Entered STN: 21 Sep 2006
 GI



I



II

AB The invention is directed to benzazole compds. of formula I that inhibit β -site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which BACE is involved. Compds. of formula I wherein A is O, S, and NH and derivs.; L1, L6, and L7 are independently CH₂, O, NH and derivs., CO, CONH and derivs., NHCO and derivs., NHCONH and derivs., NHCO₂ and derivs., NHSO₂ and derivs., etc.; Q1 and Q6 are independently a bond, alkylene, alkenylene, and alkynylene; G1 is heterocyclylene, cycloalkylene, heterocyclylene, (hetero)arylene, fused arylcycloalkylene, etc.; G6 is H, heterocyclyl, cycloalkyl, (hetero)aryl, fused arylcycloalkyl, fused cycloalkyl(hetero)aryl, etc.; R1 - R4 are independently H, NH₂, carboxy, CN, halo, NO₂, OH, alkyl, (alkylene)aryl, etc.; and their pharmaceutically acceptable salts, esters, and prodrugs thereof are claimed. Example compound II was prepared by amidation of 2,3-diaminobenzoic acid Me ester with isoquinoline-3-carboxylic acid; the resulting 2-amino-3-

[[isoquinoline-3- carbonyl]amino]benzoic acid Me ester underwent cyclization to give 2-(isoquinolin-3-yl)-1H-benzimidazole-4-carboxylic acid Me ester, which underwent hydrolysis to give the corresponding benzimidazole-4-carboxylic acid, which underwent amidation with 4-phenyl-1H-imidazol-2-ylamine to give compound II. All the invention compds. were evaluated for their β -secretase inhibitory activity. Several example compds. exhibited EC50 values of less than or equal to 2.0 μ M.


IT 910121-39-0P 910121-40-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzazole derivs. as β -secretase inhibitors useful in treatment and prevention of diseases)


RN 910121-39-0 HCAPLUS

CN 1H-Benzimidazole-7-carboxamide, N-1H-imidazol-2-yl-2-[[6-phenyl-pyrimidinyl]carbonyl]amino]- (CA INDEX NAME)



RN 910121-40-3 HCAPLUS

CN 1H-Benzimidazole-7-carboxamide, 2-[[[6-(4-fluorophenyl)-4-pyrimidinyl]carbonyl]amino]-N-1H-imidazol-2-yl- (CA INDEX NAME)



CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT	910119-76-5P	910119-77-6P	910119-78-7P	910119-80-1P	910119-82-3P
	910119-84-5P	910119-85-6P	910119-86-7P	910119-87-8P	910119-88-9P
	910119-89-0P	910119-90-3P	910119-91-4P	910119-92-5P	910119-93-6P
	910119-94-7P	910119-95-8P	910119-96-9P	910119-97-0P	910119-98-1P
	910119-99-2P	910120-00-2P	910120-01-3P	910120-02-4P	910120-03-5P
	910120-04-6P	910120-08-0P	910120-09-1P	910120-10-4P	910120-11-5P
	910120-12-6P	910120-13-7P	910120-14-8P	910120-15-9P	910120-16-0P
	910120-17-1P	910120-18-2P	910120-19-3P	910120-20-6P	910120-21-7P

910120-22-8P	910120-23-9P	910120-24-0P	910120-25-1P	910120-26-2P
910120-27-3P	910120-28-4P	910120-29-5P	910120-30-8P	910120-31-9P
910120-32-0P	910120-33-1P	910120-34-2P	910120-35-3P	910120-36-4P
910120-37-5P	910120-38-6P	910120-39-7P	910120-40-0P	910120-41-1P
910120-42-2P	910120-43-3P	910120-44-4P	910120-45-5P	910120-46-6P
910120-47-7P	910120-48-8P	910120-49-9P	910120-50-2P	910120-51-3P
910120-52-4P	910120-53-5P	910120-54-6P	910120-55-7P	910120-56-8P
910120-57-9P	910120-58-0P	910120-59-1P	910120-60-4P	910120-61-5P
910120-62-6P	910120-63-7P	910120-64-8P	910120-65-9P	910120-66-0P
910120-67-1P	910120-68-2P	910120-69-3P	910120-70-6P	910120-71-7P
910120-72-8P	910120-73-9P	910120-74-0P	910120-75-1P	910120-76-2P
910120-77-3P	910120-78-4P	910120-79-5P	910120-80-8P	910120-81-9P
910120-82-0P	910120-83-1P	910120-84-2P	910120-85-3P	910120-86-4P
910120-87-5P	910120-88-6P	910120-89-7P	910120-90-0P	910120-91-1P
910120-92-2P	910120-93-3P	910120-94-4P	910120-95-5P	910120-96-6P
910120-97-7P	910120-98-8P	910120-99-9P	910121-00-5P	910121-01-6P
910121-02-7P	910121-03-8P	910121-04-9P	910121-05-0P	910121-06-1P
910121-07-2P	910121-08-3P	910121-09-4P	910121-10-7P	910121-11-8P
910121-12-9P	910121-13-0P	910121-14-1P	910121-15-2P	910121-16-3P
910121-17-4P	910121-18-5P	910121-19-6P	910121-20-9P	910121-21-0P
910121-22-1P	910121-23-2P	910121-24-3P	910121-25-4P	910121-26-5P
910121-27-6P	910121-28-7P	910121-29-8P	910121-30-1P	910121-31-2P
910121-32-3P	910121-33-4P	910121-34-5P	910121-35-6P	910121-36-7P
910121-37-8P	910121-38-9P	910121-39-0P	910121-40-3P	
910121-41-4P	910121-42-5P	910121-43-6P	910121-44-7P	910121-45-8P
910121-46-9P	910121-47-0P	910121-48-1P	910121-50-5P	910121-51-6P
910121-52-7P	910121-53-8P	910121-54-9P	910121-55-0P	910121-56-1P
910121-57-2P	910121-58-3P	910121-59-4P	910121-60-7P	910121-61-8P
910121-62-9P	910121-63-0P	910121-64-1P	910121-65-2P	910121-66-3P
910121-67-4P	910121-68-5P	910121-69-6P	910121-70-9P	910121-71-0P
910121-72-1P	910121-73-2P	910121-74-3P	910121-75-4P	910121-76-5P
910121-77-6P	910121-78-7P	910121-79-8P	910121-80-1P	910121-81-2P
910121-83-4P	910121-84-5P	910121-85-6P	910121-86-7P	910121-87-8P
910121-88-9P	910121-89-0P	910121-91-4P	910121-93-6P	910121-94-7P
910121-96-9P	910121-97-0P	910121-98-1P	910121-99-2P	910122-00-8P
910122-01-9P	910122-02-0P	910122-03-1P	910122-04-2P	910122-05-3P
910122-07-5P	910122-08-6P	910122-09-7P	910122-10-0P	910122-11-1P
910122-12-2P	910122-13-3P	910122-15-5P	910122-17-7P	910122-18-8P
910122-19-9P	910122-20-2P	910122-21-3P	910122-22-4P	910122-23-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzazole derivs. as β -secretase inhibitors useful in treatment and prevention of diseases)

L29 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:817369 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:249516

TITLE: Preparation of peptide boronic acids as proteasome inhibitors

INVENTOR(S): Oliva, Ambrogio; Bernardini, Raffaella; D'Arasmo, Germano; Cassara, Paolo G.; Bernareggi, Alberto; Menta, Ernesto

PATENT ASSIGNEE(S): Cephalon, Inc., USA

SOURCE: PCT Int. Appl., 15pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006086600	A1	20060817	WO 2006-US4664	20060210
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060189806	A1	20060824	US 2006-351193	20060209
AU 2006213814	A1	20060817	AU 2006-213814	20060210
CA 2597273	A1	20060817	CA 2006-2597273	20060210
EP 1846424	A1	20071024	EP 2006-734698	20060210
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2007KN02726	A	20070831	IN 2007-KN2726	20070724
MX 200709664	A	20070926	MX 2007-9664	20070809
CN 101120006	A	20080206	CN 2006-80004689	20070813
PRIORITY APPLN. INFO.:			US 2005-652370P	P 20050211
			US 2006-351193	A 20060209
			WO 2006-US4664	W 20060210

OTHER SOURCE(S): MARPAT 145:249516

ED Entered STN: 17 Aug 2006

GI



AB The invention provides peptide boronic acid derivs. Hy-CONHCHR2CONHCH(CH2CHMe2)B(OR)2 [R1 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or may combine to form a ring; R2 is CHMeOH or aminomethyl; Hy is an optionally-substituted nitrogen-containing heterocyclic group optionally fused with an aryl or heteroaryl group (with provisos)] that can modulate apoptosis by inhibition of proteasome activity and are for use in treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity. Thus, compound I was prepared by a multistep sequence starting with reaction of (+)-pinanediol with 2-methylpropylboronic acid, conversion of the product to a leucine boronate analog, and subsequent acylations by Boc-protected L-threonine and 6-phenyl-2-pyrazinecarboxylic acid.

IT 966089-78-9P 986090-34-4P 906090-67-3P

906090-92-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide boronic acids as proteasome inhibitors)

RN 906089-78-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl]-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 906090-34-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-1-[(4-methylbenzoyl)amino]methyl]-2-oxoethyl]-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 906090-67-3 HCAPLUS

CN Boronic acid, B-[(1R)-1-[[[(2S,3R)-3-hydroxy-1-oxo-2-[[[(6-phenyl-4-pyrimidinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 906090-92-4 HCAPLUS

CN Boronic acid, B-[(1R)-3-methyl-1-[[[(2S)-3-[(4-methylbenzoyl)amino]-1-oxo-2-[[[(6-phenyl-4-pyrimidinyl)carbonyl]amino]propyl]amino]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7, 29, 63

IT 906089-58-5P 906089-60-9P 906089-61-0P 906089-62-1P 906089-63-2P
 906089-64-3P 906089-65-4P 906089-67-6P 906089-68-7P 906089-69-8P
 906089-70-1P 906089-71-2P 906089-73-4P 906089-74-5P 906089-76-7P
 906089-78-9P 906089-80-3P 906089-82-5P 906089-84-7P
 906089-86-9P 906089-88-1P 906089-90-5P 906089-92-7P 906089-95-0P
 906089-97-2P 906089-99-4P 906090-00-4P 906090-03-7P 906090-05-9P
 906090-07-1P 906090-10-6P 906090-13-9P 906090-16-2P 906090-19-5P
 906090-22-0P 906090-24-2P 906090-27-5P 906090-28-6P 906090-30-0P
 906090-32-2P 906090-34-4P 906090-36-6P 906090-38-8P
 906090-41-3P 906090-44-6P 906090-46-8P 906090-49-1P 906090-51-5P
 906090-52-6P 906090-53-7P 906090-54-8P 906090-55-9P 906090-56-0P
 906090-57-1P 906090-58-2P 906090-59-3P 906090-60-6P 906090-61-7P
 906090-62-8P 906090-63-9P 906090-64-0P 906090-65-1P 906090-66-2P
 906090-67-3P 906090-68-4P 906090-69-5P 906090-70-8P
 906090-71-9P 906090-72-0P 906090-73-1P 906090-74-2P 906090-75-3P
 906090-76-4P 906090-77-5P 906090-78-6P 906090-79-7P 906090-80-0P
 906090-81-1P 906090-82-2P 906090-83-3P 906090-84-4P 906090-85-5P
 906090-86-6P 906090-87-7P 906090-88-8P 906090-89-9P 906090-90-2P
 906090-91-3P 906090-92-4P 906090-93-5P 906090-94-6P
 906090-95-7P 906090-96-8P 906090-98-0P 906090-99-1P 906091-00-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)



(preparation of peptide boronic acids as proteasome inhibitors)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:796732 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 145:211069
 TITLE: Preparation of phenyl-substituted pyrimidines as kinase inhibitors for treating an inflammatory disorder and/or cancer
 INVENTOR(S): Wrobelski, Stephen T.; Lin, Shuqun; Leftheris, Katerina; He, Liqi; Seitz, Steven, P.; Lin, Tai-An; Vaccaro, Wayne
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 216pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084017	A2	20060810	WO 2006-US3659	20060202
WO 2006084017	A3	20061214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060178388	A1	20060810	US 2006-344881	20060201
EP 1848714	A2	20071031	EP 2006-734200	20060202
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2005-650077P	P 20050204
			US 2006-344881	A 20060201
			WO 2006-US3659	W 20060202

OTHER SOURCE(S): MARPAT 145:211069
 ED Entered STN: 11 Aug 2006
 GI



II

AB The title compds. I [two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is CR1; R1 = H, CN; n = 0-3; R2 = alkyl, cycloalkyl, alkenyl, etc.; G = (un)substituted monocyclic 5-6 membered heteroaryl; Z = H, alkyl, cycloalkyl, etc.; with provisos], useful for inhibiting p38 kinase, LIM kinase 1, and/or LIM kinase 2 (no specific data given), were prepared E.g., a multi-step synthesis of II, starting from n-propylthiourea, was given. Also disclosed are pharmaceutical compns. containing compds. I, and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

IT 905300-63-2P 905300-64-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM

kinases

inhibitors for treating an inflammatory disorder and cancer)


RN 905300-63-2 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(2-chlorophenyl)-2-(2-pyridinyl)-, 2-[[1-(1-methylethyl)amino]carbonyl]hydrazide (CA INDEX NAME)



RN 905300-64-3 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(2-chlorophenyl)-2-(2-pyridinyl)-, 2-[[1-(1-methylethyl)amino]thioxomethyl]hydrazide (CA INDEX NAME)



CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT	201294-64-6P	405939-39-1P	635283-90-8P	905300-33-6P	905300-34-7P
	905300-35-8P	905300-36-9P	905300-37-0P	905300-38-1P	905300-39-2P
	905300-40-5P	905300-41-6P	905300-42-7P	905300-43-8P	905300-44-9P
	905300-45-0P	905300-46-1P	905300-47-2P	905300-48-3P	905300-49-4P
	905300-50-7P	905300-51-8P	905300-52-9P	905300-53-0P	905300-54-1P
	905300-55-2P	905300-56-3P	905300-57-4P	905300-58-5P	905300-59-6P
	905300-60-9P	905300-61-0P	905300-62-1P	905300-63-2P	
	905300-64-3P	905300-65-4P	905300-66-5P	905300-67-6P	

905300-68-7P 905300-69-8P 905300-70-1P 905300-71-2P 905300-72-3P
 905300-73-4P 905300-74-5P 905300-75-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM
 kinases
 inhibitors for treating an inflammatory disorder and cancer)

L29 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:577803 HCAPLUS Full-text

DOCUMENT NUMBER: 145:62687

TITLE: Preparation of N-acylantranilic acid derivatives or
 salts thereof as inhibitor for production of matrix
 metalloproteinase (MMP-13)

INVENTOR(S): Yokotani, Junichi; Taniguchi, Yoichi; Hara, Eiichi;
 Akitsu, Hitoshi; Tada, Yukie

PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006062093	A1	20060615	WO 2005-JP22367	20051206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005312721	A1	20060615	AU 2005-312721	20051206
CA 2588633	A1	20060615	CA 2005-2588633	20051206
EP 1820795	A1	20070822	EP 2005-814561	20051206
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101094829	A	20071226	CN 2005-80045781	20051206
IN 2007KN01796	A	20070810	IN 2007-KN1796	20070521
NO 2007002605	A	20070905	NO 2007-2605	20070524
MX 200706790	A	20070815	MX 2007-6790	20070607
KR 2007100888	A	20071012	KR 2007-715347	20070704
PRIORITY APPLN. INFO.:			JP 2004-353725	A 20041207
			WO 2005-JP22367	W 20051206


OTHER SOURCE(S): MARPAT 145:62687

ED Entered STN: 16 Jun 2006


GI




- AB The title compds. [I; wherein R1 = H, a carboxy-protecting group; R2 = each (un)substituted Ph, cycloalkyl, or heterocyclic group; R3 = each (un)substituted Ph, cycloalkyl, cycloalkenyl, or monocyclic or bicyclic heterocyclic group; X1 = CO or SO2; X2 = a bond, each (un)substituted alkylene, alkenylene, or alkynylene; X3 = O, S, a bond; X4 = -X5-X6- or -X6-X5- (the left side bond is linked to R3) (wherein X5 = O, S, (un)protected NH, SO, SO2, a bond; X6 = each (un)substituted alkylene, alkenylene, or alkynylene)] or salts thereof are prepared. These compds. have an MMP-13 production inhibitory activity and are hence useful as therapeutic agents for articular rheumatism, osteoarthritis, cancer, etc. Thus, Me 2-(benzoylamino)-4-bromobenzoate was coupled with benzofuran-2-boronic acid in the presence of polymer-supported Bis(acetato)bis(triphenylphosphine)palladium and Na2CO3 in N,N-dimethylacetamide at 90° for 11 h followed by saponification and acidification with 1.0 M aqueous HCl solution to give 2-(benzoylamino)-4-(3-methoxyphenyl)benzoic acid (II). II and 2-(benzoylamino)-4-((E)-2-(3-chlorophenyl)vinyl)benzoic acid inhibited the IL-1 β -stimulated production of MMP-13 in human cartilage-derived SW1353 cells by 95 and 99%, resp., at 30 μ M.
- IT 890313-33-4P, 4-Phenyl-2-[[6-phenylpyrimidin-4-yl)carbonyl]amino]benzoic acid 890313-58-3P, 4-Phenoxy-2-[[6-phenylpyrimidin-4-yl)carbonyl]amino]benzoic acid 890314-22-4P, 4-Phenethyl-2-[[6-phenylpyrimidin-4-yl)carbonyl]amino]benzoic acid
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (preparation of N-acylanthranilic acid derivs. as inhibitors for production of matrix metalloproteinase (MMP-13))
- RN 890313-33-4 HCAPLUS
- CN [1,1'-Biphenyl]-4-carboxylic acid, 3-[[6-phenyl-4-pyrimidinyl)carbonyl]amino]- (CA INDEX NAME)



- RN 890313-58-3 HCAPLUS
- CN Benzoic acid, 4-phenoxy-2-[[6-phenyl-4-pyrimidinyl)carbonyl]amino]- (CA INDEX NAME)



RN 890314-22-4 HCAPLUS
 CN Benzoic acid, 4-(2-phenylethyl)-2-[(6-phenyl-4-pyrimidinyl)carbonyl]amino]- (CA INDEX NAME)



CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 IT 890312-31-9P, 2-(2,3-Dimethylbenzoylamino)-4-phenethylbenzoic acid
 890312-32-0P, 2-(3-Nitrobenzoylamino)-4-phenethylbenzoic acid
 890312-33-1P, 4-Phenethyl-2-[4-(trifluoromethyl)benzoylamino]benzoic acid
 890312-34-2P, 2-[(Benzo[b]thien-2-yl)carbonyl]amino]-4-phenethylbenzoic acid
 890312-35-3P, 2-(2-Fluorobenzoylamino)-4-phenethylbenzoic acid
 890312-36-4P, 2-(3-Fluorobenzoylamino)-4-phenethylbenzoic acid
 890312-37-5P, 2-(2,6-Difluorobenzoylamino)-4-phenethylbenzoic acid
 890312-38-6P, 4-Phenethyl-2-[3-(trifluoromethyl)benzoylamino]benzoic acid
 890312-39-7P, 2-(2-Chlorobenzoylamino)-4-phenethylbenzoic acid
 890312-40-0P, 2-(3-Chlorobenzoylamino)-4-phenethylbenzoic acid
 890312-41-1P, 2-(4-Chlorobenzoylamino)-4-phenethylbenzoic acid
 890312-42-2P, 2-[2,4-Bis(trifluoromethyl)benzoylamino]-4-phenethylbenzoic acid
 890312-43-3P, 2-(2,4-Dichlorobenzoylamino)-4-phenethylbenzoic acid
 890312-45-5P, 4-Phenethyl-2-[(E)-3-(pyridin-4-yl)-2-propenoyl]amino]benzoic acid trifluoroacetate 890312-46-6P,
 4-Phenethyl-2-[[[5-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890312-47-7P, 4-Phenethyl-2-[[[2-(pyrrolidin-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890312-48-8P, 2-(4-Aminobenzoylamino)-4-phenethylbenzoic acid 890312-50-2P, 2-(2,6-Dichlorobenzoylamino)-4-phenethylbenzoic acid 890312-51-3P, 2-(2,6-Dichlorobenzoylamino)-4-phenylbenzoic acid 890312-52-4P, 2-(2,6-Dichlorobenzoylamino)-4-phenoxybenzoic acid 890312-53-5P, 2-(2-Fluorobenzoylamino)-4-phenylbenzoic acid 890312-54-6P, 2-(3-Fluorobenzoylamino)-4-phenylbenzoic acid 890312-55-7P, 2-(4-Fluorobenzoylamino)-4-phenylbenzoic acid 890312-56-8P, 2-(2,4-Difluorobenzoylamino)-4-phenylbenzoic acid 890312-57-9P, 2-(2,6-Difluorobenzoylamino)-4-phenylbenzoic acid 890312-58-0P, 2-(2-Methylbenzoylamino)-4-phenylbenzoic acid 890312-59-1P, 2-(3-Methylbenzoylamino)-4-phenylbenzoic acid 890312-60-4P, 2-(4-Methylbenzoylamino)-4-phenylbenzoic acid 890312-61-5P, 4-Phenyl-2-[2-(trifluoromethyl)benzoylamino]benzoic acid 890312-62-6P, 4-Phenyl-2-[3-(trifluoromethyl)benzoylamino]benzoic acid 890312-63-7P,

4-Phenyl-2-[4-(trifluoromethyl)benzoylamino]benzoic acid 890312-64-8P,
 3,4-Dimethylbenzoylamino]-4-phenylbenzoic acid 890312-65-9P,
 2-(2,3-Dimethylbenzoylamino)-4-phenylbenzoic acid 890312-66-0P,
 2-[(6-Morpholinopyridin-3-yl)carbonyl]amino]-4-phenylbenzoic acid
 890312-67-1P, 2-[(Cyclohexylcarbonyl)amino]-4-phenylbenzoic acid
 890312-68-2P, 4-Phenyl-2-(2-phenylacetylaminobenzoic acid 890312-69-3P,
 2-(Cinnamoylamino)-4-phenylbenzoic acid 890312-70-6P,
 2-(2-Phenoxyacetylaminobenzoic acid 890312-71-7P,
 2-(Furan-2-ylcarbonylamino)-4-phenylbenzoic acid 890312-72-8P,
 4-Phenyl-2-[(thien-2-yl)carbonyl]amino]benzoic acid 890312-73-9P,
 2-(Benzodioxol-5-ylcarbonylamino)-4-phenylbenzoic acid 890312-74-0P,
 2-[[2,3-Dihydrobenzo[1,4]dioxin-6-yl)carbonyl]amino]-4-phenylbenzoic acid
 890312-75-1P, 2-[(Benzo[b]thien-5-yl)carbonyl]amino]-4-phenylbenzoic acid
 890312-76-2P, 2-[(1-Methyl-1H-benzotriazol-5-yl)carbonyl]amino]-4-
 phenylbenzoic acid 890312-78-4P, 2-[(Benzofuran-5-yl)carbonyl]amino]-4-
 phenylbenzoic acid 890312-79-5P, 2-[(Benzothiazol-2-yl)carbonyl]amino]-
 4-phenylbenzoic acid 890312-80-8P, 2-[(Benzo[b]thien-3-
 yl)carbonyl]amino]-4-phenylbenzoic acid 890312-81-9P,
 2-[(Benzofuran-2-yl)carbonyl]amino]-4-phenylbenzoic acid 890312-82-0P,
 2-[(Benzo[b]thien-2-yl)carbonyl]amino]-4-phenylbenzoic acid
 890312-83-1P, 4-Phenyl-2-[(1-phenyl-1H-pyrazol-5-
 yl)carbonyl]amino]benzoic acid 890312-84-2P, 2-(2,2-Diphenylacetylaminobenzoic acid 890312-85-3P, 2-(2-Chlorobenzoylamino)-4-
 phenylbenzoic acid 890312-86-4P, 2-(3-Chlorobenzoylamino)-4-
 phenylbenzoic acid 890312-87-5P, 2-(4-Chlorobenzoylamino)-4-
 phenylbenzoic acid 890312-88-6P, 2-(2,4-Dichlorobenzoylamino)-4-
 phenylbenzoic acid 890312-89-7P, 4-Phenyl-2-[2,4-
 bis(trifluoromethyl)benzoylamino]benzoic acid 890312-90-0P,
 4-Phenyl-2-(3-phenylpropanoylamino)benzoic acid 890312-91-1P,
 4-Phenoxy-2-[[16-(piperidin-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid
 890312-92-2P, 2-(2-Fluorobenzoylamino)-4-phenoxybenzoic acid
 890312-93-3P, 4-Phenoxy-2-[2-(trifluoromethyl)benzoylamino]benzoic acid
 890312-94-4P, 4-Phenoxy-2-[4-(trifluoromethyl)benzoylamino]benzoic acid
 890312-95-5P, 2-(2-Methylbenzoylamino)-4-phenoxybenzoic acid
 890312-96-6P, 2-(3-Methylbenzoylamino)-4-phenoxybenzoic acid
 890312-97-7P, 2-(4-Methylbenzoylamino)-4-phenoxybenzoic acid
 890312-99-9P, 2-(3,4-Dimethylbenzoylamino)-4-phenoxybenzoic acid
 890313-00-5P, 2-(2,3-Dimethylbenzoylamino)-4-phenoxybenzoic acid
 890313-01-6P, 2-[(6-Morpholinopyridin-3-yl)carbonyl]amino]-4-
 phenoxybenzoic acid 890313-02-7P, 4-Phenoxy-2-(2-
 phenylacetylaminobenzoic acid 890313-03-8P,
 2-(3-Fluorobenzoylamino)-4-phenoxybenzoic acid 890313-04-9P,
 2-(2,6-Difluorobenzoylamino)-4-phenoxybenzoic acid 890313-05-0P,
 4-Phenoxy-2-[3-(trifluoromethyl)benzoylamino]benzoic acid 890313-06-1P,
 2-(3-Nitrobenzoylamino)-4-phenoxybenzoic acid 890313-07-2P,
 2-(2-Chlorobenzoylamino)-4-phenoxybenzoic acid 890313-08-3P,
 2-(3-Chlorobenzoylamino)-4-phenoxybenzoic acid 890313-09-4P,
 2-(4-Chlorobenzoylamino)-4-phenoxybenzoic acid 890313-12-9P,
 2-(2,4-Dichlorobenzoylamino)-4-phenoxybenzoic acid 890313-15-2P,
 2-[(Benzo[b]thien-5-yl)carbonyl]amino]-4-phenoxybenzoic acid
 890313-16-3P, 2-[(Benzo[b]thien-2-yl)carbonyl]amino]-4-phenoxybenzoic
 acid 890313-19-6P, 4-Phenoxy-2-[[1-phenyl-1H-pyrazol-5-
 yl)carbonyl]amino]benzoic acid 890313-22-1P, 4-Phenoxy-2-[2,4-
 bis(trifluoromethyl)benzoylamino]benzoic acid 890313-23-2P,
 4-Phenoxy-2-(3-phenylpropanoylamino)benzoic acid 890313-25-4P,
 (E)-2-[[3-(3,4-Dimethoxyphenyl)-2-propenoyl]amino]-4-phenylbenzoic acid
 890313-28-7P, 4-Phenyl-2-[(E)-3-(pyridin-4-yl)-2-propenoyl]amino]benzoic
 acid trifluoroacetate 890313-29-8P, 2-[(3-Methylpyridin-2-
 yl)carbonyl]amino]-4-phenylbenzoic acid 890313-31-2P,
 4-Phenyl-2-(3-phenyl-2-propynoylamino)benzoic acid 890313-33-4P,

4-Phenyl-2-[[[6-phenylpyrimidin-4-yl]carbonyl]amino]benzoic acid
 890313-34-5P 890313-35-6P 890313-37-8P, 4-Phenyl-2-[[[3-phenylisoxazol-5-yl]carbonyl]amino]benzoic acid 890313-39-0P, 2-(4-Acetoxybenzoylamino)-4-phenylbenzoic acid 890313-40-3P, 2-[[[(E)-3-(4-Acetoxyphenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-41-4P, 2-[[[(E)-3-(3-Methoxyphenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-42-5P, 2-[[[(E)-3-(4-Chlorophenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-43-6P, 2-[[[(E)-3-(3-Chlorophenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-44-7P, 2-[[[(E)-3-(3,4-Dichlorophenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-45-8P, 2-[[[(E)-3-(Benzodioxol-5-yl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-46-9P, 4-Phenyl-2-[[[(E)-3-(thiophen-2-yl)-2-propenoyl]amino]benzoic acid 890313-47-0P, 2-(4-Morpholinobenzoylamino)-4-phenylbenzoic acid 890313-48-1P, 2-[[[2-(4-Nitrophenyl)acetyl]amino]-4-phenylbenzoic acid 890313-49-2P, 2-[[[(E)-3-(3-Nitrophenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-50-5P, 2-[[[(E)-3-(4-Nitrophenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-51-6P, 4-Phenyl-2-(4-phenylbutanoylamino)benzoic acid 890313-52-7P, 4-Phenyl-2-((E)-4-phenyl-3-butenoylamino)benzoic acid 890313-53-8P, 4-Phenyl-2-[[[6-(piperidin-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890313-54-9P, (E)-2-[[[3-(3,4-Dimethoxyphenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-56-1P, 4-Phenoxy-2-[[[(E)-3-(pyridin-4-yl)-2-propenoyl]amino]benzoic acid trifluoroacetate 890313-57-2P, 4-Phenoxy-2-[[[5-(thiophen-2-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890313-58-3P, 4-Phenoxy-2-[[[6-phenylpyrimidin-4-yl]carbonyl]amino]benzoic acid 890313-59-4P 890313-60-7P 890313-61-8P, 4-Phenoxy-2-[[[3-phenylisoxazol-5-yl]carbonyl]amino]benzoic acid 890313-63-0P, 2-(2-Hydroxybenzoylamino)-4-phenoxybenzoic acid 890313-64-1P, 2-(4-Acetoxybenzoylamino)-4-phenoxybenzoic acid 890313-65-2P, 2-[[[(E)-3-(3-Methoxyphenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-66-3P, 2-[[[(E)-3-(4-Chlorophenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-67-4P, 2-[[[(E)-3-(3-Chlorophenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-68-5P, 2-[[[(E)-3-(3,4-Dichlorophenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-69-6P, 2-[[[(E)-3-(Benzodioxol-5-yl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-70-9P, 4-Phenoxy-2-[[[(E)-3-(thiophen-2-yl)-2-propenoyl]amino]benzoic acid 890313-71-0P, 2-(4-Morpholinobenzoylamino)-4-phenoxybenzoic acid 890313-72-1P, 2-[[[2-(4-Nitrophenyl)acetyl]amino]-4-phenoxybenzoic acid 890313-74-3P, 4-Phenoxy-2-[[[5-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890313-75-4P, 4-Phenyl-2-[3-(1H-pyrrol-1-yl)benzoylamino]benzoic acid 890313-76-5P, 4-Phenyl-2-[[[5-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890313-77-6P, 4-Phenyl-2-[[[2-(pyrrolidin-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890313-78-7P, 4-Phenyl-2-[[[(E)-2-phenylethynyl]sulfonylamino]benzoic acid 890313-79-8P, 2-(Benzylsulfonylamino)-4-phenylbenzoic acid 890313-80-1P, 2-(3-Bromobenzoylamino)-4-phenylbenzoic acid 890313-81-2P, 4-Phenoxy-2-[[[(E)-2-phenylethynyl]sulfonylamino]benzoic acid 890313-82-3P, 2-[[[(E)-3-(4-Acetoxyphenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890313-83-4P, 2-(2-Hydroxybenzoylamino)-4-phenylbenzoic acid 890313-84-5P, 2-(3-Hydroxybenzoylamino)-4-phenylbenzoic acid 890313-85-6P, 2-(4-Hydroxybenzoylamino)-4-phenylbenzoic acid 890313-86-7P, 2-[[[(E)-3-(4-Hydroxyphenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-87-8P, 2-(3-Hydroxybenzoylamino)-4-phenoxybenzoic acid 890313-88-9P, 2-(4-Hydroxybenzoylamino)-4-phenoxybenzoic acid 890313-89-0P, 2-[[[(E)-3-(4-Hydroxyphenyl)-2-propenoyl]amino]-4-phenylbenzoic acid 890313-93-6P, tert-Butyl 2-(benzoylamino)-4-(1H-indol-1-yl)benzoate 890313-94-7P, tert-Butyl 2-(benzoylamino)-4-(3,4-dimethoxyphenyl)benzoate 890313-95-8P, 2-(Benzoylamino)-4-(1H-pyrrol-1-yl)benzoic acid

890313-96-9P, 2-(Benzoylamino)-4-(1H-indol-1-yl)benzoic acid
 890313-97-0P, 2-(Benzoylamino)-4-(3,4-dimethoxyphenyl)benzoic acid
 890314-01-9P, 2-(Benzoylamino)-4-(1H-benzimidazol-1-yl)benzoic acid
 hydrochloride 890314-02-0P, 2-(Benzoylamino)-4-(3-chloro-4-fluorophenyl)benzoic acid 890314-03-1P, 2-(Benzoylamino)-4-(3,4-difluorophenyl)benzoic acid 890314-04-2P, 2-(Benzoylamino)-4-(2,5-difluorophenyl)benzoic acid 890314-05-3P, 2-(Benzoylamino)-4-(2,4-dichlorophenyl)benzoic acid 890314-06-4P, 2-(Benzoylamino)-4-(4-fluoro-2-methylphenyl)benzoic acid 890314-07-5P, 2-(Benzoylamino)-4-(2-trifluoromethoxyphenyl)benzoic acid 890314-08-6P, 2-(Benzoylamino)-4-(3,4-dimethylphenyl)benzoic acid 890314-09-7P, 2-(Benzoylamino)-4-(3-chloro-4-methoxyphenyl)benzoic acid 890314-10-0P, 2-(Benzoylamino)-4-(2,3-dichlorophenyl)benzoic acid 890314-11-1P, 2-(Benzoylamino)-4-(2,5-dichlorophenyl)benzoic acid 890314-12-2P, 2-(Benzoylamino)-4-(3-chloro-4-methylphenyl)benzoic acid 890314-13-3P, 2-(Benzoylamino)-4-(3-chloro-2-methylphenyl)benzoic acid 890314-14-4P, 2-(Benzoylamino)-4-(5-chloro-2-methylphenyl)benzoic acid 890314-15-5P, 2-(Benzoylamino)-4-(5-chloro-2-methoxyphenyl)benzoic acid 890314-16-6P, 2-(3,5-Dichlorobenzoylamino)-4-phenethylbenzoic acid 890314-17-7P, 2-(3,4-Dichlorobenzoylamino)-4-phenethylbenzoic acid 890314-18-8P, 2-(3,5-Difluorobenzoylamino)-4-phenethylbenzoic acid 890314-19-9P, 2-(3,4-Difluorobenzoylamino)-4-phenethylbenzoic acid 890314-20-2P, 2-(3,5-Dimethylbenzoylamino)-4-phenethylbenzoic acid 890314-22-4P, 4-Phenethyl-2-[[6-phenylpyrimidin-4-yl]carbonyl]amino]benzoic acid 890314-23-5P, 4-Phenethyl-2-[[4-(3-phenylisoxazol-5-yl)carbonyl]amino]benzoic acid 890314-25-7P, 2-((E)-2-Methyl-3-phenyl-2-propenoylamino)-4-phenethylbenzoic acid 890314-26-8P, 2-[(E)-3-(4-Nitrophenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890314-27-9P, 2-(3,5-Dichlorobenzoylamino)-4-phenoxybenzoic acid 890314-28-0P, 2-(3,4-Dichlorobenzoylamino)-4-phenoxybenzoic acid 890314-29-1P, 2-(3,5-Difluorobenzoylamino)-4-phenoxybenzoic acid 890314-30-4P, 2-(3,4-Difluorobenzoylamino)-4-phenoxybenzoic acid 890314-31-5P, 2-(3,5-Dimethylbenzoylamino)-4-phenoxybenzoic acid 890314-32-6P, 2-((E)-2-Methyl-3-phenyl-2-propenoylamino)-4-phenoxybenzoic acid 890314-33-7P, 2-(3,5-Dichlorobenzoylamino)-4-phenylbenzoic acid 890314-34-8P, 2-(3,4-Dichlorobenzoylamino)-4-phenylbenzoic acid 890314-35-9P, 2-(3,5-Difluorobenzoylamino)-4-phenylbenzoic acid 890314-36-0P, 2-(3,4-Difluorobenzoylamino)-4-phenylbenzoic acid 890314-37-1P, 2-(3,5-Dimethylbenzoylamino)-4-phenylbenzoic acid 890314-38-2P, 2-((E)-2-Methyl-3-phenyl-2-propenoylamino)-4-phenylbenzoic acid 890314-39-3P, 2-(2-Methoxybenzoylamino)-4-phenoxybenzoic acid 890314-40-6P, 2-(3-Methoxybenzoylamino)-4-phenoxybenzoic acid 890314-41-7P, 2-(4-Methoxybenzoylamino)-4-phenoxybenzoic acid 890314-42-8P, 2-(2-Methoxybenzoylamino)-4-phenylbenzoic acid 890314-43-9P, 2-(3-Methoxybenzoylamino)-4-phenylbenzoic acid 890314-44-0P, 4-Phenethyl-2-(3-phenylpropanoylamino)benzoic acid 890314-45-1P, 4-Phenethyl-2-[3,5-bis(trifluoromethyl)benzoylamino]benzoic acid 890314-46-2P, 4-Phenyl-2-[3,5-bis(trifluoromethyl)benzoylamino]benzoic acid 890314-47-3P, 4-Phenoxy-2-[3,5-bis(trifluoromethyl)benzoylamino]benzoic acid 890314-48-4P, 2-[(E)-3-(3-Nitrophenyl)-2-propenoyl]amino]-4-phenoxybenzoic acid 890314-49-5P, 2-(4-Methoxybenzoylamino)-4-phenylbenzoic acid 890314-50-8P 890314-51-9P, 2-(2-Hydroxybenzoylamino)-4-phenethylbenzoic acid 890314-52-0P, 2-(4-Hydroxybenzoylamino)-4-phenethylbenzoic acid 890314-53-1P, 4-Phenoxy-2-(4-phenylbutanoylamino)benzoic acid 890314-54-2P, 4-Phenethyl-2-(4-phenylbutanoylamino)benzoic acid 890314-56-4P, tert-Butyl 4-phenyl-2-[[[6-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoate 890314-57-5P, tert-Butyl 4-phenyl-2-[[[2-(1H-pyrrol-1-yl)pyridin-4-yl]carbonyl]amino]benzoate 890314-58-6P, tert-Butyl 4-phenyl-2-[3-(1H-pyrazol-1-yl)benzoylamino]benzoate

890314-59-7P, tert-Butyl 2-(biphenyl-4-ylcarbonylamino)-4-phenylbenzoate
 890314-60-0P, tert-Butyl 2-(3-acetylbenzoylamino)-4-phenylbenzoate
 890314-62-2P, tert-Butyl 2-[3-(3,5-dimethyl-1H-pyrazol-1-yl)benzoylamino]-4-phenylbenzoate 890314-64-4P, tert-Butyl 4-phenoxy-2-[[[6-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoate 890314-65-5P, tert-Butyl 4-phenoxy-2-[[[2-(1H-pyrrol-1-yl)pyridin-4-yl]carbonyl]amino]benzoate 890314-66-6P, tert-Butyl 4-phenoxy-2-[[[2-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoate 890314-67-7P, tert-Butyl 4-phenoxy-2-[3-(1H-pyrazol-1-yl)benzoylamino]benzoate 890314-68-8P, tert-Butyl 2-(biphenyl-4-ylcarbonylamino)-4-phenoxybenzoate 890314-69-9P, tert-Butyl 2-(3-acetylbenzoylamino)-4-phenoxybenzoate 890314-70-2P, tert-Butyl 2-[3-(3,5-dimethyl-1H-pyrazol-1-yl)benzoylamino]-4-phenoxybenzoate 890314-72-4P, tert-Butyl 4-phenethyl-2-[[[2-(1H-pyrrol-1-yl)pyridin-4-yl]carbonyl]amino]benzoate 890314-73-5P, tert-Butyl 2-(biphenyl-3-ylcarbonylamino)-4-phenethylbenzoate 890314-74-6P, tert-Butyl 2-(biphenyl-4-ylcarbonylamino)-4-phenethylbenzoate 890314-76-8P, tert-Butyl 2-(biphenyl-2-ylcarbonylamino)-4-phenylbenzoate 890314-78-0P, tert-Butyl 2-(biphenyl-2-ylcarbonylamino)-4-phenoxybenzoate 890314-80-4P, tert-Butyl 2-(biphenyl-3-ylcarbonylamino)-4-phenylbenzoate 890314-82-6P, tert-Butyl 2-(biphenyl-3-ylcarbonylamino)-4-phenoxybenzoate 890314-84-8P, 4-Phenoxy-2-[4-(1H-pyrrol-1-yl)benzoylamino]benzoic acid 890314-85-9P, tert-Butyl 2-[(E)-3-(3,4-dimethoxyphenyl)-2-propenoyl]amino]-4-phenethylbenzoate 890314-87-1P, 2-(3-Cyanobenzoylamino)-4-phenoxybenzoic acid 890314-88-2P, 4-Phenoxy-2-[[[6-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890314-89-3P, 4-Phenoxy-2-[[[2-(1H-pyrrol-1-yl)pyridin-4-yl]carbonyl]amino]benzoic acid 890314-90-6P, 4-Phenoxy-2-[[[2-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890314-91-7P, 4-Phenoxy-2-[3-(1H-pyrazol-1-yl)benzoylamino]benzoic acid 890314-92-8P, 2-(Biphenyl-3-ylcarbonylamino)-4-phenoxybenzoic acid 890314-93-9P, 2-(Biphenyl-4-ylcarbonylamino)-4-phenoxybenzoic acid 890314-94-0P, 2-(3-Acetylbenzoylamino)-4-phenoxybenzoic acid 890314-95-1P, 2-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)benzoylamino]-4-phenoxybenzoic acid 890314-96-2P, 2-(Biphenyl-2-ylcarbonylamino)-4-phenoxybenzoic acid 890314-97-3P, 2-(3-Cyanobenzoylamino)-4-phenylbenzoic acid 890314-98-4P, 4-Phenyl-2-[[[6-(1H-pyrrol-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid 890314-99-5P, 4-Phenyl-2-[[[2-(1H-pyrrol-1-yl)pyridin-4-yl]carbonyl]amino]benzoic acid 890315-00-1P, 4-Phenyl-2-[3-(1H-pyrazol-1-yl)benzoylamino]benzoic acid 890315-01-2P, 2-(Biphenyl-3-ylcarbonylamino)-4-phenylbenzoic acid 890315-02-3P, 2-(Biphenyl-4-ylcarbonylamino)-4-phenylbenzoic acid 890315-03-4P, 2-(3-Acetylbenzoylamino)-4-phenylbenzoic acid 890315-04-5P, 2-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)benzoylamino]-4-phenylbenzoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylanthranilic acid derivs. as inhibitors for production

of

matrix metalloproteinase (MMP-13))

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:30413 HCAPLUS Full-text

DOCUMENT NUMBER: 144:129001



TITLE: Preparation of azine-carboxamides as anti-cancer agents

INVENTOR(S): Aquila, Brian; Ioannidis, Stephanos; Lyne, Paul; Pontz, Timothy

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006003378	A1	20060112	WO 2005-GB2522	20050629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005258996	A1	20060112	AU 2005-258996	20050629
CA 2570169	A1	20060112	CA 2005-2570169	20050629
EP 1765790	A1	20070328	EP 2005-755467	20050629
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 101023063	A	20070822	CN 2005-80028484	20050629
JP 2008050166	T	20080221	JP 2007-519860	20050629
BR 2005012796	A	20080408	BR 2005-12796	20050629
US 20070259849	A1	20071108	US 2006-570065	20061205
MX 2006PA14745	A	20070321	MX 2006-PA14745	20061215
NO 2007000566	A	20070130	NO 2007-566	20070130
IN 2007DN00805	A	20070803	IN 2007-DN805	20070131
KR 2007029837	A	20070314	KR 2007-702599	20070201
PRIORITY APPLN. INFO.:			US 2004-584129P	P 20040701
			WO 2005-GB2522	W 20050629
OTHER SOURCE(S):		CASREACT 144:129001; MARPAT 144:129001		
ED Entered STN: 12 Jan 2006				
GI				



AB The title compds. I [ring A = (un)substituted carbocyclyl, heterocyclyl; R1 = halo, NO₂, CN, etc.; R2 = H, halo, NO₂, etc.; X1 = N and X2-X5 = CR₁₂; or two of X1-X5 = N and the other X1-X5 = CR₁₂; n = 0-4; R12 = H, halo, NO₂, etc.] which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body, were prepared. Thus, reacting N-(3-amino-4-methylphenyl)-3-(1-cyano-1-methylethyl)benzamide with 6-methyl-2-(piperidin-1-yl)pyrimidine-4-carboxylic acid (preps. given) in the presence of HATU and DIEA in DMF afforded II which showed IC₅₀ of 5.7 μM when tested in B-Raf in vitro ELISA assay. The invention also relates to processes for the manufacture of said compds. I, to pharmaceutical compns. containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.


IT 573449-78-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azine-carboxamides as B-Raf inhibitors for treating cancer)

RN 873449-78-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[5-[[3-(1-cyano-1-methylethyl)benzoyl]amino]-2-methylphenyl]-2-(4-morpholinyl)-6-(1H-pyrazol-4-yl)- (CA INDEX NAME)



IC ICM C07D239-42

ICS C07D213-81; C07D403-04; C07D405-12; C07D401-04; C07D403-06; C07D213-82; C07D241-24; C07D239-28; A61K031-495; A61K031-435;

A61P035-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 873449-11-7P 873449-12-8P 873449-14-0P 873449-15-1P 873449-16-2P
 873449-17-3P 873449-18-4P 873449-19-5P 873449-21-9P 873449-22-0P
 873449-23-1P 873449-24-2P 873449-26-4P 873449-27-5P 873449-28-6P
 873449-29-7P 873449-30-0P 873449-31-1P 873449-33-3P 873449-36-6P
 873449-37-7P 873449-38-8P 873449-40-2P 873449-41-3P 873449-42-4P
 873449-43-5P 873449-44-6P 873449-45-7P 873449-46-8P 873449-47-9P
 873449-48-0P 873449-49-1P 873449-50-4P 873449-51-5P 873449-52-6P
 873449-53-7P 873449-54-8P 873449-55-9P 873449-56-0P 873449-57-1P
 873449-58-2P 873449-59-3P 873449-60-6P 873449-61-7P 873449-62-8P
 873449-63-9P 873449-64-0P 873449-65-1P 873449-66-2P 873449-67-3P
 873449-68-4P 873449-69-5P 873449-70-8P 873449-71-9P 873449-72-0P
 873449-73-1P 873449-74-2P 873449-75-3P 873449-76-4P 873449-77-5P
 873449-78-6P 873449-80-0P 873449-81-1P 873449-82-2P
 873449-83-3P 873449-85-5P 873449-86-6P 873449-87-7P 873449-88-8P
 873449-89-9P 873449-90-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of azine-carboxamides as B-Raf inhibitors for treating cancer)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1259559 HCAPLUS Full-text

DOCUMENT NUMBER: 144:22935

TITLE: Preparation of substituted pyrimidines as inhibitors
 of bacterial type III protein secretion systems

INVENTOR(S): Li, Xiaobing

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113514	A2	20051201	WO 2005-US16106	20050506
WO 2005113514	A3	20060119		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 20050282824 A1 20051222 US 2005-124226 20050506


PRIORITY APPLN. INFO.: US 2004-568850P P 20040507

OTHER SOURCE(S): CASREACT 144:22935; MARPAT 144:22935

ED Entered STN: 01 Dec 2005

GI


10/588757



RN 870265-24-0 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(4-(dimethylamino)phenyl)-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870265-25-1 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870265-26-2 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/588757



RN 870265-27-3 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(4-fluorophenyl)-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870265-28-4 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[2-(4-cyanophenyl)-6-(3,4-dihydro-2(1H)-isoquinolinyl)-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870265-31-9 HCAPLUS

10/588757

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-1(2H)-quinolinyl)-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870265-34-2 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-1(2H)-quinolinyl)-2-(4-phenoxyphenyl)-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870265-50-2 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[2-(4-phenyl-1-piperazinyl)-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/588757

RN 870265-51-3 HCAPLUS

CN L-Serine, N-[[6-(3,4-dichlorophenyl)-2-(4-phenyl-1-piperazinyl)-4-pyrimidinyl]carbonyl]-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870265-52-4 HCAPLUS


CN D-Phenylalanine, N-[[2-[1,1'-biphenyl]-4-yl-6-(3,4-dihydro-1(2H)-quinolinyl)-4-pyrimidinyl]carbonyl]-4-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 870265-63-7 HCAPLUS

CN Phenylalanine, 4-chloro-N-[[2-[4-(2-pyridinyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]- (CA INDEX NAME)



IT 870266-15-2P 870266-16-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrimidines as inhibitors of bacterial type III protein secretion systems)

RN 870266-15-2 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[2-chloro-6-(3,4-dihydro-2(1H)-isoquinolinyl)-4-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870266-16-3 HCAPLUS

CN D-Phenylalanine, 4-chloro-N-[[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-[4-(dimethylamino)phenyl]-4-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D239-00
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 870265-17-1P, 2-[[[2-(Biphenyl-4-yl)-6-methylpyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid 870265-19-3P, (R)-3-Benzylsulfanyl-2-[[[6-methyl-2-(4-phenylpiperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-21-7P, (R)-3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-22-8P, (R)-3-(4-Chlorophenyl)-2-[[[2-(4-phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-23-9P
 870265-24-0P 870265-25-1P 870265-26-2P
 870265-27-3P 870265-28-4P 870265-29-5P 870265-30-8P
 870265-31-9P 870265-32-0P 870265-33-1P 870265-34-2P
 870265-35-3P 870265-36-4P 870265-37-5P 870265-38-6P 870265-39-7P
 870265-40-0P 870265-41-1P 870265-43-3P 870265-44-4P 870265-45-5P
 870265-46-6P 870265-47-7P, (S)-3-Benzylsulfanyl-2-[[[2-(4-phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-48-8P, (R)-3-Benzylsulfanyl-2-[[[2-(4-phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-49-9P, (2S,3R)-3-Benzylsulfanyl-2-[[[2-(4-phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoic acid 870265-50-2P, (R)-3-(4-Chlorophenyl)-2-[[[2-(4-phenylpiperidin-1-yl)-6-(3-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-51-3P, (S)-3-Benzylsulfanyl-2-[[[6-(3,4-dichlorophenyl)-2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-52-4P 870265-53-5P, (R)-2-[[[2-(Biphenyl-4-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid 870265-54-6P, 3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-methylpyrimidin-4-yl]carbonyl]amino]propionic acid 870265-55-7P, (S)-3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-methylpyrimidin-4-yl]carbonyl]amino]propionic acid 870265-56-8P, (R)-3-Benzylsulfanyl-2-[[[6-(4-methylpiperidin-1-yl)-2-(4-phenoxyphenyl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-57-9P, (S)-3-Benzylsulfanyl-2-[[[6-(4-methylpiperidin-1-yl)-2-(4-phenoxyphenyl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-59-1P, 3-(4-Chlorophenyl)-2-[[[6-(4-methylpiperidin-1-yl)-2-(4-phenoxyphenyl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-60-4P, (R)-3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-(4-methylpiperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-61-5P, (S)-3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-(4-methylpiperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-62-6P, 2-[[[2-(Biphenyl-4-yl)-6-(4-methylpiperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid 870265-63-7P, 3-(4-Chlorophenyl)-2-

[[[2-[4-(pyridin-2-yl)piperazin-1-yl]-6-(4-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-64-8P 870265-65-9P
 870265-66-0P 870265-67-1P 870265-68-2P, 3-(4-Chlorophenyl)-2-[[[2-(4-methylpiperidin-1-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-69-3P
 870265-70-6P 870265-71-7P 870265-72-8P 870265-73-9P,
 3-(4-Chlorophenyl)-2-[[[2-(4-nitrophenyl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-74-0P 870265-75-1P 870265-76-2P, 3-(4-Chlorophenyl)-2-[[[2-(4-fluorophenyl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-77-3P,
 (S)-3-Benzoyloxy-2-[[[2-(thiophen-2-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-78-4P, (R)-3-Benzylsulfanyl-2-[[[2-(thiophen-2-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-79-5P, 3-(4-Chlorophenyl)-2-[[[2-(thiophen-2-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-80-8P,
 (S)-3-Benzoyloxy-2-[[[2-(furan-3-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-81-9P, (R)-3-Benzylsulfanyl-2-[[[2-(furan-3-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-83-1P, 3-(4-Chlorophenyl)-2-[[[2-(furan-3-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-84-2P,
 2-[[[2-(furan-3-yl)-6-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]acrylic acid 870265-85-3P
 870265-86-4P 870265-87-5P 870265-88-6P, 2-[[[2,6-Bis[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid 870265-89-7P, 3-(4-Chlorophenyl)-2-[[[2-(4-nitrophenyl)-6-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid 870265-90-0P 870265-91-1P,
 3-(4-Chlorophenyl)-2-[[[2-(4-dimethylaminophenyl)-6-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-92-2P, (S)-3-Benzoyloxy-2-[[[6-[4-(pyridin-2-yl)piperazin-1-yl]-2-(thiophen-2-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-93-3P, (R)-3-Benzylsulfanyl-2-[[[2-(furan-3-yl)-6-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-94-4P, (S)-3-Benzoyloxy-2-[[[2-(furan-3-yl)-6-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-95-5P, (R)-3-Benzylsulfanyl-2-[[[6-(4-methylpiperidin-1-yl)-2-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-96-6P, (R)-3-Benzylsulfanyl-2-[[[6-(4-methylpiperazin-1-yl)-2-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-97-7P, (S)-3-Benzoyloxy-2-[[[6-(4-methylpiperazin-1-yl)-2-[4-(pyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl]carbonyl]amino]propionic acid
 870265-98-8P 870265-99-9P 870266-00-5P, 2-[[[6-(4-Benzylpiperidin-1-yl)-2-(4-chlorophenyl)pyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidines as inhibitors of bacterial type III protein secretion systems)

IT 107973-00-2P, 2-Chloro-6-(piperidin-1-yl)pyrimidine-4-carboxylic acid methyl ester 870266-01-6P, 2-(Biphenyl-4-yl)-6-methylpyrimidine-4-carboxylic acid methyl ester 870266-02-7P, 2-(Biphenyl-4-yl)-6-methylpyrimidine-4-carboxylic acid 870266-03-8P, 2-[[[2-(Biphenyl-4-yl)-6-methylpyrimidin-4-yl]carbonyl]amino]-3-(4-chlorophenyl)propionic acid ethyl ester 870266-04-9P, 6-Methyl-2-(4-phenylpiperidin-1-yl)pyrimidine-

4-carboxylic acid methyl ester 870266-05-0P, 6-Methyl-2-(4-phenylpiperidin-1-yl)pyrimidine-4-carboxylic acid 870266-06-1P, (R)-3-Benzylsulfanyl-2-[[[6-methyl-2-(4-phenylpiperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid methyl ester 870266-07-2P, 2-(Biphenyl-4-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxylic acid methyl ester 870266-08-3P, 2-(Biphenyl-4-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxylic acid 870266-09-4P, (R)-3-Benzylsulfanyl-2-[[[2-(biphenyl-4-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid methyl ester 870266-10-7P, 2-(4-Phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxylic acid methyl ester 870266-11-8P, 2-(4-Phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxylic acid 870266-12-9P, (R)-3-(4-Chlorophenyl)-2-[[[2-(4-phenylpiperidin-1-yl)-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]propionic acid methyl ester 870266-13-0P, 2-Chloro-6-(3,4-dihydro-1H-isoquinolin-2-yl)pyrimidine-4-carboxylic acid methyl ester 870266-14-1P, 2-Chloro-6-(3,4-dihydro-1H-isoquinolin-2-yl)pyrimidine-4-carboxylic acid 870266-15-2P
870266-16-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrimidines as inhibitors of bacterial type III protein secretion systems)

L29 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:962045 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:266942

TITLE: Preparation of pyrimidine carboxamides as purine receptor, particularly adenosine receptor antagonists
INVENTOR(S): Gillespie, Roger John; Todd, Richard Simon; Stratton, Gemma Caroline; Jordan, Allan Michael

PATENT ASSIGNEE(S): Vernalis R & D Ltd., UK

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079801	A1	20050901	WO 2005-GB498	20050211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1720553	A1	20061115	EP 2005-708321	20050211
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, MK			
US 20070281936	A1	20071206	US 2007-588757	20070625 <---
PRIORITY APPLN. INFO.:			GB 2004-3155	A 20040212
			WO 2005-GB498	W 20050211

OTHER SOURCE(S): MARPAT 143:266942

ED Entered STN: 02 Sep 2005

GI




AB The invention is related to the use of pyrimidines of formula (I) (R1 = H, NH2; R2 = (un)substituted hetero/aryl attached via a C atom; R3 = H, halo, OH and derivs., (un)substituted alk(en/yn)yl, cycloalkyl; R4 = H, (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl; R5 = H, (un)substituted alk(en/yn)yl, cycloalkyl; NR4R5 = 5 or 6-membered heterocycle) and their pharmaceutically acceptable salts and prodrugs, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial, provided that when R2 = (un)substituted aryl the said use is not the manufacture of a medicament for the treatment or prevention of inflammatory pain. I are purine receptor, particularly adenosine receptor antagonists, useful for treatment of movement disorders such as Parkinson disease. The invention is also related to the preparation of pyrimidines I. For example, coupling 2-amino-6-(2-furyl)pyrimidine-4-carboxylic acid (preparation given) with indole-5-methanamine gave pyrimidine carboxamide II in 59% yield. I displayed Ki values of < 5 μ M in an assay measuring in vitro binding to human adenosine A2A receptors.

IT 863546-62-7P, 2-Amino-6-(2-furyl)-N-[(6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-66-1P, 2-Amino-6-(2-furyl)-N-(3-methyl-4-nitrobenzyl)pyrimidine-4-carboxamide 863547-20-8P, 2-Amino-6-(2-furyl)-N-[(1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-23-3P, 2-Amino-N-(6-bromopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-42-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-59-5P 863547-60-8P, 2-Amino-6-(2-furyl)-N-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-61-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[[[(tert-butyl)dimethylsilyl]oxy]methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-62-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-56-5P, 2-Amino-6-(2-furyl)-N-[(1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide dihydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)


RN 863546-62-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(6-(hydroxymethyl)-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-66-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methyl-4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 863547-20-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1H-imidazol-2-ylmethyl)- (CA INDEX NAME)




RN 863547-23-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-bromo-2-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-42-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-59-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-(triphenylmethoxy)methyl]-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863547-60-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]methyl]- (CA INDEX NAME)




RN 863547-61-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-pyridinyl]methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-62-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-(hydroxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)



RN 863548-56-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furyl)-N-(1H-imidazol-2-ylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HC1

IT 863546-30-9P, 2-Amino-N-(2-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-31-0P, 2-Amino-N-(3,4-difluorophenyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-32-1P, 2-Amino-6-(2-furyl)-N-(3-methoxybenzyl)pyrimidine-4-carboxamide 863546-33-2P, 2-Amino-6-(2-furyl)-N,N-dimethylpyrimidine-4-carboxamide 863546-35-4P, 2-Amino-6-(2-furyl)-N-(2-methoxybenzyl)pyrimidine-4-carboxamide 863546-36-5P, 2-Amino-6-(2-furyl)-N-[(2-furyl)methyl]pyrimidine-4-carboxamide 863546-37-6P, 2-Amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-38-7P, 2-Amino-6-(2-furyl)-N-(4-dimethylaminobenzyl)pyrimidine-4-carboxamide 863546-39-8P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-40-1P, 2-Amino-6-(2-furyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-41-2P,

2-Amino-6-(2-furyl)-N-[3-(dimethylaminocarbonyl)benzyl]pyrimidine-4-carboxamide 863546-42-3P, 2-Amino-6-(2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863546-43-4P, 2-Amino-6-(2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863546-44-5P, 2-Amino-6-(2-furyl)-N-(2-methylbenzyl)pyrimidine-4-carboxamide 863546-45-6P, 2-Amino-N-(3-trifluoromethylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-46-7P, 2-Amino-N-(1H-benzimidazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-47-8P, 2-Amino-6-(2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863546-48-9P, 2-Amino-6-(2-furyl)-N-(3-methylbenzyl)pyrimidine-4-carboxamide 863546-49-0P, 2-Amino-6-(2-furyl)-N-[(3-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-50-3P, 2-Amino-6-(2-furyl)-N-[[3-(dimethylamino)methyl]pyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-51-4P, 2-Amino-6-(2-furyl)-N-[[3-[(4-morpholinyl)methyl]pyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-52-5P, 2-Amino-6-(2-furyl)-N-[[3,6-dimethylpyridin-2-yl]methyl]pyrimidine-4-carboxamide 863546-53-6P, 2-Amino-6-(2-furyl)-N-[[2-(2-thienyl)thiazol-4-yl]methyl]pyrimidine-4-carboxamide 863546-54-7P, 2-Amino-6-(2-furyl)-N-[(2-thienyl)methyl]pyrimidine-4-carboxamide 863546-55-8P, 2-Amino-6-(2-furyl)-N-[[5-(2-pyridyl)thien-2-yl]methyl]pyrimidine-4-carboxamide 863546-56-9P, 2-Amino-6-(2-furyl)-N-[(5-methyl-2-trifluoromethylfuran-3-yl)methyl]pyrimidine-4-carboxamide 863546-57-0P, 2-Amino-6-(2-furyl)-N-[(5-methylisoxazol-3-yl)methyl]pyrimidine-4-carboxamide 863546-58-1P, 2-Amino-6-(2-furyl)-N-[(2-methoxy-6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-59-2P, 2-Amino-N-[(6-fluoro-[1,3]benzodioxin-8-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-60-5P, 2-Amino-6-(2-furyl)-N-[(6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-61-6P, 2-Amino-6-(2-furyl)-N-[(3-indolyl)methyl]pyrimidine-4-carboxamide 863546-63-8P, 2-Amino-6-(2-furyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863546-64-9P, 2-Amino-6-(2-furyl)-N-[(5-indolyl)methyl]pyrimidine-4-carboxamide 863546-65-0P, 2-Amino-N-(2,3-dimethylindol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-67-3P, N-[[6-[(N-Acetyl-N-methylamino)methyl]-3-methylpyridin-2-yl]methyl]-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-68-3P, 2-Amino-6-(2-furyl)-N-methyl-N-[2-(2-pyridyl)ethyl]pyrimidine-4-carboxamide 863546-69-4P, 2-Amino-6-(2-furyl)-N-[(2-methylindol-5-yl)methyl]pyrimidine-4-carboxamide 863546-70-7P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl isopropylcarbamate 863546-71-8P, 2-Amino-N-benzyl-6-(2-furyl)pyrimidine-4-carboxamide 863546-72-9P, N-Allyl-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-73-0P, (R)-2-Amino-6-(2-furyl)-N-(2-hydroxypropyl)pyrimidine-4-carboxamide 863546-74-1P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethyl-3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-76-3P, Methyl [[[(2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]acetate 863546-77-4P, 2-Amino-6-(2-furyl)-N-[(6-indolyl)methyl]pyrimidine-4-carboxamide 863546-78-5P, 2-Amino-6-(2-furyl)-N-[(quinolin-8-yl)methyl]pyrimidine-4-carboxamide 863546-79-6P, 2-Amino-6-(2-furyl)-N-[2-(pyridin-2-yl)ethyl]pyrimidine-4-carboxamide 863546-80-9P, 2-Amino-N-(2-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-81-0P, 2-Amino-6-(2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863546-82-1P, 2-Amino-N-(2,1,3-benzothiadiazol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-83-2P, [6-[[[(2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl dimethylcarbamate

863546-84-3P, 2-Amino-6-(2-furyl)-N-[(isoquinolin-3-yl)methyl]pyrimidine-4-carboxamide 863546-86-5P, 2-Amino-6-(2-furyl)-N-[(quinolin-2-yl)methyl]pyrimidine-4-carboxamide 863546-87-6P, 2-Amino-N-(benzothiazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-88-7P, 2-Amino-N-[[6-[(cyclopropylmethoxy)methyl]-3-methylpyridin-2-yl]methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-89-8P, (S)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-90-1P, 2-Amino-N-(4-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-91-2P, 2-Amino-N-(4-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-92-3P, (R)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-93-4P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl ester 863546-94-5P, 2-Amino-6-(2-furyl)-N-(4-methoxybenzyl)pyrimidine-4-carboxamide 863546-96-7P, 2-Amino-6-(2-furyl)-N-(2-methoxyethyl)pyrimidine-4-carboxamide 863546-97-8P, 2-Amino-N-(cyanomethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-98-9P, 2-Amino-6-(2-furyl)-N-(4-methylbenzyl)pyrimidine-4-carboxamide 863546-99-0P, 2-Amino-6-(2-furyl)-N-(1-phenyl-1-methylethyl)pyrimidine-4-carboxamide 863547-02-8P, 2-Amino-N-(3-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-03-9P, 2-Amino-N-(3-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-05-1P, 2-Amino-6-(2-furyl)-N-(3-methylphenyl)pyrimidine-4-carboxamide 863547-06-2P, 2-Amino-6-(2-furyl)-N-(3-methylpyridin-2-yl)pyrimidine-4-carboxamide 863547-07-3P, (R)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-08-4P, (S)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-09-5P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl piperidine-1-carboxylate 863547-10-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl pyrrolidine-1-carboxylate 863547-11-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl allylcarbamate 863547-12-0P, 2-Amino-6-(2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-13-1P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-14-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl n-propylcarbamate 863547-15-3P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl tert-butylcarbamate 863547-16-4P, 2-Amino-N-benzyl-6-(2-furyl)-N-methylpyrimidine-4-carboxamide 863547-17-5P, 2-Amino-6-(2-furyl)-N-[(5-methylpyrazin-2-yl)methyl]pyrimidine-4-carboxamide 863547-18-6P, 2-Amino-6-(2-furyl)-N-(1,2,3,4-tetrahydro-1-naphthyl)pyrimidine-4-carboxamide 863547-19-7P, 2-Amino-6-(2-furyl)-N-(2-indanyl)pyrimidine-4-carboxamide 863547-21-1P, 2-Amino-6-(2-furyl)-N-[(1-n-propyl-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-22-2P, 2-Amino-N-(2-bromobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-24-4P, 2-Amino-N-(6-aminopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-25-5P, 2-Amino-6-(2-furyl)-N-[3-(1H-imidazol-1-yl)propyl]pyrimidine-4-carboxamide 863547-26-6P, 2-Amino-6-(2-furyl)-N-[[1-(2-methoxyethyl)-1H-imidazol-2-yl]methyl]pyrimidine-4-carboxamide 863547-27-7P, 2-Amino-N-[(1-ethyl-1H-imidazol-2-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-28-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl benzylcarbamate 863547-29-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl cyclopentylcarbamate

863547-30-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl hexylcarbamate 863547-31-3P, 2-Amino-N-[2-(dimethylamino)-6-methylpyridin-3-ylmethyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-32-4P, (R)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-33-5P, (S)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-34-6P, 2-Amino-N-(2,6-dichlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-35-7P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]-5-methylpyrimidine-4-carboxamide 863547-36-8P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-37-9P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-38-0P, 2-Amino-N-[[6-(n-propyl)pyridin-2-yl]methyl]-6-1H-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-39-1P, 2-Amino-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-40-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-41-5P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]pyrimidine-4-carboxamide 863547-43-7P, [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl tert-butylcarbamate 863547-44-8P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl]methyl ester 863547-45-9P, 2-Amino-5-chloro-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-46-0P, 2-Amino-5-bromo-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-47-1P, 2-Amino-5-bromo-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-48-2P, 2-Amino-N-(2-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-49-3P, 2-Amino-N-(3-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-50-6P, 2-Amino-N-(4-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-51-7P, 2-Amino-N-(2-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-52-8P, 2-Amino-N-(3-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-53-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863547-54-0P, 2-Amino-6-(5-methyl-2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863547-55-1P, 2-Amino-N-(2-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-56-2P, 2-Amino-N-(3-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-57-3P, 2-Amino-N-(3-fluorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-58-4P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-63-1P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-64-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(5-methylisoxazol-3-yl)methyl]pyrimidine-4-carboxamide 863547-65-3P, 2-Amino-6-(5-methyl-2-furyl)-N-[(tetrahydrofuran-2-yl)methyl]pyrimidine-4-carboxamide 863547-66-4P, 2-Amino-N-(cyclopropylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-67-5P, 2-Amino-6-(5-methyl-2-furyl)-N-(2-phenylethyl)pyrimidine-4-carboxamide 863547-68-6P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-69-7P, 2-Amino-N-benzyl-N-ethyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-70-0P, 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylpropyl)pyrimidine-4-carboxamide 863547-71-1P, 2-Amino-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-72-2P,

2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-73-3P, (S)-2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-74-4P, 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenyl-1-methylthethyl)pyrimidine-4-carboxamide 863547-75-5P, 2-Amino-N-isobutyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-76-6P, 2-Amino-N-hexyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-77-7P, 2-Amino-N-butyl-N-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-78-8P, 2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-pentylpyrimidine-4-carboxamide 863547-79-9P, 2-Amino-N-benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-80-2P, 2-Amino-6-(5-methyl-2-furyl)-N-phenylpyrimidine-4-carboxamide 863547-81-3P, 2-Amino-N-benzyl-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-82-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-5-yl)methyl]pyrimidine-4-carboxamide 863547-83-5P, 2-Amino-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-84-6P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-85-7P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-86-8P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-87-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]pyrimidine-4-carboxamide 863547-88-0P, 2-Amino-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-89-1P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-90-4P, 6-(5-Methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-91-5P, N-Benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-92-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[(isopropoxy)methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-93-7P, 6-(5-Methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-94-8P, N-(3,6-Dimethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-95-9P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-96-0P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-97-1P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-98-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]pyrimidine-4-carboxamide 863547-99-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyrimidin-4-yl)methyl]pyrimidine-4-carboxamide 863548-00-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(4-methylthiazol-2-yl)methyl]pyrimidine-4-carboxamide 863548-01-0P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-02-1P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-03-2P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-3-yl)methyl]pyrimidine-4-carboxamide 863548-04-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-05-4P, 2-Amino-N-(2-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-06-5P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-07-6P, 2-Amino-N-(3-methoxybenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-08-7P, 2-Amino-N-(3-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-09-8P, 2-Amino-N-(3-fluorobenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-10-1P, 2-Amino-N-(3-chlorobenzyl)-6-(4-methylthiazol-2-


yl)pyrimidine-4-carboxamide 863548-11-2P, 2-Amino-N-(6-methylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-12-3P, 2-Amino-6-phenyl-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-13-4P, 2-Amino-6-phenyl-N-(pyridin-2-ylmethyl)pyrimidine-4-carboxamide 863548-14-5P, 2-Amino-6-(2-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-15-6P, 2-Amino-6-(4-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-16-7P, 2-Amino-6-(3-cyanophenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-17-8P, 2-Amino-6-(2-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-18-9P, 2-Amino-6-(3-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-19-0P, 2-Amino-6-(4-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-20-3P, 2-Amino-6-(3-cyanophenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-21-4P, 2-Amino-6-(3-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-22-5P, 2-Amino-6-(3-methoxyphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-23-6P, 2-Amino-6-(3-methoxyphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-24-7P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-phenylpyrimidine-4-carboxamide 863548-59-8P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)


RN 863546-30-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)



RN 863546-31-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-(3,4-difluorophenyl)-6-(2-furanyl)-
(CA INDEX NAME)



RN 863546-32-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methoxyphenyl)methyl]-

(CA INDEX NAME)




RN 863546-33-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N,N-dimethyl- (CA INDEX NAME)




RN 863546-35-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 863546-36-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 863546-37-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-38-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-(dimethylamino)phenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-39-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(6-(methoxymethyl)-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-40-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-41-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[3-[(dimethylamino)carbonyl]phenyl]methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-42-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-43-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-44-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 863546-45-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863546-46-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(1H-benzimidazol-2-ylmethyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-47-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863546-48-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 863546-49-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[3-(methoxymethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 863546-50-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-([3-[(dimethylamino)methyl]-2-pyridinyl]methyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-51-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-([3-(4-morpholinylmethyl)-2-pyridinyl]methyl)- (CA INDEX NAME)




RN 863546-52-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-([3,6-dimethyl-2-pyridinyl]methyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-53-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-([2-(2-thienyl)-4-thiazolyl]methyl)- (CA INDEX NAME)




RN 863546-54-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 863546-55-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-(2-pyridinyl)-2-thienyl)methyl]- (CA INDEX NAME)




RN 863546-56-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-2-(trifluoromethyl)-3-furanyl)methyl]- (CA INDEX NAME)




RN 863546-57-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 863546-58-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methoxy-6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-59-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-60-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(6-methyl-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 863546-61-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[2-(1H-indol-3-yl)ethyl]-
(CA INDEX NAME)




RN 863546-63-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 863546-64-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1H-indol-5-ylmethyl)-
(CA INDEX NAME)




RN 863546-65-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2,3-dimethyl-1H-indol-5-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-67-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[6-[(acetylmethylamino)methyl]-3-methyl-2-pyridinyl)methyl]-2-amino-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-68-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 863546-69-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2-methyl-1H-indol-5-yl)methyl]- (CA INDEX NAME)



RN 863546-70-7 HCAPLUS


CN Carbamic acid, (1-methylethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)



RN 863546-71-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)

INDEX NAME)



RN 863546-72-9 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-2-propen-1-yl- (CA INDEX NAME)



RN 863546-73-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 863546-74-1 HCAPLUS

CN Carbamic acid, (3,5-dimethyl-4-isoxazolyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)


RN 863546-78-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(8-quinolinylmethyl)-
(CA INDEX NAME)

RN 863546-79-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[2-(2-pyridinyl)ethyl]-
(CA INDEX NAME)

RN 863546-80-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863546-81-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[2-(trifluoromethyl)phenyl]methyl]-
(CA INDEX NAME)




RN 863546-82-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2,1,3-benzothiadiazol-5-ylmethyl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-83-2 HCAPLUS

CN Carbamic acid, dimethyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)




RN 863546-84-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-isoquinolinylmethyl)- (CA INDEX NAME)




RN 863546-86-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-quinolinylmethyl)- (CA INDEX NAME)




RN 863546-87-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2-benzothiazolymethyl)-6-(2-furanyl)-
(CA INDEX NAME)

RN 863546-88-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-[(cyclopropylmethoxy)methyl]-3-methyl-2-pyridinyl]methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863546-89-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1S)-1-phenylethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 863546-90-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863546-91-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)

RN 863546-92-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1R)-1-phenylethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 863546-93-4 HCAPLUS


CN 4-Morpholinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (CA INDEX NAME)




RN 863546-94-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(4-methoxyphenyl)methyl]-
(CA INDEX NAME)


RN 863546-96-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(2-methoxyethyl)-
(CA INDEX NAME)


RN 863546-97-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(cyanomethyl)-6-(2-furanyl)-
(CA INDEX NAME)


RN 863546-98-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(4-methylphenyl)methyl]-
(CA INDEX NAME)


RN 863546-99-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)

RN 863547-02-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)

RN 863547-03-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(2-furanyl)-
(CA INDEX NAME)


RN 863547-05-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-methylphenyl)- (CA INDEX NAME)



RN 863547-06-2 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 863547-07-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-6-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 863547-08-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 863547-09-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (CA INDEX NAME)




RN 863547-10-8 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (CA INDEX NAME)




RN 863547-11-9 HCAPLUS

CN Carbamic acid, 2-propenyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl methyl ester (9CI) (CA INDEX NAME)




RN 863547-12-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 863547-13-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-amino-3-methylphenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-14-2 HCAPLUS

CN Carbamic acid, propyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-15-3 HCAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-16-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 863547-17-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(5-methyl-2-pyrazinyl)methyl]- (CA INDEX NAME)




RN 863547-18-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




RN 863547-19-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(2,3-dihydro-1H-inden-2-yl)-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-21-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[(1-propyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 863547-22-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-bromophenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-24-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-amino-2-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-25-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 863547-26-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[1-(2-methoxyethyl)-1H-imidazol-2-yl]methyl]- (CA INDEX NAME)




RN 863547-27-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-ethyl-1H-imidazol-2-yl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-28-8 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-29-9 HCAPLUS

CN Carbamic acid, cyclopentyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)




RN 863547-30-2 HCAPLUS

CN Carbamic acid, hexyl-, [6-[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (9CI) (CA INDEX NAME)



RN 863547-31-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-[[2-(dimethylamino)-6-methyl-3-pyridinyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)



RN 863547-32-4 HCAPLUS

CN Benzeacetic acid, α -[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]-, methyl ester, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 863547-33-5 HCAPLUS


CN Benzeacetic acid, α -[[[2-amino-6-(2-furanyl)-4-pyrimidinyl]carbonyl]amino]-, methyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 863547-34-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2,6-dichlorophenyl)methyl]-6-(2-furanyl)- (CA INDEX NAME)




RN 863547-35-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-furanyl)-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-5-methyl- (CA INDEX NAME)




RN 863547-36-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-37-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methyl-2-pyridinyl)methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-38-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-propyl-2-pyridinyl)methyl]-6-(2-thiazolyl)- (CA INDEX NAME)




RN 863547-39-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-40-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-41-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]- (CA INDEX NAME)




RN 863547-43-7 HCAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, [6-[[[2-amino-6-(5-methyl-2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 863547-44-8 HCAPLUS

CN 4-Morpholinecarboxylic acid, [6-[[[2-amino-6-(5-methyl-2-furanyl)-4-pyrimidinyl]carbonyl]amino]methyl]-2-pyridinyl)methyl ester (CA INDEX NAME)




RN 863547-45-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-chloro-N-[[6-(methoxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-46-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-bromo-N-[[6-(methoxymethyl)-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-47-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-5-bromo-6-(5-methyl-2-furanyl)-N-[[2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 863547-48-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-49-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-50-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 863547-51-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-chlorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-52-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-53-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-54-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-55-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-methoxyphenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-56-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methoxyphenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-57-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-58-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-63-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-64-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 863547-65-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 863547-66-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-(cyclopropylmethyl)-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-67-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 863547-68-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(3-phenylpropyl)-
(CA INDEX NAME)

RN 863547-69-7 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-ethyl-6-(5-methyl-2-furanyl)-N-(phenylmethyl)-
(CA INDEX NAME)

RN 863547-70-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-phenylpropyl)-
(CA INDEX NAME)

RN 863547-71-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-6-(5-methyl-2-furanyl)-
(CA INDEX NAME)




RN 863547-72-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-phenylethyl)-
(CA INDEX NAME)

RN 863547-73-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-methyl-6-(5-methyl-2-furanyl)-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 863547-74-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 863547-75-5 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(2-methylpropyl)-

(CA INDEX NAME)




RN 863547-76-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-hexyl-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-77-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-butyl-N-methyl-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-78-8 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-N-methyl-6-(5-methyl-2-furanyl)-N-pentyl- (CA INDEX NAME)




RN 863547-79-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-(phenylmethyl)-
(CA INDEX NAME)


RN 863547-80-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-phenyl- (CA
INDEX NAME)

RN 863547-81-3 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(phenylmethyl)-
(CA INDEX NAME)

RN 863547-82-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-
pyrazol-5-yl)methyl]- (CA INDEX NAME)


RN 863547-83-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-84-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-85-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863547-86-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-87-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]- (CA INDEX NAME)




RN 863547-88-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-89-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-90-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 863547-91-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 863547-92-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1-methylethoxy)methyl]-2-pyridinylmethyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-93-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863547-94-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,6-dimethyl-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-95-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863547-96-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863547-97-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863547-98-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(5-methyl-2-furanyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 863547-99-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(4-pyrimidinylmethyl)- (CA INDEX NAME)




RN 863548-00-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[(4-methyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 863548-01-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-02-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-03-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-04-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methyl-2-thiazolyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863548-05-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(2-methylphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-06-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[[6-(methoxymethyl)-2-pyridinyl]methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-07-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methoxyphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-08-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methylphenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-09-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-fluorophenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-10-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-chlorophenyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-11-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(6-methyl-2-pyridinyl)methyl]-6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 863548-12-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-phenyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863548-13-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-14-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-15-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-16-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-cyanophenyl)-N-(2-pyridinylmethyl)-
(CA INDEX NAME)




RN 863548-17-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(2-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-18-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-19-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(4-methylphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-20-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-cyanophenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-21-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methylphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-22-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863548-23-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-6-(3-methoxyphenyl)-N-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 863548-24-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(3-methyl-2-pyridinyl)methyl]-6-phenyl-
(CA INDEX NAME)

RN 863548-59-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-amino-N-[(4-amino-3-methylphenyl)methyl]-6-(2-furanyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HC1

IC ICM A61K031-496

ICS A61K031-506; A61P021-00; C07D239-48

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): i, 63

IT Pain
(inflammatory; preparation of pyrimidine carboxamides as adenosine receptor antagonists)IT Pain
(neuropathic; preparation of pyrimidine carboxamides as adenosine receptor antagonists)IT Alzheimer's disease
Analgesics
Anti-Alzheimer's agents
Anti-ischemic agents
Antidepressants
Antidiabetic agents
Antiparkinsonian agents
Antipsychotics

Antitumor agents
 Anxiety
 Anxiolytics
 Bone marrow, disease
 Cardiovascular agents
 Cardiovascular system, disease
 Cognition enhancers
 Cognitive disorders
 Diabetes mellitus
 Eye, disease
 Granulomatous disease
 Human
 Hyperkinesia
 Hypnotics and Sedatives
 Ischemia
 Memory disorders
 Movement disorders
 Muscle relaxants
 Narcolepsy
 Nervous system agents
 Pain
 Parkinson's disease
 Psychotropics
 Purinoceptor antagonists
 Schizophrenia
 Sleep disorders
 Wernicke-Korsakoff syndrome
 Wilson's disease

(preparation of pyrimidine carboxamides as adenosine receptor antagonists)

IT 863546-62-7P, 2-Amino-6-(2-furyl)-N-[6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-66-1P,
 2-Amino-6-(2-furyl)-N-(3-methyl-4-nitrobenzyl)pyrimidine-4-carboxamide
 863547-20-8P, 2-Amino-6-(2-furyl)-N-[1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-23-3P,
 2-Amino-N-(6-bromopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide
 863547-42-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide
 863547-59-5P 863547-60-8P, 2-Amino-6-(2-furyl)-N-[[1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863547-61-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[(tert-butyl)dimethylsilyl]oxy]methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-62-0P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-hydroxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide
 863548-56-5P, 2-Amino-6-(2-furyl)-N-[1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide dihydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)

IT 863546-30-9P, 2-Amino-N-(2-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-31-0P, 2-Amino-N-(3,4-difluorophenyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-32-1P,
 2-Amino-6-(2-furyl)-N-(3-methoxybenzyl)pyrimidine-4-carboxamide 863546-33-2P, 2-Amino-6-(2-furyl)-N,N-dimethylpyrimidine-4-carboxamide 863546-34-3P, 1-[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonylpiperidine 863546-35-4P, 2-Amino-6-(2-furyl)-N-(2-methoxybenzyl)pyrimidine-4-carboxamide 863546-36-5P,
 2-Amino-6-(2-furyl)-N-[2-(2-furyl)methyl]pyrimidine-4-carboxamide 863546-37-6P, 2-Amino-6-(2-furyl)pyrimidine-4-carboxamide

863546-38-7P, 2-Amino-6-(2-furyl)-N-(4-dimethylaminobenzyl)pyrimidine-4-carboxamide 863546-39-8P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-40-1P, 2-Amino-6-(2-furyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-41-2P, 2-Amino-6-(2-furyl)-N-[3-(dimethylaminocarbonyl)benzyl]pyrimidine-4-carboxamide 863546-42-3P, 2-Amino-6-(2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863546-43-4P, 2-Amino-6-(2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863546-44-5P, 2-Amino-6-(2-furyl)-N-(2-methylbenzyl)pyrimidine-4-carboxamide 863546-45-6P, 2-Amino-N-(3-trifluoromethylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-46-7P, 2-Amino-N-(1H-benzimidazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-47-8P, 2-Amino-6-(2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863546-48-9P, 2-Amino-6-(2-furyl)-N-(3-methylbenzyl)pyrimidine-4-carboxamide 863546-49-0P, 2-Amino-6-(2-furyl)-N-[(3-methoxymethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-50-3P, 2-Amino-6-(2-furyl)-N-[(3-(dimethylamino)methyl)pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-51-4P, 2-Amino-6-(2-furyl)-N-[(3-(4-morpholinyl)methyl)pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-52-5P, 2-Amino-6-(2-furyl)-N-[(3,6-dimethylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-53-6P, 2-Amino-6-(2-furyl)-N-[(2-(2-thienyl)thiazol-4-yl)methyl]pyrimidine-4-carboxamide 863546-54-7P, 2-Amino-6-(2-furyl)-N-[(2-thienyl)methyl]pyrimidine-4-carboxamide 863546-55-8P, 2-Amino-6-(2-furyl)-N-[(5-(2-pyridyl)thien-2-yl)methyl]pyrimidine-4-carboxamide 863546-56-9P, 2-Amino-6-(2-furyl)-N-[(5-methyl-2-trifluoromethylfuran-3-yl)methyl]pyrimidine-4-carboxamide 863546-57-0P, 2-Amino-6-(2-furyl)-N-[(5-methylisoxazol-3-yl)methyl]pyrimidine-4-carboxamide 863546-58-1P, 2-Amino-6-(2-furyl)-N-[(2-methoxy-6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-59-2P, 2-Amino-N-[(6-fluoro-[1,3]benzodioxin-8-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-60-5P, 2-Amino-6-(2-furyl)-N-[(6-methylpyridin-3-yl)methyl]pyrimidine-4-carboxamide 863546-61-6P, 2-Amino-6-(2-furyl)-N-[(3-indolyl)methyl]pyrimidine-4-carboxamide 863546-63-8P, 2-Amino-6-(2-furyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]pyrimidine-4-carboxamide 863546-64-9P, 2-Amino-6-(2-furyl)-N-[(5-indolyl)methyl]pyrimidine-4-carboxamide 863546-65-0P, 2-Amino-N-(2,3-dimethylindol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-67-2P, N-[[6-[(N-Acetyl-N-methylamino)methyl]-3-methylpyridin-2-yl)methyl]-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-68-3P, 2-Amino-6-(2-furyl)-N-methyl-N-[2-(2-pyridyl)ethyl]pyrimidine-4-carboxamide 863546-69-4P, 2-Amino-6-(2-furyl)-N-[(2-methylindol-5-yl)methyl]pyrimidine-4-carboxamide 863546-70-7P, [6-[[[(2-Amino-6-(2-furyl)pyrimidin-4-yl)carbonyl]amino]methyl]pyridin-2-yl)methyl isopropylcarbamate 863546-71-8P, 2-Amino-N-benzyl-6-(2-furyl)pyrimidine-4-carboxamide 863546-72-9P, N-Allyl-2-amino-6-(2-furyl)pyrimidine-4-carboxamide 863546-73-0P, (R)-2-Amino-6-(2-furyl)-N-(2-hydroxypropyl)pyrimidine-4-carboxamide 863546-74-1P, 863546-75-2P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethyl-3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863546-76-3P, Methyl [[(2-amino-6-(2-furyl)pyrimidin-4-yl)carbonyl]amino]acetate 863546-77-4P, 2-Amino-6-(2-furyl)-N-[(6-indolyl)methyl]pyrimidine-4-carboxamide 863546-78-5P, 2-Amino-6-(2-furyl)-N-[(quinolin-8-yl)methyl]pyrimidine-4-carboxamide 863546-79-6P, 2-Amino-6-(2-furyl)-N-[2-(pyridin-2-yl)ethyl]pyrimidine-4-carboxamide 863546-80-9P, 2-Amino-N-(2-chlorobenzyl)-6-(2-furyl)pyrimidine-4-

carboxamide 863546-81-0F, 2-Amino-6-(2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863546-82-1P, 2-Amino-N-(2,1,3-benzothiadiazol-5-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-83-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl dimethylcarbamate 863546-84-3P, 2-Amino-6-(2-furyl)-N-[isoquinolin-3-yl)methyl]pyrimidine-4-carboxamide 863546-85-4P, 1-[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]-4-(2-pyridyl)piperazine 863546-86-5P, 2-Amino-6-(2-furyl)-N-[quinolin-2-yl)methyl]pyrimidine-4-carboxamide 863546-87-6P, 2-Amino-N-(benzothiazol-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-88-7P, 2-Amino-N-[[6-(cyclopropylmethoxy)methyl]-3-methylpyridin-2-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863546-89-8P, (S)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-90-3P, 2-Amino-N-(4-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-91-2F, 2-Amino-N-(4-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-92-3P, (R)-2-Amino-6-(2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863546-93-4P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl ester 863546-94-5P, 2-Amino-6-(2-furyl)-N-(4-methoxybenzyl)pyrimidine-4-carboxamide 863546-95-6P, 2-[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]-2,3-dihydro-1H-isoindole 863546-96-7P, 2-Amino-6-(2-furyl)-N-(2-methoxyethyl)pyrimidine-4-carboxamide 863546-97-8P, 2-Amino-N-(cyanomethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863546-98-9P, 2-Amino-6-(2-furyl)-N-(4-methylbenzyl)pyrimidine-4-carboxamide 863546-99-0P, 2-Amino-6-(2-furyl)-N-(1-phenyl-1-methylethyl)pyrimidine-4-carboxamide 863547-00-6P, 2-[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]-1,2,3,4-tetrahydroisoquinoline 863547-01-7P, 1-[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]-1,2,3,4-tetrahydroquinoline 863547-02-8P, 2-Amino-N-(3-fluorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-03-9P, 2-Amino-N-(3-chlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-04-0P, 1-[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]-2,3-dihydroindole 863547-05-1P, 2-Amino-6-(2-furyl)-N-(3-methylphenyl)pyrimidine-4-carboxamide 863547-06-2P, 2-Amino-6-(2-furyl)-N-(3-methylpyridin-2-yl)pyrimidine-4-carboxamide 863547-07-3P, (R)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-08-4P, (S)-2-Amino-6-(2-furyl)-N-(1-indanyl)pyrimidine-4-carboxamide 863547-09-5P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl piperidine-1-carboxylate 863547-10-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl pyrrolidine-1-carboxylate 863547-11-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl allylcarbamate 863547-12-0P, 2-Amino-6-(2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-13-1P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-14-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl n-propylcarbamate 863547-15-3P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl tert-butylcarbamate 863547-16-4P, 2-Amino-N-benzyl-6-(2-furyl)-N-methylpyrimidine-4-carboxamide 863547-17-5P, 2-Amino-6-(2-furyl)-N-[(5-methylpyrazin-2-yl)methyl]pyrimidine-4-carboxamide 863547-18-6P, 2-Amino-6-(2-furyl)-N-(1,2,3,4-tetrahydro-1-naphthyl)pyrimidine-4-carboxamide 863547-19-7P, 2-Amino-6-(2-furyl)-N-(2-indanyl)pyrimidine-4-carboxamide 863547-21-1P, 2-Amino-6-(2-furyl)-N-[(1-n-propyl-1H-imidazol-2-yl)methyl]pyrimidine-4-

carboxamide 863547-22-2P, 2-Amino-N-(2-bromobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-24-4P, 2-Amino-N-(6-aminopyridin-2-ylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-25-5P, 2-Amino-6-(2-furyl)-N-[3-(1H-imidazol-1-yl)propyl]pyrimidine-4-carboxamide 863547-26-6P, 2-Amino-6-(2-furyl)-N-[1-(2-methoxyethyl)-1H-imidazol-2-yl]methylpyrimidine-4-carboxamide 863547-27-7P, 2-Amino-N-[(1-ethyl-1H-imidazol-2-yl)methyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-28-8P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl benzylcarbamate 863547-29-9P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl cyclopentylcarbamate 863547-30-2P, [6-[[[2-Amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl hexylcarbamate 863547-31-3P, 2-Amino-N-[2-(dimethylamino)-6-methylpyridin-3-ylmethyl]-6-(2-furyl)pyrimidine-4-carboxamide 863547-32-4P, (R)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-33-5P, (S)-Methyl 2-[[[2-amino-6-(2-furyl)pyrimidin-4-yl]carbonyl]amino]-2-phenylacetate 863547-34-6P, 2-Amino-N-(2,6-dichlorobenzyl)-6-(2-furyl)pyrimidine-4-carboxamide 863547-35-7P, 2-Amino-6-(2-furyl)-N-[(6-methoxymethylpyridin-2-yl)methyl]-5-methylpyrimidine-4-carboxamide 863547-36-8P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-37-9P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-38-0P, 2-Amino-N-[[6-(n-propyl)pyridin-2-yl)methyl]-6-1H-(thiazol-2-yl)pyrimidine-4-carboxamide 863547-39-1P, 2-Amino-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-40-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-41-5P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]pyrimidine-4-carboxamide 863547-43-7P, [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl tert-butylcarbamate 863547-44-8P, Morpholine-4-carboxylic acid [6-[[[2-Amino-6-(5-methyl-2-furyl)pyrimidin-4-yl]carbonyl]amino]methyl]pyridin-2-yl)methyl ester 863547-45-9P, 2-Amino-5-chloro-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-46-0P, 2-Amino-5-bromo-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-47-1P, 2-Amino-5-bromo-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-48-2P, 2-Amino-N-(2-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-49-3P, 2-Amino-N-(3-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-50-6P, 2-Amino-N-(4-methylbenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-51-7P, 2-Amino-N-(2-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-52-6P, 2-Amino-N-(3-chlorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-53-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(3-pyridyl)methyl]pyrimidine-4-carboxamide 863547-54-0P, 2-Amino-6-(5-methyl-2-furyl)-N-[(4-pyridyl)methyl]pyrimidine-4-carboxamide 863547-55-1P, 2-Amino-N-(2-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-56-2P, 2-Amino-N-(3-methoxybenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-57-3P, 2-Amino-N-(3-fluorobenzyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-58-4P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-63-1P, 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-64-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(5-methylisoxazol-3-

yl)methyl]pyrimidine-4-carboxamide 863547-65-3P,
 2-Amino-6-(5-methyl-2-furyl)-N-[(tetrahydrofuran-2-yl)methyl]pyrimidine-4-carboxamide 863547-66-4P, 2-Amino-N-(cyclopropylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-67-5P,
 2-Amino-6-(5-methyl-2-furyl)-N-(2-phenylethyl)pyrimidine-4-carboxamide 863547-68-6P, 2-Amino-6-(5-methyl-2-furyl)-N-(3-phenylpropyl)pyrimidine-4-carboxamide 863547-69-7P,
 2-Amino-N-benzyl-N-ethyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-70-0P, 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylpropyl)pyrimidine-4-carboxamide 863547-71-1P,
 2-Amino-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-72-2P,
 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-73-3P, (S)-2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 863547-74-4P,
 2-Amino-6-(5-methyl-2-furyl)-N-(1-phenyl-1-methylthyl)pyrimidine-4-carboxamide 863547-75-5P, 2-Amino-N-isobutyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-76-6P,
 2-Amino-N-hexyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-77-7P, 2-Amino-N-butyl-N-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-78-8P,
 2-Amino-N-methyl-6-(5-methyl-2-furyl)-N-pentylpyrimidine-4-carboxamide 863547-79-9P, 2-Amino-N-benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-80-2P, 2-Amino-6-(5-methyl-2-furyl)-N-phenylpyrimidine-4-carboxamide 863547-81-3P,
 2-Amino-N-benzyl-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-82-4P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-5-yl)methyl]pyrimidine-4-carboxamide 863547-83-5P,
 2-Amino-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-84-6P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-85-7P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-86-8P,
 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-87-9P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]pyrimidine-4-carboxamide 863547-88-0P, 2-Amino-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-89-1P,
 N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-90-4P, 6-(5-Methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863547-91-5P,
 N-Benzyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-92-6P, 2-Amino-6-(5-methyl-2-furyl)-N-[[6-[(isopropoxy)methyl]pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-93-7P,
 6-(5-Methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863547-94-8P, N-(3,6-Dimethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-95-9P,
 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863547-96-0P,
 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863547-97-1P, 2-Amino-6-(5-methyl-2-furyl)-N-[(6-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863547-98-2P, 2-Amino-6-(5-methyl-2-furyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]pyrimidine-4-carboxamide 863547-99-3P,
 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyrimidin-4-yl)methyl]pyrimidine-4-carboxamide 863548-00-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(4-methylthiazol-2-yl)methyl]pyrimidine-4-carboxamide 863548-01-0P,
 2-Amino-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-02-1P, 2-Amino-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-(4-methylthiazol-2-yl)pyrimidine-4-

carboxamide 863548-03-2P, 2-Amino-6-(4-methylthiazol-2-yl)-N-[(pyridin-3-yl)methyl]pyrimidine-4-carboxamide 863548-04-3P, 2-Amino-6-(4-methylthiazol-2-yl)-N-(3-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-05-4P, 2-Amino-N-(2-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-06-5P, 2-Amino-N-(6-methoxymethylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-07-6P, 2-Amino-N-(3-methoxybenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-08-7P, 2-Amino-N-(3-methylbenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-09-8P, 2-Amino-N-(3-fluorobenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-10-1P, 2-Amino-N-(3-chlorobenzyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-11-2P, 2-Amino-N-(6-methylpyridin-2-ylmethyl)-6-(4-methylthiazol-2-yl)pyrimidine-4-carboxamide 863548-12-3P, 2-Amino-6-phenyl-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863548-13-4P, 2-Amino-6-phenyl-N-(pyridin-2-ylmethyl)pyrimidine-4-carboxamide 863548-14-5P, 2-Amino-6-(2-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-15-6P, 2-Amino-6-(4-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-16-7P, 2-Amino-6-(3-cyanophenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-17-8P, 2-Amino-6-(2-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-18-9P, 2-Amino-6-(3-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-19-0P, 2-Amino-6-(4-methylphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-20-3P, 2-Amino-6-(3-cyanophenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-21-4P, 2-Amino-6-(3-methylphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-22-5P, 2-Amino-6-(3-methoxyphenyl)-N-[(pyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-23-6P, 2-Amino-6-(3-methoxyphenyl)-N-[(3-methylpyridin-2-yl)methyl]pyrimidine-4-carboxamide 863548-24-7P, 2-Amino-N-(3-methylpyridin-2-ylmethyl)-6-phenylpyrimidine-4-carboxamide 863548-59-8P, 2-Amino-N-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine carboxamides as adenosine receptor antagonists)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:962044 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:248409

TITLE: Preparation of pyrimidine compounds as purine receptor, particularly adenosine receptor antagonists

INVENTOR(S): Gillespie, Roger John; Williamson, Douglas Stewart

PATENT ASSIGNEE(S): Vernalis R & D Ltd., UK

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079800	A1	20050901	WO 2005-GB497	20050211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LE, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1722798 A1 20061122 EP 2005-708320 20050211



R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, MK

PRIORITY APPLN. INFO.: GB 2004-3155 A 20040212
WO 2005-GB497 W 20050211

OTHER SOURCE(S): CASREACT 143:248409; MARPAT 143:248409

ED Entered STN: 02 Sep 2005

GI




AB The invention is related to the use of pyrimidines of formula (I) [R1 = (un)substituted alk(en/yn)yl, halo, NR6R7 and derivs., etc.; R2 = (un)substituted hetero/aryl attached via a C atom; R3 = H, halo, OH and derivs., (un)substituted alk(en/yn)yl, cycloalkyl; R4 = H, (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl; R5 = H, (un)substituted alk(en/yn)yl, cycloalkyl; NR4R5 = 5 or 6-membered heterocycle; R6 = H, (un)substituted alk(en/yn)yl, cycloalkyl; R7 = (un)substituted alk(en/yn)yl, cycloalkyl; NR6R7 = (un)substituted alk(en/yn)yl, cycloalkyl] and their pharmaceutically acceptable salts and prodrugs, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial. I are purine receptor, particularly adenosine receptor antagonists, useful for treatment of movement disorders such as Parkinsons disease. The invention is also related to the preparation of pyrimidines I. For example, coupling of 2-methylamino-6-(5-methylfuran-2-

yl)pyrimidine-4-carboxylic acid with pyridine-2-methanamine gave pyrimidine II in 9% yield. I displayed K_i values of $< 5 \mu\text{M}$ in an assay measuring in vitro binding to human adenosine A2A receptors.

IT 863495-30-1P, 2-Methylamino-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863495-31-2P, 2-Dimethylamino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-32-3P, 2-Dimethylamino-N-(3,6-dimethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-33-4P, N-Benzyl-2-dimethylamino-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-34-5P, 2-Dimethylamino-N-(2-pyridylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-35-6P, 2-Dimethylamino-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-36-7P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-37-3P, 2-Methyl-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-38-9P, N-Benzyl-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-39-0P, 2-Methyl-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863495-40-3P, N-(3,6-Dimethylpyridin-2-ylmethyl)-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-41-4P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-42-5P, 2-Isopropyl-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-43-6P, N-(3,6-Dimethylpyridin-2-ylmethyl)-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-44-7P, N-Benzyl-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-45-8P, 2-Isopropyl-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrimidines as adenosine receptor antagonists)


RN 863495-30-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(methylamino)-6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863495-31-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863495-32-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-N-[(3,6-dimethyl-2-pyridinyl)methyl]-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863495-33-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(5-methyl-2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 863495-34-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 863495-35-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(dimethylamino)-6-(5-methyl-2-furanyl)-N-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 863495-40-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,6-dimethyl-2-pyridinyl)methyl]-2-methyl-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863495-41-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-2-(1-methylethyl)-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863495-42-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-methylethyl)-6-(5-methyl-2-furanyl)-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 863495-43-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,6-dimethyl-2-pyridinyl)methyl]-2-(1-methylethyl)-6-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 863495-44-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-methylethyl)-6-(5-methyl-2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 863495-45-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(1-methylethyl)-6-(5-methyl-2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)



IC ICM A61K031-496

ICS A61K031-506; A61P021-00; C07D239-48

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT Alzheimer's disease

Anti-Alzheimer's agents

Anti-ischemic agents

Antidepressants

Antidiabetic agents

Antiparkinsonian agents

Antipsychotics

Antitumor agents

Anxiety

Anxiolytics

Bone marrow, disease

Cardiovascular agents

Cardiovascular system, disease

Cognition enhancers

Cognitive disorders

Diabetes mellitus
 Eye, disease
 Granulomatous disease
 Human
 Hyperkinesia
 Hypnotics and Sedatives
 Ischemia
 Memory disorders
 Movement disorders
 Muscle relaxants
 Narcolepsy
 Nervous system agents
 Parkinson's disease
 Psychotropics
 Furinoreceptor antagonists
 Schizophrenia
 Sleep disorders
 Wernicke-Korsakoff syndrome
 Wilson's disease

(preparation of pyrimidines as adenosine receptor antagonists)
 IT 863495-30-1P, 2-Methylamino-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863495-31-2P, 2-Dimethylamino-N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-32-3P, 2-Dimethylamino-N-(3,6-dimethylpyridin-2-ylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-33-4P, N-Benzyl-2-dimethylamino-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-34-5P, 2-Dimethylamino-N-(2-pyridylmethyl)-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-35-6P, 2-Dimethylamino-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-36-7P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-37-8P, 2-Methyl-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-38-9P, N-Benzyl-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-39-0P, 2-Methyl-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide 863495-40-3P, N-(3,6-Dimethylpyridin-2-ylmethyl)-2-methyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-41-4P, N-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-42-5P, 2-Isopropyl-6-(5-methyl-2-furyl)-N-(2-trifluoromethylbenzyl)pyrimidine-4-carboxamide 863495-43-6P, N-(3,6-Dimethylpyridin-2-ylmethyl)-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-44-7P, N-Benzyl-2-isopropyl-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide 863495-45-8P, 2-Isopropyl-6-(5-methyl-2-furyl)-N-[(2-pyridyl)methyl]pyrimidine-4-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidines as adenosine receptor antagonists)


REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:1127093 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:74591
 TITLE: Preparation of 2-arylcarbonyl- and 2-heteroarylcarbonylpyrimidine derivatives as

INVENTOR(S): cannabinoid receptor ligands
 DOW, Robert L.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040259887	A1	20041223	US 2004-846963	20040513
PRIORITY APPLN. INFO.: OTHER SOURCE(S):		MARPAT 142:74591	US 2003-479746P	P 20030618
ED Entered STN: 24 Dec 2004				

GI



AB The title compds. (I) [wherein R1, R2 = independently aryl or heteroaryl, where said aryl and said heteroaryl moieties are optionally substituted with one or more substituents, provided that R1 and R2 are not both a monosubstituted C1-4 alkoxyphenyl; R3 = H, C1-4 alkyl, or halo-substituted C1-4 alkyl; R4 = (NH)nN(R4a)(R4a') (where n = 0 or 1; R4a = H or optionally substituted C1-8 alkyl; R4b' = C1-8 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, partially or fully saturated C3-10 cycloalkyl, heteroaryl-C1-3 alkyl, 5- to 6-membered lactone, 5- to 6-membered lactam, 3- to 6-membered partially or fully saturated heterocycle, where said group is optionally substituted with one or more substituents; or R4a and R4a' taken together with the nitrogen to which they are attached form an optionally substituted 5- to 8-membered heterocycle)], pharmaceutically acceptable salts thereof, prodrugs of said compds. or said salts, or solvates or hydrates of said compds., said salts or said prodrugs are prepared. These compds. act as cannabinoid receptor ligands and are useful in the treatment of disease, condition or disorder modulated by a cannabinoid receptor antagonist which is selected from the group consisting of eating disorders, weight loss, obesity, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, substance abuse, addictive disorders, impulsivity, alcoholism, tobacco abuse, dementia, sexual dysfunction in males, seizure disorders, epilepsy, inflammation, gastrointestinal disorders, attention deficit activity disorder, Parkinson's disease, and type II diabetes. Thus, a stirred slurry of 5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl chloride (50 mg) and 4-acetyl-4-

phenylpiperidine hydrochloride (45 mg) in CH₂Cl₂ (1 mL) was cooled to 5° and treated dropwise with Et₃N (57 mg in 0.5 mL in CH₂Cl₂) to produce an orange solution which was allowed to warm to ambient temperature and then allowed to react for 1 h, concentrated, and purified by chromatog. to give 43 mg 1-[1-[[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl]carbonyl]-4-phenylpiperidin-4-yl]ethanone.


IT 812698-60-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylcarbonyl- and heteroarylcarbonylpyrimidine derivs. as cannabinoid receptor antagonists for treating diseases, conditions or disorders modulated by cannabinoid receptor antagonists)

RN 812698-60-5 HCAPLUS

CN 2,4-Pyrimidinedicarboxamide, 6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N2,N2-bis(phenylmethyl)- (CA INDEX NAME)



IC ICM A61K031-505

ICS A61K031-506; C07D043-02

INCL 5142560000; 5443330000; 544334000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT	811447-03-7P	811447-04-8P	811447-05-9P	811447-06-0P	811447-07-1P
	811447-08-2P	811447-09-3P	811447-10-6P	811447-11-7P	811447-12-8P
	811447-13-9P	811447-14-0P	811447-16-2P	811447-17-3P	811447-18-4P
	811447-19-5P	811447-20-8P	811447-21-9P	811447-22-0P	811447-23-1P
	811447-24-2P	811447-25-3P	811447-26-4P	811447-27-5P	811447-28-6P
	811447-29-7P	811447-30-0P	811447-31-1P	811447-32-2P	811447-33-3P
	811447-34-4P	811447-35-5P	811447-37-7P	811447-38-8P	811447-39-9P
	811447-40-2P	811447-41-3P	811447-42-4P	811447-43-5P	811447-44-6P
	811447-45-7P	811447-46-8P	811447-47-9P	811447-49-1P	811447-50-6P
	811447-51-5P	811447-52-6P	811447-53-7P	811447-54-8P	811447-55-9P
	811447-56-0P	811447-57-1P	811447-59-3P	811447-61-7P	811447-62-8P
	811447-63-9P	811447-64-0P	811447-65-1P	811447-66-2P	811447-67-3P
	811447-68-4P	811447-69-5P	811447-70-8P	811447-71-9P	811447-73-1P
	811447-74-2P	811447-75-3P	811447-76-4P	811447-77-5P	811447-78-6P
	811447-79-7P	811447-80-0P	811447-81-1P	811447-82-2P	811447-84-4P
	811447-85-5P	811447-86-6P	811447-87-7P	811447-89-9P	811447-91-3P
	811447-92-4P	811447-93-5P	811447-94-6P	811447-95-7P	811447-97-9P
	811447-99-1P	811448-00-7P	811448-01-8P	811448-02-9P	811448-03-0P
	811448-04-1P	811448-05-2P	811448-06-3P	811448-07-4P	811448-08-5P
	811448-09-6P	811448-10-9P	811448-11-0P	811448-12-1P	811448-14-3P
	811448-15-4P	811448-17-6P	811448-18-7P	811448-23-4P	811448-25-6P
	811448-27-8P	811448-29-0P	811448-31-4P	811448-33-6P	811448-35-8P

811448-37-0P	811448-39-2P	811448-41-6P	811448-43-8P	811448-45-0P
811448-46-1P	811448-47-2P	811448-48-3P	811448-49-4P	811448-50-7P
811448-51-8P	811448-52-9P	811448-53-0P	811448-54-1P	811448-55-2P
811448-56-3P	811448-57-4P	811448-58-5P	811448-59-6P	811448-60-9P
811448-61-0P	811448-62-1P	811448-63-2P	811448-64-3P	811448-65-4P
811448-66-5P	811448-67-6P	811448-68-7P	811448-69-8P	811448-70-1P
811448-71-2P	811448-72-3P	811448-73-4P	811448-74-5P	811448-75-6P
811448-76-7P	811448-77-8P	811448-78-9P	811448-79-0P	811448-80-3P
811448-81-4P	811448-82-5P	811448-83-6P	811448-84-7P	811448-85-8P
812698-54-7P	812698-55-8P	812698-56-9P	812698-57-0P	812698-58-1P
812698-60-5P	812698-61-6P	812698-64-9P	812698-65-0P	
812698-78-5P	812698-81-0P	812698-84-3P	812698-86-5P	812698-89-8P
812698-91-2P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of arylcarbonyl- and heteroarylcarbonylpyrimidine derivs. as
cannabinoid receptor antagonists for treating diseases, conditions or
disorders modulated by cannabinoid receptor antagonists)

L29 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1124645 HCAPLUS Full-text

DOCUMENT NUMBER: 142:56347

TITLE: Preparation of pyrimidine derivatives as cannabinoid
receptor ligands

INVENTOR(S): Dow, Robert L.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110453	A1	20041223	WO 2004-IB1971	20040609
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2529068	A1	20041223	CA 2004-2529068	20040609
EP 1638570	A1	20060329	EP 2004-736431	20040609
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004011617	A	20060808	BR 2004-11617	20040609
JP 2006527759	T	20061207	JP 2006-516548	20040609
MX 2005PA13282	A	20060309	MX 2005-PA13282	20051207
PRIORITY APPLN. INFO.:			US 2003-479746P	P 20030618
			WO 2004-IB1971	W 20040609

OTHER SOURCE(S): CASREACT 142:56347; MARPAT 142:56347

ED Entered STN: 23 Dec 2004

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1-2 = (hetero)aryl; R3 = H, (halo)alkyl; R4 = amino] are prepared For instance, II is prepared from 5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl chloride (preparation given) and 4-acetyl-4-phenylpiperidine hydrochloride. I are cannabinoid receptor; example compds. exhibit binding to the CB-1 receptor in the range of 0.1-10000 nM. I are useful for the treatment of a disease, condition or disorder which is modulated by a cannabinoid receptor antagonist.

IT 911447-72-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as cannabinoid receptor ligands)

RN 811447-72-0 HCAPLUS

CN 2,4-Pyrimidinedicarboxamide, 6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N2,N4-bis(phenylmethyl)- (CA INDEX NAME)



IC ICM A61K031-506

ICS C07D239-28; C07D401-06; C07D401-12; C07D403-06; C07D403-12;
C07D407-12; C07D407-14; C07D417-12; C07D487-08; A61P003-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 811447-03-7P, 1-[1-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl]-4-phenylpiperidin-4-yl]ethanone 811447-04-8P,
[1-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-yl]carbonyl]-4-phenylpiperidin-4-yl (pyrrolidin-1-yl)methanone 811447-05-9P,
5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811447-06-0P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (morpholin-4-yl)methanone 811447-07-1P,
(S)-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] [2-(methoxymethyl)pyrrolidin-1-yl]methanone 811447-08-2P,
[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] [4-(pyridin-2-yl)piperazin-1-yl]methanone 811447-09-3P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (4-hydroxypiperidin-1-yl)methanone 811447-10-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(2,2,6,6-tetramethylpiperidin-4-yl)amide 811447-11-7P,
5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(tetrahydropyran-4-yl)amide 811447-12-8P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-ethylpiperidin-3-yl)amide

811447-13-9P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] [3,4-dihydro-1H-isoquinolin-2-yl)methanone 811447-14-0P,
 cis-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (3,5-dimethylpiperidin-1-yl)methanone 811447-15-1P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-carboxylic acid N-(methoxymethyl)-N-propylamide
 811447-16-2P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (piperidin-1-yl)methanone 811447-17-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-carboxylic acid N-(6-fluorochroman-4-yl)amide
 811447-18-4P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] [4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)methanone 811447-19-5P
 811447-20-8P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(cyclohexyl)methyl]amide 811447-21-9P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-benzylamide 811447-22-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(adamantyl)amide
 811447-23-1P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (4-methylpiperazin-1-yl)methanone 811447-24-2P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (4-ethylpiperazin-1-yl)methanone
 811447-25-3P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (3-hydroxypiperidin-1-yl)methanone 811447-26-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3,3,5-trimethylcyclohexyl)amide 811447-27-5P, 1-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl]-4-phenylpiperidine-4-carbonitrile
 811447-28-6P, 1-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl]piperidine-4-carboxylic acid amide 811447-29-7P, ([1,4']Bipiperidinyl-1'-yl) [5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl)methanone 811447-30-0P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-methyl-N-(pyridin-2-yl)amide 811447-31-1P, [4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidin-2-yl] [4-(pyridin-2-yl)piperazin-1-yl)methanone
 811447-32-2P, 4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811447-33-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(indan-2-yl)amide
 811447-34-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(4-cyanocyclohexyl)methyl]amide 811447-35-5P
 811447-36-6P 811447-37-7P 811447-38-8P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(5-methylpyridin-2-yl)amide
 811447-39-9P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(6-methylpyridin-2-yl)amide 811447-40-2P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(pyridin-3-yl)amide 811447-41-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3-methylisothiazol-5-yl)amide
 811447-42-4P 811447-43-5P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-benzylpiperidin-4-yl)amide
 811447-44-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(piperidin-4-yl)amide
 811447-45-7P, cis-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (2,6-dimethylpiperidin-1-yl)methanone 811447-46-8P 811447-47-9P
 811447-48-0P 811447-49-1P 811447-50-4P 811447-51-5P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3,4,5,6-tetrahydro[1,2']bipyridinyl-4-yl)amide 811447-52-6P,
 cis-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] (2,6-dimethylmorpholin-4-yl)methanone 811447-53-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[1-(pyrimidin-2-yl)pyrrolidin-3-yl]amide
 811447-54-8P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl] [4-(pyrimidin-2-yl)piperazin-1-yl)methanone
 811447-55-9P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(pyridin-4-yl)methyl]amide 811447-56-0P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(1R,2R)-2-benzylcyclopentan-1-yl]amide 811447-57-1P,

5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[(2,3-dihydrobenzofuran-5-yl)methyl]amide 811447-58-2P 811447-59-3P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-(2-methoxy-1-methylethyl)amide 811447-60-6P 811447-61-7P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[4-[(cyclopropyl)methyl]carbamoylethyl]amide 811447-62-8P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[(1S,2R)-2-hydroxycycloheptyl)methyl]amide 811447-63-9P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[(pyridin-2-yl)methyl]amide 811447-64-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(pyridin-3-yl)methyl]amide
 811447-65-1P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(2-fluoro-4-trifluoromethylbenzyl)amide 811447-66-2P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[4-(trifluoromethoxy)benzyl]amide 811447-67-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-fluorobenzyl)amide
 811447-68-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-phenylethyl)amide 811447-69-5P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[4-(1-hydroxy-1-methylethyl)benzyl]amide 811447-70-8P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[5-chloro-2-(isopropoxy)benzyl]amide 811447-71-9P 811447-72-0P
 811447-73-1P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-isopropylbenzyl)amide 811447-74-2P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-(4-chlorobenzyl)amide 811447-75-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(2-hydroxyethyl)-N-propylamide 811447-76-4P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl][4-(2-hydroxyethyl)piperidin-1-yl]methanone
 811447-77-5P, 5-(4-Chlorophenyl)-4-methyl-6-(pyridin-4-yl)pyrimidine-2-carboxylic acid N-(cyclohexyl)amide 811447-78-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-methyl-N-(1-methylpyrrolidin-3-yl)amide 811447-79-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(1S)-1-phenylethyl]amide
 811447-80-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(1R)-1-phenylethyl]amide 811447-81-1P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-(1-benzylpyrrolidin-3-yl)-N-methylamide 811447-82-2P,
 (R)-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl](2-hydroxymethylpyrrolidin-1-yl)methanone 811447-83-3P 811447-84-4P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-(indan-1-yl)amide 811447-85-5P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(cyano)(phenyl)methyl]amide
 811447-86-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[1-(4-fluorophenyl)ethyl]amide 811447-87-7P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[1-(4-chlorophenyl)ethyl]amide 811447-89-9P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-phenylpropyl)amide
 811447-91-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[1-(2-methoxyphenyl)ethyl]amide 811447-92-4P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[(1S)-1-(4-methylphenyl)ethyl]amide 811447-93-5P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811447-94-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[1-(4-cyanophenyl)ethyl]amide 811447-95-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]methyl]amide 811447-97-9P,
 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid
 N-[(6-methylpyridin-2-yl)methyl]amide 811447-99-1P, 5-(4-Chlorophenyl)-4-

(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(6-methylpyridin-3-yl)methyl]amide 811448-00-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(tetrahydrofuran-2-yl)methyl]amide 811448-01-8P 811448-02-9P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl](4-methyl[1,4]diazepan-1-yl)methanone 811448-03-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-cyanobenzyl)amide 811448-04-1P, [5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl](4-phenylpiperidin-1-yl)methanone 811448-05-2P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(cyclopentyl)amide 811448-06-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(cyclobutyl)amide 811448-07-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(cyclooctyl)amide 811448-08-5P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid isobutylamide 811448-09-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-methylcyclohexyl)amide 811448-10-9P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-tert-butylcyclohexyl)amide 811448-11-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-isopropyl-2-methylpropyl)amide 811448-12-1P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(cis-4-tert-butylcyclohexyl)amide 811448-14-3P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3,3-dimethylbutyl)amide 811448-15-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(2,2,2-trifluoroethyl)amide 811448-17-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-[(1R)-1-(cyclohexyl)ethyl]amide 811448-18-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1S)-1,2,2-trimethylpropyl)amide 811448-19-8P 811448-21-2P 811448-23-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(2,3,3,3-pentafluoropropyl)amide 811448-25-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4,4,4-trifluoro-2-methylbutyl)amide 811448-27-8P 811448-29-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1,1-dimethylpropyl)amide 811448-31-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3-methylcyclohexyl)amide 811448-33-6P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1,2-dimethylpropyl)amide 811448-35-8P, 4-(4-Chloro-2-fluorophenyl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-37-0P, 4-(4-Chloro-2-fluorophenyl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid benzylamide 811448-39-2P 811448-41-6P, 5-(4-Chlorophenyl)-4-(2-chlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-43-8P, 5-(4-Chlorophenyl)-4-(2-chlorophenyl)pyrimidine-2-carboxylic acid benzylamide 811448-45-0P 811448-46-1P, 4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-47-2P 811448-48-3P, 4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-49-4P, 5-(4-Chlorophenyl)-4-(5-chloropyridin-2-yl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-50-7P, 5-(4-Chlorophenyl)-4-(5-chloropyridin-2-yl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-51-8P, 4-(2-Chloro-4-fluorophenyl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-52-9P, 5-(4-Chlorophenyl)-4-(2-trifluoromethylphenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-53-0P, 5-(4-Chlorophenyl)-4-(2-trifluoromethylphenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-54-1P 811448-55-2P 811448-56-3P, 4-(2-Chloro-4-fluorophenyl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-57-4P 811448-58-5P 811448-59-6P, 5-(4-Chlorophenyl)-4-(4-fluoro-2-trifluoromethylphenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-

phenylethyl)amide 811448-60-9P, 5-(4-Chlorophenyl)-4-(4-fluoro-2-trifluoromethylphenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-61-0P, 4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid N-((1R)-1-phenylethyl)amide 811448-62-1P, 4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid N-[2-(4-fluorophenyl)-1,1-dimethylethyl]amide 811448-63-2P, 4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carboxylic acid N-(indan-2-yl)amide 811448-64-3P, 1-[4-(5-Bromopyridin-2-yl)-5-(4-chlorophenyl)pyrimidine-2-carbonyl]-4-phenylpiperidine-4-carbonitrile 811448-65-4P, 5-(4-Chlorophenyl)-4-(2,4-dimethylphenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-66-5P, 5-(4-Chlorophenyl)-4-(2,4-dimethylphenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-67-6P 811448-68-7P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid cyclohexylamide 811448-69-8P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(1-methyl-1-phenylethyl)amide 811448-70-1P 811448-71-2P, 1-[5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carbonyl]-4-phenylpiperidine-4-carbonitrile 811448-72-3P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(indan-2-yl)amide 811448-73-4P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-((1R)-1-phenylethyl)amide 811448-74-5P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(4-methylcyclohexyl)amide 811448-75-6P, 5-(5-Chloropyridin-2-yl)-4-(2,4-dichlorophenyl)pyrimidine-2-carboxylic acid N-(3-methylcyclohexyl)amide 811448-76-7P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-6-methylpyrimidine-2-carboxylic acid cyclohexylamide 811448-77-8P, 4-(2,4-Dichlorophenyl)-5-(4-fluorophenyl)-6-methylpyrimidine-2-carboxylic acid cyclohexylamide 811448-78-9P, 4-(2,4-Dichlorophenyl)-5-(4-fluorophenyl)-6-methylpyrimidine-2-carboxylic acid benzylamide 811448-79-0P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-6-methylpyrimidine-2-carboxylic acid benzylamide 811448-80-3P 811448-81-4P, 5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-6-methylpyrimidine-2-carboxylic acid N-((1R)-1-phenylethyl)amide 811448-82-5P, 5-(4-Chlorophenyl)-4-(3-chloropyridin-4-yl)-6-methylpyrimidine-2-carboxylic acid cyclohexylamide 811448-83-6P 811448-84-7P, 5-(4-Chlorophenyl)-4-(3-chloropyridin-4-yl)-6-methylpyrimidine-2-carboxylic acid benzylamide 811448-85-8P, 5-(4-Chlorophenyl)-4-methyl-6-(pyridin-4-yl)pyrimidine-2-carboxylic acid N-benzylamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as cannabinoid receptor ligands)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857577 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:350188

TITLE: Preparation of 2,4,6-trisubstituted pyrimidine derivatives as apoptosis inducers for the treatment of neoplastic and autoimmune diseases

INVENTOR(S): Obrecht, Daniel; Ermert, Philipp; Luther, Anatol; Eberle, Martin; Bachmann, Felix

PATENT ASSIGNEE(S): Aponetics Ag, Switz.

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087679	A1	20041014	WO 2004-EP3296	20040329
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
EP 1644338	A1	20060412	EP 2004-723991	20040329
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK</p>				
PRIORITY APPLN. INFO.:			EP 2003-405219	A 20030401
			EP 2003-405642	A 20030903
			WO 2004-EP3296	W 20040329
OTHER SOURCE(S): MARPAT 141:350188				
ED Entered SIN: 18 Oct 2004				
GI				




AB Title compds. I [wherein V = bond, CR6R7; W = bond, NR8, O; X = S, NH, NR5; Y = CH2, CH2CH2, CO, CS; R1 = (un)substituted (hetero)aryl; R2, R3 = independently H, (un)substituted alkyl, cycloalkyl(alkyl), (hetero)aryl(alkyl), heterocyclyl, alkenyl, alkynyl, etc.; or R2 = OH, (un)substituted NH2; or NR2R3 = (un)substituted heterocyclyl; R4, R5 = independently (un)substituted alkyl, cycloalkyl(alkyl), alkenyl, alkynyl, (hetero)aryl(alkyl); or NR4R5 = (un)substituted heterocyclyl; R6, R7 = independently H, alkyl; or CR6R7 = carbocyclyl, heterocyclyl; R8 = H, alkyl; and pharmaceutically acceptable salts thereof] were prepared as selective inducers of apoptosis in cancer cells. For example, amidation of 2-(hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid with 1-(3-aminopropyl)-4-methylpiperazine (preparation of starting materials given)

and workup provided II•HCl. In Hoechst 33342 nuclear staining assays, the latter exhibited strong apoptotic activity (>50% cell death) at 48 h after administration at concns. of 10 μ M against K562, Jurkat, A20, HeLa, KB, and DM human carcinoma cell lines. Thus, I and their pharmaceutical compns. are useful for the treatment of neoplastic disease, autoimmune disease, transplantation related pathol., and /or degenerative disease (no data).

- IT 775348-91-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-00-3P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-tert-butoxycarbonylpiperazin-1-yl)ethyl]amide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (apoptosis inducer; preparation of trisubstituted pyrimidines as apoptosis inducers for treatment of neoplastic and autoimmune diseases)
- RN 775348-91-9 HCAPLUS
- CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-(4-methyl-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



- RN 775349-00-3 HCAPLUS
- CN 1-Piperazinecarboxylic acid, 4-[2-[[2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



- IT 775348-93-1F 775349-01-4P 775349-02-5P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-(4-dimethylaminobenzyl)amide 775349-03-6P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(1-methylpyrrolidin-2-yl)ethyl]amide 775349-04-7P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(dimethylamino)ethyl]amide 775349-05-8P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(dimethylamino)propyl]amide 775349-06-9P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(1H-imidazol-1-yl)propyl]amide 775349-07-0P,
 2-[(6-Hydroxyhexyl)mercapto]-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide


775349-08-1P, 2-[(4-Methoxybenzyl)mercapto]-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-09-2P, 2-(Octylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-10-5P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-ethylpiperazin-1-yl)ethyl]amide 775349-11-6P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-benzylpiperazin-1-yl)ethyl]amide 775349-12-7P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(pyrrolidin-1-yl)ethyl]amide 775349-13-8P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(piperidin-1-yl)ethyl]amide 775349-14-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)ethyl]amide 775349-15-0P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(diethylamino)ethyl]-N-methylamide 775349-16-1P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(2-methylpiperidin-1-yl)propyl]amide 775349-17-2P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(diethylamino)ethyl]amide 775349-18-3P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[(1-ethylpyrrolidin-2-yl)methyl]amide 775349-19-4P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(pyrrolidin-1-yl)propyl]amide 775349-20-7P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-benzylpiperazin-1-yl)propyl]amide 775349-21-3P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]amide 775349-22-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-(1-benzylpyrrolidin-3-yl)-N-methylamide 775349-23-0P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-methyl-N-(1-methylpiperidin-4-yl)amide 775349-24-1P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(diethylamino)propyl]-N-methylamide 775349-25-2P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-ethylpiperazin-1-yl)propyl]amide 775349-26-3P, 2-(Ethylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-27-4P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(dimethylamino)ethyl]-N-methylamide 775349-28-5P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(diethylamino)propyl]amide 775349-36-5P, 2-(Hexylmercapto)-6-(3,4-methylenedioxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-37-6P, 2-(Hexylmercapto)-6-(3,4-methylenedioxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)ethyl]amide 775349-46-9P, 2-(N-Hexyl-N-methylamino)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide 775349-66-1P 775349-67-2P 775349-68-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(apoptosis inducer; preparation of trisubstituted pyrimidines as apoptosis inducers for treatment of neoplastic and autoimmune diseases)

RN 775348-93-1 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 775349-01-4 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(1-piperazinyl)ethyl]-6-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 775349-02-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[4-(dimethylamino)phenylmethyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-03-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-04-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-05-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(dimethylamino)propyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-06-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-(1H-imidazol-1-yl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-07-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(6-hydroxyhexyl)thio]-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-08-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[[[4-(4-methoxyphenyl)methyl]thio]-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-09-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-2-(octylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-10-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[2-(4-ethyl-1-piperazinyl)ethyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-11-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-12-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(1-pyrrolidinyl)ethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-13-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(1-piperidinyl)ethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-14-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(4-methyl-1-piperazinyl)ethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-15-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[2-(diethylamino)ethyl]-2-(hexylthio)-N-methyl-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-16-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-(2-methyl-1-piperidinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-17-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[2-(diethylamino)ethyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-18-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-19-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-(1-pyrrolidiny)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-20-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[3-[4-(phenylmethyl)-1-piperazinyl]propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-21-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-[2-(4-methyl-1-piperazinyl)-1-phenylethyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-22-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-methyl-N-[1-(phenylmethyl)-3-pyrrolidiny]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-23-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylthio)-N-methyl-N-(1-methyl-4-piperidinyl)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-24-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(diethylamino)propyl]-2-(hexylthio)-N-methyl-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-25-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(4-ethyl-1-piperazinyl)propyl]-2-(hexylthio)-N-methyl-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-26-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(ethylthio)-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-27-4 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-2-(hexylthio)-N-methyl-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-28-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(diethylamino)propyl]-2-(hexylthio)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-36-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(1,3-benzodioxol-5-yl)-2-(hexylthio)-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 775349-37-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-(1,3-benzodioxol-5-yl)-2-(hexylthio)-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 775349-48-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylmethylamino)-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-66-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-(hexylamino)-N-[3-(4-methyl-1-piperazinyl)propyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 775349-67-2 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-2-[4-(phenylmethyl)-1-piperidinyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 775349-68-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-2-[4-(phenylmethyl)-1-piperazinyl]-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



IC ICM C07D239-40

ICS C07D239-42; C07D403-12; C07D401-06; C07D405-04; C07D401-04;
A61K031-505; A61P035-00; A61P037-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 775349-91-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-00-3P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-tert-butoxycarbonylpiperazin-1-yl)ethyl]amide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(apoptosis inducer; preparation of trisubstituted pyrimidines as apoptosis inducers for treatment of neoplastic and autoimmune diseases)

IT 775349-93-1P 775349-01-4P 775349-02-5P,
2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-(4-dimethylaminobenzyl)amide 775349-03-6P,
2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(1-methylpyrrolidin-2-yl)ethyl]amide 775349-04-7P,
2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(dimethylamino)ethyl]amide 775349-05-8P,

2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(dimethylamino)propyl]amide 775349-06-9P,
 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(1H-imidazol-1-yl)propyl]amide 775349-07-0P,
 2-[(6-Hydroxyhexyl)mercapto]-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-08-1P, 2-[(4-Methoxybenzyl)mercapto]-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-09-2P, 2-(Octylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-10-5P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-ethylpiperazin-1-yl)ethyl]amide 775349-11-6P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-benzylpiperazin-1-yl)ethyl]amide 775349-12-7P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(pyrrolidin-1-yl)ethyl]amide 775349-13-6P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(piperidin-1-yl)ethyl]amide 775349-14-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)ethyl]amide 775349-15-0P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(diethylamino)ethyl]-N-methylamide 775349-16-1P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(2-methylpiperidin-1-yl)propyl]amide 775349-17-2P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(diethylamino)ethyl]amide 775349-18-3P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[(1-ethylpyrrolidin-2-yl)methyl]amide 775349-19-4P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(pyrrolidin-1-yl)propyl]amide 775349-20-7P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-benzylpiperazin-1-yl)propyl]amide 775349-21-8P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]amide 775349-22-9P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-(1-benzylpyrrolidin-3-yl)-N-methylamide 775349-23-0P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-methyl-N-(1-methylpiperidin-4-yl)amide 775349-24-1P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(diethylamino)propyl]-N-methylamide 775349-25-2P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-ethylpiperazin-1-yl)propyl]amide 775349-26-3P, 2-(Ethylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-27-4P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[2-(dimethylamino)ethyl]-N-methylamide 775349-28-5P, 2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid N-[3-(diethylamino)propyl]amide 775349-29-6P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-[2-(dimethylamino)ethyl]piperazine 775349-30-9P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-(piperidin-1-yl)piperidine 775349-31-0P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-(pyrimidin-2-yl)piperazine 775349-32-1P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-(4-ethylpiperazin-1-yl)piperidine 775349-33-2P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-(pyridin-2-yl)piperazine 775349-34-3P, 1-[[2-(Hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]carbonyl]-4-(pyrrolidin-1-yl)piperidine 775349-36-5P, 2-(Hexylmercapto)-6-(3,4-5-

methylenedioxyphenyl)pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-37-6P, 2-(Hexylmercapto)-6-(3,4-methylenedioxyphenyl)pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)ethyl]amide 775349-38-7P, 3-(4-Methylpiperazin-1-yl)propionic acid N-[(2-(hexylmercapto)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl)methyl]amide 775349-42-3P, 2-(Hexylmercapto)-4-[[[3-(4-methylpiperazin-1-yl)propyl]amino]methyl]-6-(3,4,5-trimethoxyphenyl)pyrimidine dihydrochloride 775349-46-7P, 2-(Hexylmercapto)-4-[[[methyl]3-(4-methylpiperazin-1-yl)propyl]amino]methyl]-6-(3,4,5-trimethoxyphenyl)pyrimidine dihydrochloride 775349-48-9P, 2-(N-Hexyl-N-methylamino)-6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide 775349-52-5P, 2-(Hexylmercapto)-6-[(3,4,5-trimethoxyphenyl)amino]pyrimidine-4-carboxylic acid N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]amide 775349-57-0P, 2-(Hexylmercapto)-4-[[[3-(4-methylpiperazin-1-yl)propyl]amino]methyl]-6-[(3,4,5-trimethoxyphenyl)amino]pyrimidine 775349-62-7P, 2-(Hexylmercapto)-6-[(3,4,5-trimethoxyphenyl)amino]pyrimidine-4-carboxylic acid N-[3-(4-methylpiperazin-1-yl)propyl]amide 775349-63-8P 775349-64-9P 775349-65-0P 775349-66-1P 775349-67-2P 775349-68-3P 775349-69-4P 775349-70-7P 775349-71-8P 775349-72-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(apoptosis inducer; preparation of trisubstituted pyrimidines as apoptosis inducers for treatment of neoplastic and autoimmune diseases)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780678 HCAPLUS Full-text

DOCUMENT NUMBER: 141:277637

TITLE: Preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives for inhibition of angiogenesis

INVENTOR(S): Lee, Jinho; Kim, Hak Joong; Choi, Seihyun; Choi, Hwan Geun; Yoon, Seunghyun; Kim, Jong-Hyun; Jo, Kiwon; Kim, Semi; Koo, Sun-Young; Kim, Min-Hyeung; Kim, Jung In; Hong, Sang-Yong; Kim, Mi Sun; Ahn, Shinyoung; Yoon, Hae-Seong; Cho, Heung-Soo

PATENT ASSIGNEE(S): LG Life Sciences Ltd., S. Korea

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080979	A1	20040923	WO 2004-KR301	20040213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			

10/588757


ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2003-454335P P 20030314
 OTHER SOURCE(S): CASREACT 141:277637; MARPAT 141:277637
 ED Entered SIN: 24 Sep 2004
 GI




AB Title compds. I [R1 = (hetero)aromatic ring; R2 = H, alkyl, aryl, etc.; R3 = H, alkyl, X1n1NX2X3, etc.; X1 = H, alkylene, etc.; X2 = H, alkoxy, pyrrolidine, etc.; n1 = 0-1; X3 = H, alkyl, (hetero)aryl, etc.] are prepared For instance, [3-(2-aminopyrimidin-4-yl)-4-hydroxyphenyl]phenylmethanone (II) is prepared from 3-(2-aminopyrimidin-4-yl)-4-benzyloxy-N-methoxy-N-methylbenzamide (preparation given) and bromobenzene (THF, n-BuLi, -78°) in 47.5% yield. II has IC50 > 0.1 µM for KDR kinase. I are angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ('KDR'); they are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy.

IT 761001-00-7P 761001-01-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs. for inhibition of angiogenesis)

RN 761001-00-7 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-amino-6-[5-(2-fluoro-4-methylbenzoyl)-2-hydroxyphenyl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 761001-01-8 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-amino-6-[5-(2-fluoro-4-methylbenzoyl)-2-hydroxyphenyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IC ICM C07D239-42
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 761000-95-7P 761000-96-8P 761000-97-9P 761000-99-1P
 761001-00-7P 761001-01-3P 761001-02-9P 761001-03-0P
 761001-04-1P 761001-05-2P 761001-06-3P 761001-07-4P 761001-08-5P
 761001-09-6P 761001-10-9P 761001-11-0P 761001-12-1P 761001-13-2P
 761001-14-3P 761001-15-4P 761001-16-5P 761001-17-6P 761001-18-7P
 761001-19-8P 761001-20-1P 761001-21-2P 761001-22-3P 761001-23-4P
 761001-24-5P 761001-25-6P 761001-26-7P 761001-27-8P 761001-28-9P
 761001-29-0P 761001-30-3P 761001-31-4P 761001-32-5P 761001-33-6P
 761001-34-7P 761001-35-8P 761001-36-9P 761001-37-0P 761001-38-1P
 761001-39-2P 761001-40-5P 761001-41-6P 761001-42-7P 761001-43-8P
 761001-44-9P 761001-45-0P 761001-46-1P 761001-47-2P 761001-48-3P
 761001-49-4P 761001-50-7P 761001-51-8P 761001-52-9P 761001-53-0P
 761001-54-1P 761001-55-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs.
 for inhibition of angiogenesis)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:261809 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:287519

TITLE: Preparation of phenethylamines for the treatment of
 Alzheimer's disease

INVENTOR(S): Gailunas, Andrea; Tucker, John Alan; John, Varghese

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027068	A2	20030403	WO 2002-US30231	20020924
WO 2003027068	A3	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2461603 A1 20030403 CA 2002-2461603 20020924
 AU 2002356525 A1 20030407 AU 2002-356525 20020924
 EP 1430032 A2 20040623 EP 2002-799615 20020924
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002012787 A 20050125 BR 2002-12787 20020924
 JP 2005514330 T 20050519 JP 2003-530659 20020924
 MX 2004PA02785 A 20040729 MX 2004-PA2785 20040324
 US 20060100196 A1 20060511 US 2004-490682 20041213
 PRIORITY APPLN. INFO.: US 2001-324407P P 20010924
 WO 2002-US30231 W 20020924

OTHER SOURCE(S): MARPAT 138:287519
 ED Entered STN: 04 Apr 2003
 GI




- AB Title compds. and heteroarylalkyl-substituted derivs. I [wherein R1 = (un)substituted (CH2)1-2SO0-2-alkyl, alkyl, alkenyl, alkynyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = (un)substituted R2', SO2R2', (CRR')1-6R2', CO(CRR')0-6R2, CO(CRR')1-6OR2', CO(CRR')1-6SR2', CO(CRR')1-6COR2, CO(CRR')1-6SO2R2, or CO(CRR')1-6NR2R2'; R and R' = independently H, alkyl, or alkyl(hetero)aryl; R2 and R2' = independently (un)substituted (hetero)aryl, heterocyclyl, (hetero)aryl-W-(hetero)aryl; (hetero)aryl-W-heterocyclyl, heterocyclyl-W-(hetero)aryl, etc.; W = (CH2)0-4, O, SO0-2, NR4, CR(OH), or CO; R4 = alkyl, alkenyl, alkynyl, cycloalkyl, (CH2)0-2-(hetero)aryl, or (CH2)0-2-heterocyclyl; Ra = H, CH2OH, or CH(OH)CH2CH2R2a; R2a = (un)substituted heteroaryl or heterocyclyl; or pharmaceutically acceptable salts thereof] were prepared for treating Alzheimer's disease and other similar disease (no data). For example, Me N,N-dipropylisophthalamic acid was coupled with the toxic acid salt of 3,5-difluorophenethylamine in the presence of N-methylmorpholine, 1-hydroxy-7-azabenzotriazole, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl in DMF to give II. I include inhibitors of the β -secretase enzyme that are useful in the treatment of diseases characterized by deposition of a β peptide (no data).
- IT 503611-04-9P, N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-Alzheimer's agent; preparation of phenethylamines for treatment of Alzheimer's disease)

RN 503611-04-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[1-[(3,5-difluorophenyl)methyl]-2-hydroxy-4-(1H-pyrazol-3-yl)butyl]-2-(dipropylamino)-6-(2-oxazolyl)- (CA INDEX NAME)



IC ICM C07D207-00

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT 503610-83-1P, N-[2-(3,5-Difluorophenyl)ethyl]-5-methyl-N',N'-dipropylisophthalamide 503610-85-3P, N'-[1-(1S)-1-(3,5-Difluorobenzyl)-2-hydroxyethyl]-5-methyl-N,N-dipropylisophthalamide 503610-87-5P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-2-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-88-6P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-89-7P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-90-0P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-91-1P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-92-2P, N'-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-5-methyl-N,N-dipropylisophthalamide 503610-93-3P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-94-4P, N'-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-5-methyl-N,N-dipropylisophthalamide 503610-95-5P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-2-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503610-96-6P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503610-97-7P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503610-98-8P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503610-99-9P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503611-00-5P, N3-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503611-01-6P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-N1,N1-dipropylbenzene-1,3,5-tricarboxamide 503611-02-7P, N3-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-N1,N1-

dipropylbenzene-1,3,5-tricarboxamide 503611-03-8P, N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-04-9P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-05-0P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-06-1P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-07-2P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-08-3P,
 N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-09-4P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-10-7P,
 N-[1-(3,5-Difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-11-8P,
 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-12-9P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-13-0P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-14-1P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-15-2P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-16-3P,
 N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-1-butyl-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-17-4P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-18-5P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-19-6P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-20-9P,
 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-21-0P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-22-1P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-23-2P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-24-3P,
 N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-4-butyl-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-25-4P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-26-5P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-27-6P,
 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-28-7P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-29-8P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-30-1P, 4-Butyl-N-[1-(3,5-

difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-31-2P,
 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide
 503611-32-3P, N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-4-butyl-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-33-4P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-34-5P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-35-6P,
 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide
 503611-36-7P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide
 503611-37-8P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-38-9P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-39-0P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-40-3P,
 N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-4-butyl-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide
 503611-41-4P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-42-5P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-43-6P,
 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrrol-2-yl)butyl]-1H-indole-6-carboxamide 503611-44-7P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-pyrazol-5-yl)butyl]-1H-indole-6-carboxamide 503611-45-8P,
 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,4-triazol-5-yl)butyl]-1H-indole-6-carboxamide 503611-46-9P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-1,2,3-triazol-5-yl)butyl]-1H-indole-6-carboxamide 503611-47-0P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(1H-indol-2-yl)butyl]-1H-indole-6-carboxamide 503611-48-1P,
 N-[4-(1H-Benzimidazol-2-yl)-1-(3,5-difluorobenzyl)-2-hydroxybutyl]-1-butyl-1H-indole-6-carboxamide 503611-49-2P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(5-oxopyrrolidin-2-yl)butyl]-1H-indole-6-carboxamide
 503611-50-5P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxy-4-(6-oxopiperidin-2-yl)butyl]-1H-indole-6-carboxamide 503611-51-6P,
 1-Butyl-N-[2-(3,5-difluorophenyl)ethyl]-1H-indole-6-carboxamide
 503611-52-7P, 4-Butyl-N-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-53-8P,
 4-Butyl-N-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-54-9P, 4-Butyl-N-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-55-0P, 1-Butyl-N-[2-(3,5-difluorophenyl)ethyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoline-7-carboxamide 503611-56-1P,
 N-[2-(3,5-Difluorophenyl)ethyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide 503611-57-2P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxyethyl]-1H-indole-6-carboxamide 503611-58-3P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxyethyl]-8-(1,3-oxazol-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide 503611-59-4P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxyethyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide 503611-60-7P, 4-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxyethyl]-8-(1,3-oxazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide 503611-61-8P, 1-Butyl-N-[1-(3,5-difluorobenzyl)-2-hydroxyethyl]-5-(1,3-oxazol-2-yl)-1,2,3,4-

tetrahydroquinoline-7-carboxamide 503611-62-9P, N-[1-(3,5-Difluorobenzyl)-2-hydroxyethyl]-2-(dipropylamino)-6-(1,3-oxazol-2-yl)isonicotinamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-Alzheimer's agent; preparation of phenethylamines for treatment of Alzheimer's disease)

L29 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:466008 HCAPLUS Full-text

DOCUMENT NUMBER: 137:33325

TITLE: Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents
INVENTOR(S): Boyd, F. Leslie; Chamberlain, Stanley D.; Cheung, Mui; Gudmundsson, Kristjan; Harris, Philip Anthony; Johns, Brian A.; Jung, David Kendall; Peel, Michael Robert; Stanford, Jennifer Badiang; Sexton, Connie Jo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048148	A2	20020620	WO 2001-US44231	20011126
WO 2002048148	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002039348	A	20020624	AU 2002-39348	20011126
EP 1377573	A2	20040107	EP 2001-987099	20011126
EP 1377573	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515550	T	20040527	JP 2002-549679	20011126
AT 300541	T	20050815	AT 2001-987099	20011126
ES 2243579	T3	20051201	ES 2001-987099	20011126
US 20050049259	A1	20050303	US 2003-433881	20030605
US 7163940	B2	20070116		
US 20070287721	A1	20071213	US 2006-538462	20061004
PRIORITY APPLN. INFO.:			US 2000-255763P	P 20001215
			US 2001-274284P	P 20010308
			WO 2001-US44231	W 20011126
			US 2003-433881	A3 20030605

OTHER SOURCE(S): MARPAT 137:33325

ED Entered STN: 21 Jun 2002

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I; R1 = cyclopentylamino, CH₃(CH₂)₃NH, Cl, NNNH₂, H₂NCH₂CH₂NH, NH₂, 4-methylpiperiziny, 4-CH₃OC₆H₄NH, Br, CH₃OCOCCH₂NH, HO₂CCH₂NH, cyclopropylamino, (CH₃)₂N, 4-morpholinyl; R₂ = NH₂,, cyclopentylamino, CH₃(CH₂)₃NH, CH₃S:O, HO(CH₂)₃NH, CH₂:CHCH₂NH, 4-morpholinyl, cyclopropylamino, pyrrolidinyl, (CH₃)₂N, 3-(4-morpholinyl)propylamino, CH₃(HOOCCH₂)N; R₃ = H, CH₃, (CH₃)₂NCH₂, (tetrahydro-2H-pyran-2-yloxy)methyl, HOCH₂, C₆H₅, COOH, 4-pyridinyl; R₄ = H, CH₃; R₅ = F, Br, Cl; X = N, CH], salts, and pharmaceutical compns. containing the same are prepared as antiviral agents. Title compds. I are tested for HSV-1 inhibition and the results demonstrate that title compds. I are useful for the treatment and prophylaxis of herpes viral infections. Thus, the title compound II was prepared from 6-chloro-2-picoline, Et 4-fluorobenzoate, and cyclopentylamine via cyclization.

IT 437612-70-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)

RN 437612-70-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-(cyclopentylamino)- (CA INDEX NAME)




IT 437612-71-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)

RN 437612-71-0 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



IC ICM C07D471-04
 ICS A61K031-437; A61P031-12; C07D471-04; C07D231-00; C07D221-00
 CC 28-18 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 437612-03-8P 437612-12-9P 437612-13-0P 437612-20-9P 437612-22-1P
 437612-23-2P 437612-33-4P 437612-46-9P 437612-48-1P 437612-50-5P
 437612-52-7P 437612-57-2P 437612-60-7P 437612-70-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)
 IT 437611-97-7P 437611-98-8P 437611-99-9P 437612-00-5P 437612-01-6P
 437612-02-7P 437612-04-9P 437612-05-0P 437612-06-1P 437612-07-2P
 437612-08-3P 437612-09-4P 437612-10-7P 437612-11-8P 437612-14-1P
 437612-15-2P 437612-16-3P 437612-17-4P 437612-18-5P 437612-19-6P
 437612-21-0P 437612-24-3P 437612-25-4P 437612-26-5P 437612-27-6P
 437612-28-7P 437612-29-8P 437612-30-1P 437612-31-2P 437612-32-3P
 437612-34-5P 437612-35-6P 437612-36-7P 437612-37-8P 437612-38-9P
 437612-39-0P 437612-40-3P 437612-41-4P 437612-42-5P 437612-43-6P
 437612-44-7P 437612-45-8P 437612-47-0P 437612-49-2P 437612-51-6P
 437612-53-8P 437612-54-9P 437612-55-0P 437612-56-1P 437612-58-3P
 437612-59-4P 437612-61-8P 437612-62-9P 437612-63-0P 437612-64-1P
 437612-65-2P 437612-66-3P 437612-67-4P 437612-68-5P 437612-69-6P
 437612-71-0P 437612-72-1P 437612-73-2P 437612-74-3P
 437612-75-4P 437612-76-5P 437612-77-6P 437612-78-7P 437612-79-8P
 437612-80-1P 437613-20-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)

L29 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:22757 HCAPLUS [Full-text](#)


DOCUMENT NUMBER: 132:207813

TITLE: Synthesis and reactions of some new pyrimidine derivatives and their potential biological activities

AUTHOR(S): Salman, Asmaa S. S.; Hefnawy, Mohamed A.

CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Girl's Branch, Al-Azhar University, Cairo, Egypt

SOURCE: Al-Azhar Bulletin of Science (1998), 9(1), 1-12
 CODEN: ABSCE7; ISSN: 1110-2535
 PUBLISHER: Al-Azhar University, Faculty of Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:207813
 ED Entered STN: 12 Jan 2000
 GI




AB β -(P-phenylbenzoyl)acrylic acid reacted with thiourea or urea to give pyrimidine derivs., which reacted with acrylonitrile, EtI, copper bronze and coupled with different aryl diazonium salts and/or sulfonamide diazonium salts to give (alkylthio)pyrimidines, 2,2'-bis[(4-carboxy-6- biphenyl)pyrimidinyl] disulfide and 5-(arylaazo)pyrimidine-2-thiones [I; R = (un)substituted aryl]. I and 2 other derivs. showed antibacterial and antifungal activities in vitro. Some reaction pathways were discussed.

IT 260556-38-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (desynthesis and reactions of some new pyrimidine derivs. and their potential biol. activities)

RN 260556-38-5 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[1,1'-biphenyl]-4-yl-1,2-dihydro-2-oxo-, [(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




IT 260556-22-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and reactions of some new pyrimidine derivs. and their potential biol. activities)

RN 260556-22-7 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[1,1'-biphenyl]-4-yl-1,2-dihydro-2-oxo-, hydrazide (9CI) (CA INDEX NAME)



IT 260556-23-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and reactions of some new pyrimidine derivs. and their
 potential biol. activities)
 RN 260556-23-8 HCAPLUS
 CN 4-Pyrimidinecarboxylic acid, 6-[1,1'-biphenyl]-4-yl-1,2-dihydro-2-oxo-,
 [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 260556-36-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (desynthesis and reactions of some new pyrimidine derivs. and their
 potential biol. activities)
 IT 260556-22-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and reactions of some new pyrimidine derivs. and their
 potential biol. activities)
 IT 260556-16-9P 260556-17-0P 260556-18-1P 260556-19-2P 260556-20-5P
 260556-21-6P 260556-23-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and reactions of some new pyrimidine derivs. and their
 potential biol. activities)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1975:16861 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 82:16861
 ORIGINAL REFERENCE NO.: 82:2705a,2708a
 TITLE: 6-Phenyl-4-carboxypyridine
 PATENT ASSIGNEE(S): Ferlux-Chimie S. A.
 SOURCE: Fr. Demande, 15 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2201083	A1	19740426	FR 1972-34327	19720928
FR 2201083	B1	19751128		

PRIORITY APPLN. INFO.: FR 1972-34327 A 19720928

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB Phenylpyrimidines I (R = OH, H; R1 = H, OMe, Me; R2 = OH, NHC6H4-SO2NH2-p; R3 = NH2, NHSO2C6H4NH2-p, NHNO2, OH, SH) were prepared. Thus, I (R = OH, R1 = H, R2 = OH, R3 = NH2) was prepared by treating 2-chromonecarboxylic acid with guanidine nitrate. I (R = H, R1 = OMe, R2 = OH, NHET2, R3 = OH) was a peripheral vasodilator at 5 mg/kg i.v. in dogs. Some I also demonstrated analgesic activity.


IT 55558-73-1F 55558-75-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic activity of)


RN 55558-73-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[[4-(aminophenyl)sulfonyl]amino]-N-[4-(aminosulfonyl)phenyl]-6-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 55558-75-3 HCAPLUS

CN 4-Pyrimidinecarboxamide, N,N-diethyl-6-(2-hydroxyphenyl)-2-(nitroamino)- (CA INDEX NAME)




IT 55558-78-6P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacological activity of)

RN 55558-78-6 HCAPLUS


CN 4-Pyrimidinecarboxamide, N,N-diethyl-1,2-dihydro-6-(4-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




IT 55558-70-8P 55558-72-0P 55613-05-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55558-70-8 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-amino-N,N-diethyl-6-(2-hydroxyphenyl)- (CA
 INDEX NAME)



RN 55558-72-0 HCAPLUS
 CN 4-Pyrimidinecarboxamide, 2-amino-N-[4-(aminosulfonyl)phenyl]-6-(2-
 hydroxyphenyl)- (CA INDEX NAME)



RN 55613-05-3 HCAPLUS
 CN 4-Pyrimidinecarboxamide, N,N-diethyl-1,2-dihydro-6-(4-methylphenyl)-2-oxo-
 (9CI) (CA INDEX NAME)



IC A61K; C07D
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 55558-73-1P 55558-75-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and analgesic activity of)
 IT 55558-79-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and pharmacological activity of)
 IT 30162-05-1P 55558-69-5P 55558-70-8P 55558-71-9P
 55558-72-0P 55558-74-2P 55558-76-4P 55558-79-7P
 55558-80-0P 55558-82-2P 55613-05-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

***** SEARCH HISTORY *****

=> d his nofile

(FILE 'HOME' ENTERED AT 11:45:46 ON 06 JUN 2008)

FILE 'HCAPLUS' ENTERED AT 11:46:13 ON 06 JUN 2008

L1 1 SEA ABB=ON PLU=ON US20070281936/PN
 D IBIB AB IT SC
 SEL RN

FILE 'REGISTRY' ENTERED AT 11:47:40 ON 06 JUN 2008

L2 271 SEA ABB=ON PLU=ON (105-58-8/BI OR 116986-13-1/BI OR 118486-94
 -5/BI OR 153936-26-6/BI OR 154696-52-3/BI OR 155269-58-2/BI OR
 1795-48-8/BI OR 18162-48-6/BI OR 28565-40-4/BI OR 50501-31-0/BI
 OR 534-22-5/BI OR 56-05-3/BI OR 569657-93-8/BI OR 6299-83-8/BI
 OR 68164-77-2/BI OR 7533-07-5/BI OR 79-16-3/BI OR 79-44-7/BI
 OR 81881-74-5/BI OR 84458-63-9/BI OR 863495-46-9/BI OR
 863495-51-6/BI OR 863495-53-8/BI OR 863546-30-9/BI OR 863546-31
 -0/BI OR 863546-32-1/BI OR 863546-33-2/BI OR 863546-34-3/BI OR
 863546-35-4/BI OR 863546-36-5/BI OR 863546-37-6/BI OR 863546-38
 -7/BI OR 863546-39-8/BI OR 863546-40-1/BI OR 863546-41-2/BI OR
 863546-42-3/BI OR 863546-43-4/BI OR 863546-44-5/BI OR 863546-45
 -6/BI OR 863546-46-7/BI OR 863546-47-8/BI OR 863546-48-9/BI OR
 863546-49-0/BI OR 863546-50-3/BI OR 863546-51-4/BI OR 863546-52
 -5/BI OR 863546-53-6/BI OR 863546-54-7/BI OR 863546-55-8/BI OR
 863546-56-9/BI OR 863546-57-0/BI OR 863546-58-1/BI OR 863546-59
 -2/BI OR 863546-60-5/BI OR 863546-61-6/BI OR 863546-62-7/BI OR
 863546-63-8/BI OR 863546-64-9/BI OR 863546-65-0/BI OR 863546-66
 -1/BI OR 863546-67-2/BI OR 863546-68-3/BI OR 863546-69-4/BI OR
 863546-70-7/BI OR 863546-71-8/BI OR 863546-72-9/BI OR 863546-73
 -0/BI OR 863546-74-1/BI OR 863546-75-2/BI OR 863546-76-3/BI OR
 863546-77-4/BI OR 863546-78-5/BI OR 863546-79-6/BI OR 863546-80
 -9/BI OR 863546-81-0/BI OR 863546-82-1/BI OR 863546-83-2/BI OR
 863546-84-3/BI OR 863546-85-4/BI OR 863546-86-5/BI OR 863546-87
 -6/BI OR 863546-88-7/BI OR 863546-89-8/BI OR 863546-90-1/BI OR
 863546-91-2/BI OR 863546-92-3/BI OR 863546-93-4/BI OR 863546-94
 -5/BI OR 863546-95-6/BI OR 863546-96-7/BI OR 863546-97-8/BI OR
 863546-98-9/BI OR 863546-99-0/BI OR 863547-00-6/BI OR 863547-01
 -7/BI OR 863547-02-8/BI OR 863547-03-9/BI OR 863547-04-0/BI OR
 863547-05-1/BI OR 863547-06-2/BI OR 863547-07-3/BI
 STRUCTURE UPLOADED

L3 D
L4 50 SEA SSS SAM L3

FILE 'STNGUIDE' ENTERED AT 11:50:42 ON 06 JUN 2008


FILE 'REGISTRY' ENTERED AT 11:56:21 ON 06 JUN 2008
 STRUCTURE UPLOADED
 D L5

L6 50 SEA SSS SAM L5

FILE 'STNGUIDE' ENTERED AT 11:58:04 ON 06 JUN 2008

FILE 'REGISTRY' ENTERED AT 12:12:14 ON 06 JUN 2008
 SCREEN 2043
 STRUCTURE UPLOADED
 D

Uploading L3.str



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-7 5-11 7-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-11 7-8 7-9

exact bonds :

3-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:Atom

Generic attributes :

11:

Saturation : Unsaturated

```

L9          41 SEA SSS SAM L8 NOT L7
              E PYRAZOLOPYRIDINE/CN
L10         1 SEA ABB=ON PLU=ON PYRAZOLOPYRIMIDINONE/CN
              D CN
L11         1 SEA ABB=ON PLU=ON PYRAZOLOPYRIMIDINOL/CN
              D CN
              D STR
              E PYRAZOLOPYRIDIN?/CNS
L12         1 SEA ABB=ON PLU=ON PYRAZOLOPYRIDINE/CNS
              D IDE
L13         1 SEA ABB=ON PLU=ON ?PYRAZOLOPYRIDIN?/CNS
L14        768 SEA SSS FUL L8 NOT L7
              SAVE TEMP L14 STO757REGL1/A
L15        191 SEA ABB=ON PLU=ON L2 AND L14

```

```

L16      0 SEA ABB=ON PLU=ON L14 AND (L12 OR L11)

FILE 'HCAPLUS' ENTERED AT 12:24:40 ON 06 JUN 2008
L17      38 SEA ABB=ON PLU=ON L14
L18      1 SEA ABB=ON PLU=ON L17 AND L1
L19      21 SEA ABB=ON PLU=ON L17 AND 63/SC,SX
L20      28 SEA ABB=ON PLU=ON L17 AND 1/SC,SX
L21      28 SEA ABB=ON PLU=ON L17 AND PHARMAC?/SC,SX
L22      28 SEA ABB=ON PLU=ON L18 OR L20 OR L21
L23      10 SEA ABB=ON PLU=ON L17 NOT L22
          E ADENOSINE RECEPTORS/CT
          E E6+ALL

L24      2102 SEA ABB=ON PLU=ON "ADENOSINE RECEPTORS (L) A2A"+OLD,UF/CT
          E PURINOCEPTOR ANTAGONISTS/CT
          E E3+ALL

L25      1260 SEA ABB=ON PLU=ON "PURINOCEPTOR ANTAGONISTS"+OLD,UF/CT
          E PAIN/CT
          E E3+ALL

L26      9443 SEA ABB=ON PLU=ON PAIN (2A) (NEUROPATH? OR INFLAM?)
L27      2 SEA ABB=ON PLU=ON L17 AND (L24 OR L25)
L28      7 SEA ABB=ON PLU=ON L17 AND L26
L29      28 SEA ABB=ON PLU=ON L22 OR L27 OR L28
          SAVE TEMP L29 STO757HCA/A

L30      667 SEA ABB=ON PLU=ON GILLESPIE R?/AU
L31      615 SEA ABB=ON PLU=ON TODD R?/AU
L32      99 SEA ABB=ON PLU=ON STRATTON G?/AU
L33      537 SEA ABB=ON PLU=ON JORDAN A?/AU
L34      12 SEA ABB=ON PLU=ON L30 AND ((L31 OR L32 OR L33))
L35      3 SEA ABB=ON PLU=ON L31 AND ((L32 OR L33))
L36      2 SEA ABB=ON PLU=ON L32 AND L33
L37      12 SEA ABB=ON PLU=ON (L34 OR L35 OR L36)
L38      1 SEA ABB=ON PLU=ON ((L30 OR L31 OR L32 OR L33) AND L14) AND
          (L1 AND L14)

FILE 'REGISTRY' ENTERED AT 12:35:06 ON 06 JUN 2008
L39      0 SEA ABB=ON PLU=ON L14 AND (MEDLINE/LC OR BIOSIS/LC OR
          DRUGU/LC OR EMBASE/LC)

FILE 'MEDLINE, BIOSIS, DRUGU, EMBASE, PASCAL' ENTERED AT 12:36:29 ON 06
JUN 2008
L40      16 SEA ABB=ON PLU=ON L37
          D TI AU 1-4
          SAVE TEMP L40 STO757MULTIN/A

FILE 'STNGUIDE' ENTERED AT 12:37:20 ON 06 JUN 2008
          D QUE L38
          D QUE L40

FILE 'HCAPLUS, MEDLINE, BIOSIS, DRUGU, EMBASE, PASCAL' ENTERED AT
12:38:33 ON 06 JUN 2008
L41      13 DUP REM L38 L40 (4 DUPLICATES REMOVED)
          ANSWER '1' FROM FILE HCAPLUS
          ANSWERS '2-5' FROM FILE MEDLINE
          ANSWERS '6-11' FROM FILE BIOSIS
          ANSWERS '12-13' FROM FILE DRUGU
          D L41 1 IBIB ABS HITSTR
          D L41 2-13 IBIB AB
          D QUE L29
          D QUE L39
          D L29 1-28 IBIB ED ABS HITSTR HITIND

```